



Baillie, G. S. , Tejada, G. S. and Kelly, M. P. (2019) Therapeutic targeting of 3',5'-cyclic nucleotide phosphodiesterases: inhibition and beyond. *Nature Reviews Drug Discovery*, 18, pp. 770-796.  
(doi: [10.1038/s41573-019-0033-4](https://doi.org/10.1038/s41573-019-0033-4))

There may be differences between this version and the published version. You are advised to consult the publisher's version if you wish to cite from it.

<http://eprints.gla.ac.uk/188977/>

Deposited on 27 August 2019

Enlighten – Research publications by members of the University of  
Glasgow

<http://eprints.gla.ac.uk>

**TITLE:** Therapeutic targeting of 3',5'-cyclic nucleotide phosphodiesterases: Moving beyond inhibition

**AUTHORS:** George S. Baillie<sup>1</sup>, Gonzalo Tejada<sup>1</sup>, and Michy P. Kelly<sup>2\*</sup>

**AFFILIATIONS:**

1. Institute of Cardiovascular and Medical Science, University of Glasgow, UK
2. Department of Pharmacology, Physiology & Neuroscience, University of South Carolina School of Medicine, USA

**\*CORRESPONDING AUTHOR:**

Michy P. Kelly, Ph.D.

Associate Professor

Department of Pharmacology, Physiology & Neuroscience

University of South Carolina School of Medicine

6439 Garners Ferry Road

VA Bldg 1, 3<sup>rd</sup> Floor, D-12

Columbia, SC 29209

Phone: 803-216-3546

Fax: 803-216-3551

email: Michy.Kelly@uscmed.sc.edu

**ACKNOWLEDGEMENTS:** Work supported by 1R01MH101130 (MPK). GT and MPK have no conflicts. GSB is co-founder and director of Portage Glasgow Limited.

**KEYWORDS:** PDE, PDE1, PDE2, PDE3, PDE4, PDE5, PDE6, PDE7, PDE8, PDE9, PDE10, PDE11, PDE1A, PDE1B, PDE1C, PDE2A, PDE3A, PDE3B, PDE4A, PDE4B, PDE4C, PDE4D, PDE5A, PDE7A, PDE8A, PDE9A, PDE10A, PDE11A, drug development, therapeutics, biomarker, optogenetics, activator, inhibitor, post-translational modification, protein-protein binding, protein-protein interactions, compartmentalization, signalosome, microdomains, nanodomains, cAMP, cGMP, cyclic nucleotide

## **Abstract**

Phosphodiesterases (PDEs), the only known enzymes to degrade 3',5'-cyclic nucleotides, are being pursued as therapeutic targets for a number of diseases, including those affecting the nervous system, cardiovascular system, fertility, immunity, cancer, and metabolism. Although clinical development programmes have so far focused exclusively on catalytic inhibition, emerging evidence supports therapeutically targeting PDE function in additional ways, such as enhancement of catalytic activity and/or normalization of altered compartmentalization, as well as the potential use of PDEs as disease biomarkers. Importantly, a more refined appreciation of the intramolecular mechanisms regulating PDE function and trafficking is emerging, making these pioneering drug discovery efforts tractable.

## Introduction

Conventional 3',5'-cyclic nucleotide phosphodiesterases (PDEs) are members of a highly conserved superfamily of enzymes that degrade the canonical cyclic nucleotides 3',5'-cyclic adenosine monophosphate (cAMP) and 3',5'-cyclic guanosine monophosphate (cGMP) (1-6), as well as the non-canonical cyclic nucleotides 3',5'-cCMP, 3',5'-cUMP, 3',5'-cIMP and c-di-GMP (7-9) (Figure 1). As extensively reviewed elsewhere (1), there are 11 families of PDEs that are grouped based on the homology of their C-terminal catalytic domain, and each PDE family has multiple isoforms that differ in terms of the length and complexity of their N-terminal regulatory domains (Figure 2). PDEs do not simply control the total cellular content of cyclic nucleotides, but rather create individual pockets or nanodomains of cyclic nucleotide signaling. It is this subcellular compartmentalization of cyclic nucleotide signaling that enables a single cell to respond discretely to multiple extracellular and intracellular signals. Thus, PDEs regulate a myriad of physiological processes, and their dysfunction has been associated with a number of pathophysiological states including those affecting the nervous system, cardiovascular system, fertility, immunity, cancer, and metabolism (Box 1). Because the location of a PDE is just as important to its overall function as is its catalytic activity, how the location of a given PDE isoform can change based on tissue type, age, or disease status—possibly due to factors such as activation of receptors, alterations in calcium signaling, or elevations in cyclic nucleotides—is of paramount importance when considering the therapeutic potential of a given PDE isoform (10-19) (Table S1).

Importantly, no two PDE isoforms share the exact same combination of substrate specificity, tissue expression profile and subcellular localization (Table S1). This is quite important because there are a number of diseases where compartment-specific defects in cyclic nucleotide signaling have been identified. For example, the function of soluble guanylyl cyclase, but not particulate guanylyl cyclase, is significantly impaired in brains of Alzheimer's patients and *in vitro* models of Alzheimer's disease pathology (20-22), which would be expected to decrease cytosolic pools of cGMP. In contrast, in colon cancer, membrane-bound guanylyl cyclase

appears to be dysregulated/suppressed (23) and membrane-enriched PDE10A appears to be overexpressed (24), both of which would decrease membrane-proximal pools of cGMP. That said, cytosolic pools of cGMP may also be decreased in colorectal cancer cells, as PDE5A is also overexpressed in these cells (24), and—at least in heart and brain—PDE5 regulates pools of cGMP that are downstream of soluble guanylyl cyclases (25, 26).

With regard to compartment-specific changes in cAMP signaling, studies examining brain tissue from patients with bipolar disorder show no change in membrane but increased signaling in the cytosol, which is normalized by the classic mood stabilizer lithium (27-32). Other disease states where compartment-specific defects in cyclic nucleotide signaling have been noted include—but are not limited to—erectile dysfunction (33), hypertension (34), cardiac hypertrophy (25, 35), acrodysostosis (36-39), and Huntington’s disease (40, 41). The unique substrate/localization profile offered by each PDE isoform offers multiple degrees of freedom in the context of therapeutic targeting. As such, isoform-specific targeting could enable selective restoration of cyclic nucleotide signaling in affected compartments (i.e., provide efficacy) without affecting cyclic nucleotide signaling elsewhere (i.e., avoid side effects).

As reviewed in detail below, there has been and continues to be strong interest in developing PDE-targeted therapeutics for a number of diseases. Unfortunately, the majority of PDE-targeted therapeutics on the market are simply competitive blockers of substrate binding at the catalytic site that lack the ability to selectively target a specific isozyme within a single PDE family or sub-family. That said, novel therapeutic strategies are currently being explored to increase the selectivity and specificity with which PDEs are targeted (e.g., by targeting protein-protein interactions). Further, PDE activators are now being considered as agents for treating select diseases, as are the exploitation of PDEs as biomarkers for diagnosis and/or patient selection (Box 2). Here, we review the clinical successes and failures of PDE inhibitors to date and describe a number of ways in which the field is moving beyond pharmacological inhibition of PDEs for therapeutic gain.

## **Successes and failures in the clinic.**

Several PDE family-selective inhibitors have successfully reached the market, targeting diseases such as psoriasis, COPD and erectile dysfunction. On the other hand, many potent and selective PDE inhibitors have also failed when tested in clinical trials. We will summarize the main achievements and pitfalls in the development of marketed PDE inhibitors to consider factors that currently limit the effectiveness of such therapeutic agents.

### *Marketed PDE inhibitors (PDEi's)*

The non-selective PDE1 inhibitor (PDE1i) vinpocetine is not FDA approved but is available in over-the-counter supplements (e.g., Cavinton or Intellectol, Richter Gedeon; Cognitex, Life Extension) claiming to improve memory and recovery from stroke, likely due to increasing vasodilation (42). As extensively reviewed elsewhere (42), a number of clinical trials have examined the cognition-enhancing effects of vinpocetine—either alone or in combination with another compound (e.g., caffeine or Ginko Biloba)—and have generally found improvement in healthy volunteers, individuals with cerebral hypofusion, and possibly aged individuals, but no improvement in AD patients. Reports of side effects associated with vinpocetine have generally been minimal (Table 1, (43)).

Several PDE3i's are currently marketed, with Cilostazol and Milrinone perhaps the most widely known. Cilostazol was officially approved by the FDA in 1999 for intermittent claudication; however, its off-label uses include secondary prevention of cerebrovascular accident, percutaneous coronary intervention and coronary stent stenosis (c.f., (44)). Although cilostazol improves function across a number of domains, it is also associated with serious side effects (Table 1). As such, cilostazol is contraindicated for patients with severe heart failure, hepatic impairment, or renal impairment (45). Milrinone increases contractility of the heart and is

FDA approved for short-term management of severe congestive heart failure. It is particularly used in the context of end-stage heart failure for patients who prove resistant to optimal therapy and for those awaiting cardiac transplant (46). That said, the clinical utility of milrinone has been limited by significant side effects (Table 1) and the fact that it is cleared through the kidneys (i.e., generally not used in patients with renal failure) (46).

Three so-called “second-generation” PDE4i’s are currently FDA approved, with a 4<sup>th</sup> compound marketed as an over-the-counter supplement. Roflumilast is a PDE4i that is FDA approved as an add-on therapy for chronic obstructive pulmonary disorder (COPD; Table 1). It is considered a third line treatment due to its gastrointestinal and weight loss side effects; however, it is reported to improve sugar metabolism in obese patients and may decrease cardiovascular events in patients with COPD (47). Apremilast is FDA approved for the treatment of moderate to severe plaque psoriasis and psoriatic arthritis (48-50) and is also being tested in a Phase IV trial for active ankylosing spondylitis (see below). The most common side effects for both of these orally-administered second-generation PDE4i’s are the same that plagued first-generation PDE4i’s (i.e, gastrointestinal disturbances; Table 1), albeit with much improved therapeutic windows (48). Crisaborole is a topically-applied ointment that is FDA approved for treatment of moderate atopic dermatitis in patients >2 years old. Given the topical nature of the drug, gastrointestinal side effects are avoided and, instead, hypersensitivity reactions are the major possible side effect. Clearly, there is an anti-inflammatory theme shared amongst these FDA-approved PDE4i’s. Zembrin is a non-selective PDE4 inhibitor (also acts as a 5-HT uptake inhibitor) that is not FDA-approved but is a component of a number of herbal supplements claiming calming or mood-stabilizing properties (e.g., Calm, Doctor’s Best; Mood, Procera; Nutri-calm, Nature’s Sunshine) (51). fMRI imaging of the amygdala in humans supports an anxiolytic-like effect of Zembrin (51). Further, a Phase I trial found Zembrin was well tolerated and improved cognitive flexibility,

executive function, mood and sleep (52). As noted below, a number of PDE4i's are currently being pursued to improve cognitive functioning (see below).

There are 4 PDE5i's currently FDA approved and marketed in the U.S., with a 2 additional PDE5i's marketed outside the U.S.. All 6 PDE5i's were originally marketed for erectile dysfunction (Table 1), with the most recent approval for avanafil based on its much more rapid onset of action. Sildenafil later received a secondary approval for pulmonary hypertension (contraindicated for pediatric patients, veno-occlusive disease, or sickle cell disease), as did tadalafil. These FDA-approved PDE5i's are generally considered safe and well tolerated, with no increase in cardiac mortality or myocardial infarction (53). Given their shared mechanism of action, it is perhaps not surprising that they share largely similar side effect profiles (Table 1) with headache, flushing, dyspepsia, and vision disturbances being the most common adverse events (53). Interestingly, udenafil (Zydena, Mezzion Pharma)—one of the PDE5i's used to treat erectile dysfunction in Korea, Russia and Philippines (54, 55)—has also been reported to improve cognitive function in patients with erectile dysfunction (56, 57).

The success of a number of marketed PDEi's validates PDEs as appropriate therapeutic targets in many pathological conditions. However, the presence of unwanted side effects resulting from the inability to target individual isoforms is the major limiting factor to success. It is notable that of the 11 PDE families, only agents that attenuate the activity of PDEs 1, 3, 4 and 5 have made it to market, despite significant efforts targeting the inhibition of other PDE families (see next).

#### *Failed PDEi clinical trials*

Despite the successes noted above, a number of PDEi's that entered the clinic failed to make it to market. Pfizer's selective PDE2i PF-05180999 was originally considered a candidate for cognitive impairments associated with schizophrenia based on its preclinical profile (58); however, it was brought into the clinic for



migraine. Despite the completion of earlier Phase 1 safety and tolerability studies, additional trials were terminated early due to safety concerns (Table 2). Exisulind inhibits both PDE2A and PDE5A (which are overexpressed in a number of precancerous and cancerous cell types) and triggers apoptosis in precancerous/cancerous cells with minimal effects on healthy cells (c.f., (59, 60)). Despite promising findings in multiple clinical trials, exisulind failed to secure FDA approval in 2000 due to deficiencies in safety and efficacy (Table 2, c.f., (59, 60)).

As noted above, Cilostazol has gained FDA approval for intermittent claudication; however, clinical trials for other indications, such as type 2 diabetes mellitus peripheral neuropathy, have failed (61). That said, cilostazol significantly improved walking speed in these patients, suggesting improved peripheral blood flow as would be expected based on its current approved indication (61).

The PDE4i cilomilast (Ariflo, GlaxoSmithKline) gained FDA approval in 2003 as a second-line treatment for COPD in patients who are poorly responsive to salbutamol (62). However, cilomilast never made it to market due to the severely dose-limiting nature of gastrointestinal side effects (e.g., nausea and vomiting, diarrhea, and abdominal pain (48)). The fact that cilomilast elicited more pronounced side effects relative to the other systemically-delivered PDE4i's described above may be related to preferential inhibition of the PDE4D family relative to the other PDE4 subtypes (62). A novel PDE4i ASP9831 was tested in Phase I and II trials for non-alcoholic steatohepatitis based on preclinical findings, but failed to improve biochemical biomarkers of the disease (63). As target engagement in the organ of interest was not confirmed (63), the reasons underlying the lack of efficacy remain unclear.

A number of clinical trials have attempted to extend therapeutic indications for PDE5i's, but have failed. As reviewed extensively elsewhere (42), a number of trials have tested the effects of sildenafil or vardenafil on various measures of cognition in healthy volunteers or patients with schizophrenia and have largely found no effects (64-68). That said, one report from an Iranian clinical trial did report an improvement

in negative symptoms in patients with chronic schizophrenia when sildenafil was administered in addition to risperidone (69). Several studies were initiated to study sildenafil and/or tadalafil in patients with Duchenne or Becker Muscular dystrophy, with the hopes that the vasodilatory properties of the drugs would improve muscular ischemia; however, clinical trial outcomes have been mixed (Table 2; (70, 71)).

Two PDE9i's have been tested in the clinic for cognition-enhancing effects. Although PF-04447943 was found to be safe and well-tolerated, it failed to improve either cognition or dementia-related behavioral disturbances in a Phase II clinical trial (72). Similarly, BI 409306 was reported as safe and well tolerated in healthy subjects as well as patients with AD or schizophrenia; however, no positive effects on cognition were observed in either patient population (<https://www.boehringer-ingenelheim.com/PDE9-Inhibition-in-AD>, accessed 04/30/19; (73-76)). Despite a failure to improve cognition in patients with schizophrenia, BI 409306 is still being tested in the clinic for prevention of schizophrenia relapse and prevention of first psychotic episode (Table 3). The failure of PDE9i's to improve functioning in AD may be related to the fact that brain PDE9A is enriched in the nucleus and membrane (10) and, thus, is not in a position to directly regulate the cytosolic pools of cGMP that appear to be dysregulated in Alzheimer's disease (20-22).

A number of clinical trials have tested the PDE10i PF-02545920 in schizophrenia and Huntington's disease (Table 2-3). Despite widely replicated efficacy in a number of preclinical assays intended to measure schizophrenia-relevant behaviors (e.g., (77, 78)), PF-02545920 failed to improve symptoms in patients with either exacerbated, stable, or sub-optimally treated schizophrenia (Table 2; (79)). Further, in at least 1 trial, there were reports of motoric side effects such as dystonia (79). Pfizer attempted to reposition PF-02545920 for Huntington's disease based on decreased striatal expression of PDE10A being found in patients (Box 2) and promising efficacy of PDE10i's in preclinical models of the disease (41, 80, 81). Unfortunately, PF-02545920 failed to improve symptoms in patients with Huntington's (<https://clinicaltrials.gov/ct2/show/results/NCT02197130?sect=X70156#outcome1>, accessed 04/30/19), and so

efforts for this disease indication were terminated (<https://clinicaltrials.gov/ct2/show/NCT02342548>, accessed 04/30/19). Several other PDE10i's have also been pursued in the clinic for schizophrenia and/or HD, with some efforts subsequently suspended or terminated (Table 2) and others ongoing (Table 3—see more below).

The unsuccessful translation of these PDEi's from promising preclinical data to human testing suggest that therapeutic approaches targeting PDEs need to extend beyond occlusion of the enzyme's catalytic site. Of particular note are the numerous failures seen in nervous system disorders, even when target engagement was verified. Expression of PDEs in the brain is particularly complex, with PDE isoforms differentially expressed across circuits, cell-types, and subcellular domains (10, 43, 82, 83). Thus, the challenge in evaluating the clinical potential for the next generation of PDE-modulating drugs is to gain novel insights about disease-related changes in PDE structure, function and regulation to understand how PDEs should be targeted in a compartment-specific manner for therapeutic gain.

### **PDE inhibitors in development.**

Given the clinical successes of PDEi's noted above, it is not surprising that traditional PDEi's are still very much being pursued as potential therapeutics, particularly in the context of the central nervous system (CNS), cardiovascular system, reproductive system, cancer and metabolic disorders (Table 3). These efforts include the development of new chemical entities as well as repurposing of existing entities. Thanks to advances in our understanding of structural differences that exist between PDEs, coupled with extensive years-long medicinal chemistry efforts to optimize structure-activity relationships, more recently developed PDEi's have been vastly improved in terms of selectivity and potency and have even demonstrated novel modes of action in some cases (i.e., acting as a negative allosteric modulator instead of direct catalytic inhibitor; (84-87)). Despite these advances in new chemical entities, there is still significant efforts to repurpose older PDEi's. Drug repurposing efforts can be driven by computational or experimental approaches; however, most drug repurposing efforts

have been driven either by a better understanding of pharmacology or by a retrospective analysis of clinical effects that were observed during trials or marketed use of a drug for its original indication (c.f., (88)). Indeed, the PDE5i sildenafil was originally brought into clinical trials for angina but—following observations made by clinicians in that trial—was later repurposed for erectile dysfunction. Drug repurposing has several advantages including reduced risk and substantially reduced timelines and cost (e.g., \$300 million for repurposed drug versus \$2-3 billion for new chemical entity) due to the fact that the drug would already have passed preclinical and Phase I safety testing and possibly even formulation development (88). That said, there are a number of barriers to recouping expenses incurred by drug repurposing trials, particularly when they are carried forward by an entity other than the patent holder or following the expiration of the original patent (see (88) for further discussion).

#### *Non-selective inhibitor*

The non-selective PDE3-4-10-11 inhibitor Ibudilast, which also inhibits glial cell activation, is approved for use in Japan as a bronchodilator and has long been of interest as a therapeutic approach for neuropathic pain and substance abuse/withdrawal (89, 90). Recent clinical trials have tested Ibudilast in the context of amyotrophic lateral sclerosis, pain, as well as opiate, methamphetamine, and alcohol abuse (Table 3) and positive effects have been reported for all trials completed to date (91-94).

#### *PDE1 inhibitors*

The broad PDE1 inhibitor ITI-214, which shows picomolar IC<sub>50</sub>s for PDE1A, PDE1B and PDE1C in enzymatic assays and >1000-fold selectivity versus its nearest neighbor PDE4 (95, 96), is being explored for CNS and non-CNS indications. ITI-214 demonstrates cognition-enhancing effects in rodent models of long-term memory and working memory deficits (95-97), mimicking effects of a dopamine receptor 1 (D1) agonist (97) and occurring

at doses that leave efficacy of the antipsychotic risperidone intact (95). Although the target mediating the cognition-enhancing effects of ITI-214 remains undetermined, PDE1B may be the most likely candidate given its expression in D1-expressing neurons (97) along with the fact that the a PDE1B-selective inhibitor showed similar cognition-enhancing effects (98). ITI-214 was moved into the clinic, with potential applications for cognitive deficits associated with schizophrenia, AD, and Parkinson's Disease (96), with safety and tolerability established in healthy volunteers and patients with schizophrenia (Table 3). ITI-214 is also being explored in the clinic for heart failure (NCT03387215) given its ability to improve cardiac function in dog and rabbit models of heart failure (99) as a consequence of its inhibition of PDE1C (99).

### ***PDE2 inhibitors***

Like the PDE1i described above, a number of highly selective PDE2i's have demonstrated cognition-enhancing, anxiolytic and anti-depressant like-effects in animal models (c.f., (100)). TAK-915 entered Phase I trials to correlate plasma exposures with central target engagement with the purpose of informing dose selection for future trials targeting cognitive impairment in schizophrenia (101-103) (Table 3). Looking beyond the brain, PDE2i's may hold relevance for cardiovascular function since elevated PDE2A expression has been found in failing human hearts as well as a large number of animal models of heart disease (c.f., (104)). Further, PDE2i's may hold promise as an antifungal treatment for moderate to severe candidiasis infections, given that genetic deletion of *pde2a* reduces virulence and biofilm integrity of the fungal pathogen (c.f., (105)).

### ***PDE3 inhibitors***

Despite its existing FDA approval, the efficacy and safety of cilostazol is still very much a topic of investigation, with 27 active clinical trials registered on clinicaltrials.gov (accessed 04/30/2019) and 54 more drawn to a close within just the past 10 years. Numerous recent Phase IV studies appear focused on

broadening the therapeutic indications of cilostazol to include vasculature-related insults and nephropathies associated with Type 2 diabetes (Table 3), and recent reports suggest largely positive effects (44, 61, 106, 107). One study explored the efficacy of cilostazol in chronic tinnitus, and reported some improvement (108). Several prospective and retrospective studies have examined cilostazol as a primary or adjunctive treatment for cognitive deficits associated with AD and schizophrenia; the majority of which demonstrated positive effects of cilostazol on cognition (see (42) for review). The mechanism by which cilostazol elicits improved cognition has yet to be determined empirically. Given there is very little expression of PDE3A or PDE3B in the brain (83, 109), it may be likely that cognition-enhancing effects of cilostazol are driven by increased cerebral blood flow that comes with chronic—but not acute—dosing as opposed to inhibition of PDE3 isoforms directly in the brain (e.g., (110)).

Novel therapeutic applications of cilostazol are also being explored in preclinical studies. For example, oral cilostazol (30 mg/kg) improved retinal stress, ischemia, and ganglion cell death in a rat model of diabetic retinopathy (111). In addition, PDE3A knockout (KO) mice are infertile (112) and chronic administration of cilostazol blocks pregnancy in naturally-cycling swine (113), suggesting potential utility of PDE3i's for birth control or regulating *in vivo* oocyte maturation in the context of assisted reproduction. Indeed, administration of cilostazol to superovulated mice was able to improve *in vitro* fertilization rates of subsequently harvested oocytes, possibly by virtue of synchronizing the oocyte maturation (114). Because of the promise of PDE3 as a therapeutic target, coupled with concerns over side effect associated with cilostazol, alternative PDE3 inhibitors are currently being sought in hopes of retaining efficacy associated with this target while avoiding side effects (115-117).

### ***PDE4 inhibitors***

The PDE4 family is arguably the most studied of all the PDE families. A number of clinical trials have tested the effect of apremilast for indications beyond psoriasis and arthritis. Two Phase II studies are testing the efficacy of apremilast in combination with phototherapy to produce repigmentation in patients with Vitiligo (Table 3). Interestingly, a recent case report showed apremilast dramatically improved repigmentation in a woman with treatment-resistant Vitiligo (118). Multiple case reports have also described an ability of apremilast to improve symptoms in patients with treatment-resistant erosive oral lichen planus (119-121), perhaps motivating the recently registered Phase II study that will test the ability of apremilast to improve genital erosive lichen planus (Table 3).

Additional indications are also being explored for roflumilast. Phase IV studies showed roflumilast reduced fat mass and, thus, body weight in obese women with polycystic ovary syndrome (PCOS); however, these reductions were smaller than those elicited by liraglutide (Table 3; (122, 123)). The PDE4 inhibitor TAK-648 is being tested in the clinic in patients with Type 2 diabetes, based on preclinical data supporting such an indication (124). Roflumilast has also been tested for its ability to improve cognition and information processing in healthy humans, with promising results observed at a dose previously indicated as being devoid of side effects (125). Patients with stabilized schizophrenia receiving adjuvant roflumilast in a small Phase II trial showed no improvement in working memory but did show some improvement in verbal learning and memory (126). Given these positive findings, roflumilast was tested in elderly subjects who demonstrated no change in spatial memory but improved verbal word memory with roflumilast treatment (127). Numerous preclinical studies have long pointed to the therapeutic potential of PDE4i's in the context of schizophrenia and cognition (128-131).

Cognition-enhancing effects have also been reported for the PDE4i HT-0712, which improved long-term memory for word-lists without serious adverse events in elderly subjects experiencing cognitive decline ([http://www.dartneuroscience.com/press\\_release/july\\_22\\_2008.pdf](http://www.dartneuroscience.com/press_release/july_22_2008.pdf)). The cognition-enhancing effect of HT-

0712 in humans is consistent with previous reports in mice (132, 133). The PDE4D negative allosteric modulator BPN14770 is also being pursued for improving cognitive impairment and has been tested for safety and/or efficacy in healthy elderly subjects, healthy volunteers with scopolamine-induced cognitive impairment, and adult males with Fragile X Syndrome (Table 3). In a press release, BPN14770 was described as having good safety and oral bioavailability and an ability to improve working memory in healthy elderly adults (<http://tetradiscovery.com/wp-content/uploads/2016/11/FINAL-Tetra-Phase-1-121616-FINAL.pdf>; accessed 04/30/19). These effects in humans are consistent with preclinical studies showing BPN14770 improved a number of behaviors in a mouse model of Fragile-X Syndrome and antagonized the amnesic effects of scopolamine in mice (134, 135). Based on preclinical studies showing anxiolytic and cognition-enhancing effects (136), the PDE4i GSK356278 entered Phase I safety trials for Huntington's disease but adverse events limited the highest dose to that achieving only ~50% occupancy in brain (Table 3; (136)). Other nervous system disorders for which preclinical evidence suggests a therapeutic potential of PDE4i's include ischemic stroke (132, 137-140), traumatic brain injury (141), axon regeneration (142), and substance abuse disorders (both causes and consequences, (143-146)).

McCune-Albright Syndrome is a disease affecting endocrine tissues, skin and bones and is caused by a mutation that results in constitutive activation of the G-protein alpha subunit *Gas* (*Gas\**). Preclinical studies show that while *Gas\** triggers increased cAMP levels in some tissues, it actually results in decreased cAMP levels in other tissues due to a PKA-dependent upregulation of PDE activity, particularly that of PDE1 and PDE4 (129, 147, 148). Consistent with this upregulation of PDE4 activity, the PDE4i rolipram was able to reverse deficits in a *Gas* mouse models (129, 130). A clinical trial is currently underway that is using PET imaging to measure PDE4 expression in the brain and peripheral organs of patients with McCune-Albright Syndrome (Table 3).



More recent work is examining PDE4 in the context of cancer. Both preclinical and clinical data suggest roflumilast may exhibit anti-tumor activity for B-cell lymphomas (149). The PDE4i rolipram, in combination with cAMP-elevating agents, has been shown to suppress triple negative breast cancer both *in vitro* and *in vivo* in mice (150). Apremilast similarly induced tumor regression in mouse models of colorectal cancer (151). Perhaps even more interesting, inhibition of PDE4D specifically, either with genetic tools or the PDE4Di Gebr-7b, resensitized chemotherapy-resistant ER-positive breast cancer cells (152). Although PDE4i's have yet to be extensively explored in cancer patients, these early studies provide promise for the chemotherapeutic potential of PDE4is.

### ***PDE5 inhibitors***

A number of recent clinical trials have explored additional disease indications that might benefit from the vasodilatory properties of PDE5i's. A cream version of sildenafil has recently been tested in a Phase II study examining female sexual arousal disorder (Table 3) as well as a study in which improved blood flow in patients with secondary Raynaud phenomenon was observed (153). International consortiums are testing sildenafil in intrauterine growth restriction in hopes that the vasodilatory properties of the drug will improve uteroplacental perfusion and, thus, fetal growth (154, 155). Initial results suggest sildenafil improves fetal growth and maternal blood pressure across species, including human, sheep, rabbit, and rodents (156, 157). Several studies have also explored the effects of sildenafil, tadalafil, or vardenafil in the context of metabolic disorders such as Type 2 diabetes and obesity, with the hopes that the vasodilatory properties of these drugs would improve glucose tolerance and insulin signaling and, thus, improve other endpoints such as elevated body weight, nephropathy, and cardiomyopathy (Table 3). Tadalafil improved insulin secretion, endothelial function, and abdominal lean mass content in non-obese men (158), and chronic sildenafil improved glycometabolic control, ameliorated visceral adiposity, and prevented remodeling in diabetic cardiomyopathy

(159-162). That said, vardenafil failed to reduce cardiovascular risk in men with type 2 diabetes (163).

Interestingly, the positive effects of sildenafil on adiposity and diabetic cardiomyopathy are suggested to be independent of sildenafil's vasodilatory properties, rather being mediated by epigenetic signaling and/or a reduction of inflammatory chemokines (159-162). It is important to note, however, that one of the studies examining the effect of sildenafil on glucose homeostasis was terminated early due to safety concerns (Table 2). With regard to other indications related to nephropathy and cardiomyopathy, sildenafil has also been tested against media-induced nephropathy, and tadalafil is being explored in the context of kidney stones and endocrine cardiomyopathy (Table 3). A meta-analysis of older clinical studies suggest PDE5i's could be an effective medical expulsive therapy for distal ureteral calculi, albeit not significantly improved relative to tamsulosin (164). With regard to the brain, two early-stage clinical trials are testing the ability of sildenafil to reverse concussion-related reductions in cerebrovascular reactivity (Table 3).

As described for PDE4i's, a number of trials are exploring the therapeutic potential of PDE5i's as chemopreventives for solid tumors, multiple myeloma, and head and neck squamous cell carcinoma. Early reports suggest combining sildenafil with the chemotherapeutic regorafenib is safe in patients with solid tumors (165). Further, a number of *in vitro* and animal models of colorectal cancer suggest that PDE5i's, either alone or as part of a multi-chemotherapeutic regimen, demonstrate an ability to prevent tumor growth (e.g., (24, 165, 166)). Similarly, reports from both retrospective and prospective trials suggest tadalafil promotes tumor immunity in patients with head and neck squamous cell carcinoma (Table 3, (167, 168)). Although PDE5i's show significant anti-tumor effects, particularly with regard to colorectal cancer, they do not produce complete anti-tumorigenic effects (23). This lack of complete efficacy may be related to the fact that membrane GCs are inhibited in colorectal cancer (23), but PDE5 may be primarily regulating cytosolic GCs (25, 26). Alternatively, it may be related to the fact that both PDE5 and PDE10A—the latter a membrane-enriched PDE (82, 169)—are overexpressed in colorectal cancer cells (24). Indeed, PDE10i's also inhibit growth of colorectal

cancer cells (170, 171); however, when both PDE5 and PDE10 are inhibited, anti-tumor efficacy is improved in preclinical models (24). Although enthusiasm for PDE5i's as chemopreventives is growing (172), it should be noted that PDE5i's similarly prevented prostate carcinogenesis in preclinical models but did not appear to reduce risk or recurrence in clinical studies (173). Perhaps even more concerning, PDE5A appears to suppress melanoma cell invasion in mice (174) yet a recent systematic review and meta-analysis showed that PDE5i's actually increase risk for melanoma and basal cell carcinoma in humans (175).

### *PDE9 inhibitors*

Although PDE9i's thus far have failed in the clinic for brain diseases, they may hold therapeutic potential for cardiovascular diseases. In a mouse model of sickle cell disease, the PDE9i BAY73-6691 had immediate benefits on acute vaso-occlusive events (176), and a Phase 1 clinical trial has recently completed looking at safety, tolerability and PK/PD of the PDE9i PF-04447943 in patients with sickle cell anemia (Table 3). PDE9i's may also hold therapeutic potential for cardiovascular indications as PDE9A expression is upregulated by cardiac hypertrophy and cardiac failure. Indeed, the PDE9i PF-04449613 reverses heart disease in animal models by controlling pools of cGMP downstream of pGCs (25).

### *PDE10i inhibitors*

Despite the PDE10i clinical failures described above, TAK-063 was tested in healthy controls and patients with schizophrenia. In healthy controls, TAK-063 was reported to be safe and well tolerated (177), altering the effects of ketamine on brain activity in healthy controls, particularly in the striatum, substantia nigra, and ventrolateral prefrontal cortex (

<https://clinicaltrials.gov/ct2/show/results/NCT01892189?sect=X70156#outcome1>, accessed 04/30/19). In patients with schizophrenia, although TAK-063 failed to demonstrate a significant effect on the total PANSS score,

there was a trend that mirrored effects sizes normally seen with risperidone (178). Furthermore, TAK-063 did significantly improve a number of secondary endpoints relative to placebo (178). It is not entirely clear why TAK-063 was able to succeed where PF-254920 failed. While one study suggested that TAK-063 activates the striatal direct and indirect pathways in a balanced manner and PF-254920 activates the direct pathway more so than TAK-063 (179), other studies have reported that PF-254920 activates these pathways equally (77, 180). It is notable that TAK-063—but not PF-254920—increased sensorimotor gating in rodents as measured by prepulse inhibition of acoustic startle (PPI) (179), suggesting PPI may more accurately predict antipsychotic-like effects of novel compounds. Preclinical studies are also exploring the therapeutic potential of PDE10i's in the context of L-DOPA-induced dyskinesias (181) and alcohol abuse disorders (144).

### *Inhibition of PDE7, PDE8 or PDE11*

Studies describing the physiological function of the PDE7, PDE8, and PDE11 families are now emerging; however, inhibitors have not yet reached the clinic. Like many of the PDE families discussed above, early research suggests that PDE7i's and PDE8i's may have positive effects in diseases where cognition, neuroprotection, neuroinflammation, and/or motor function are impaired (e.g., multiple sclerosis and/or Parkinson's disease; (182-186)). Similarly, PDE11i's may hold potential for treating age-related cognitive decline (83) or as an adjunctive treatment to improve lithium responsiveness in patients with bipolar disorder (187, 188). PDE7i's may also hold promise in treating leukemia (189, 190), and PDE8i's may have potential for treating disorders associated with reduced androgen production in males as PDE8i's, particularly when applied in combination with PDE4i's, stimulate Leydig cell steroidogenesis (191, 192).

### **Therapeutic strategies beyond inhibition**

#### *Activating PDEs*

Although efforts to pharmacologically modulate PDE activity to date have largely focused on inhibition, there are several disease states where PDE activation may be warranted. Tissue-, brain region-, and subcellular domain-specific decreases in PDE expression/activity and/or increases in cyclic nucleotide signaling have been implicated in select disease states, including some age-related deficits (193-195), Huntington's disease (196), social isolation (197), migraine (198-202), retinitis pigmentosa (203), infertility (112), prostate cancer (204), melanoma and basal cell carcinoma (175), cardiac hypertrophy (35, 205), acrodysostosis (36), and polycystic kidney disease (206). Indeed, Mironid have developed PDE4 longform specific activators (mechanism as yet unknown; Table 4) for the treatment of polycystic kidney disease where increased adenylate cyclase activity caused by overexpression of vasopressin V2R receptors results in elevated cAMP levels that drive cyst growth and disease progression (207). There are several natural mechanisms by which PDE activity can be activated (Figure 3), and it is our contention that these avenues could be manipulated pharmacologically to trigger PDE activation.

One route to PDE activation is by way of tandem GAF (cGMP-specific and stimulated PDE, *Anabaena* adenyl cyclases, and *E. Coli* FhlA) domains (208) (Figure 3B). Although GAF domains have been identified in over 7400 proteins, in mammals they are only found in the PDE families 2, 5, 6, 10 and 11 (6, 209). For a vast majority of non-PDE GAF domains the activating ligand is unknown, however for PDEs we know that cyclic nucleotides bind to these pockets (Figure 3). PDE2 and PDE5 are activated when cGMP binds the GAF domain (210-212), and PDE10 is activated by cAMP binding the GAF domain (213). In the context of activation, binding of cyclic nucleotides to GAF domains is thought to cause structural changes that relieve autoinhibition of the PDEs (Figure 3). In contrast, cGMP binding the GAF-A domain of PDE6 enhances protein-protein interactions that inhibit PDE6 catalytic activity (214). This suggests that blocking cGMP binding of the PDE6 GAF domain may provide a means of promoting PDE6 activity. It also suggests it may be possible to both activate and inhibit GAF-containing PDEs with small molecules at a site distinct from the catalytic domain.

Indeed, PDE11A is activated when a cGMP analog—but not cGMP itself—binds the GAF domain (213). Further, even though cGMP binding of the GAF domain activates PDE5 (210), a number of other types of molecules that bind the GAF domain inhibit PDE5 in its activated—but not basal—state (215). This is consistent with the fact that GAF domains are known to bind a diverse array of small molecules that are unrelated to cyclic nucleotides (208). The fact that GAF domains are only found in PDEs in mammals (6) makes GAF domains of high interest in the context of drug targeting (216). Importantly, mammalian GAF domains are sufficiently structurally divergent from one another (e.g., low degree of homology between PDE families and the tandem GAF domains are preceded by variable N-terminal stretches) as to allow selective pharmacological targeting of individual PDE families (210). Together, this suggests the GAF domains may provide an inroad for targeting reagents that selectively activate a given PDE isoform while avoiding off-target activity.

PKA or PKG phosphorylation of PDE3 (217, 218), PDE4 (217, 219), PDE5 (220), and PDE8 (221) is also known to activate catalytic activity in a negative feedback loop. In the case of PDE4, for example, catalytic activity is inhibited when the UCR2 regulatory domain “trans-caps” the catalytic site; thus, occluding cAMP from reaching the enzymatic core of PDE4 (85, 222) (Figure 3C). PKA phosphorylation of the UCR1 regulatory domain blocks the ability of UCR2 to trans-cap the catalytic site, which locks PDE4 in the active state (85). Notably, select PDE4Di’s allosterically inhibit catalytic activity by promoting “trans-capping” (141); whereas, phosphatidic acid activates PDE activity by inhibiting trans-capping in a similar but mutually exclusive manner to PKA (223-225). Furthermore, the dominant negative peptide “UCR1C”, which corresponds to UCR1 sequence, also activates PDE4 activity by inhibiting trans-capping (226). These results provide proof of principle that activation of PDE4 may be achieved by either small molecules or biologics that prevent UCR2 from adopting a trans-capping conformation.

PDEs may also be activated by manipulating protein-protein binding interactions. PDE6 is unique in the fact that the heterodimeric holo-enzyme includes two inhibitory subunits that span the catalytic pockets of the dimer, thus occluding cGMP from the catalytic site (227) (Figure 3D). Binding of the GTP-bound  $\alpha$ -subunit of the heterotrimeric G-protein transducin relieves PDE6 inhibition by binding to the C-terminal region of PDE6 and its inhibitory subunits (228). The full crystal structure of PDE6 is not yet available (229); however, recent cryo-EM work (230) has confirmed the predicted structural organisation of the holo-enzyme, albeit without sufficient detail to inform pharmacological targeting. The success in upregulating PDE6 activity via gene transfer to combat retinitis pigmentosa (203) (see following section) suggests that PDE6 activation could be a viable therapeutic strategy for the treatment of vision loss. As discussed in greater detail below, it may also be possible to increase PDE activity by preventing the binding of PDEs to binding partners that sequester or suppress activity.

### *Gene therapy*

Viral transfer of PDE genes, agents that silence PDE gene expression (e.g. antisense, silencing or microRNAs) (174, 231-235), or gene editing (e.g., Crispr/Cas9) (236) might also prove a useful means of therapeutically targeting individual PDE isoforms (Figure 4). The best characterized PDE gene therapy approach to date targets PDE6 activity in the retina. A loss of transducin-mediated activation of PDE6 results in elevated cGMP levels, which causes the loss of primary rods and, ultimately, vision (237). Expression of recombinant PDE6 $\alpha$  in the retina via an adeno-associated virus (AAV-PDE6 $\alpha$ ) preserved retinal structure, photo-transduction, and vision in retinal degeneration (rd) mice, as did AAV-PDE6 $\beta$  (238, 239). AAV-PDE6 $\alpha$  similarly rescued retinal deficits in a mouse model that mimics human retinitis pigmentosa mutations (240). Experiments injecting AAV-PDE6 $\gamma$  into the retina have also proven successful in mice (241). In dogs, delivery of recombinant PDE6 $\alpha$  using a tyrosine capsid-mutant AAV8 was able to stabilize cGMP levels and improve survival of

photoreceptor rods and cones in PDE6 $\alpha$ -mutant dogs; however, several adverse effects related to the AAV injection were identified (203). The recent development of synthetic AAV vectors that target the retina in non-human primates may provide the answer to these problems in the future (242). Notably, two clinical trials are underway testing the safety and efficacy of PDE6 gene therapy in retinitis pigmentosa (PhI NCT02759952, PhII NCT03328130; clinicaltrials.gov accessed 12/04/18).

A rapidly evolving approach within the gene therapy field is optogenetic medicine, which combines viral delivery of recombinant, light-activated proteins with biomedical devices that emit light of the specific intensity and wavelength needed to activate those proteins (243). With the field of personalized bioelectronic implants quickly evolving, optogenetic-based biomedical approaches are being pursued for neurological diseases, cancer, cardiovascular disease and metabolic disorders (243). Given that optogenetic-based approaches have now entered clinical trials (243), it is worth noting here that light-activated PDEs have been identified in lower organisms (244-246) and engineered in the lab (247). Both are being explored as biological tools in higher organisms. Activating or inhibiting a given PDE by a spatially and temporally restricted light emission, as opposed to a systemically administered pharmacological agent, may prove an ideal approach for treating diseases where cyclic nucleotide signaling is down regulated in one tissue yet upregulated in another (e.g., aging; c.f., (248)). It might also provide a means of avoiding side-effects associated with targeting PDE activity in a specific tissue (e.g., nausea/emesis associated with inhibiting PDE4 in the area postrema).

### ***Targeting location***

As production of cAMP is utilized by a variety of different Gs-coupled receptors to transduce signals, compartmentalization of signaling intermediates is crucial to define physiological outcomes specific to each receptor (249). This compartmentalization of cyclic nucleotide signaling is achieved by virtue of PDEs being tethered to a precise cellular location via binding partners (Table S1). Thus, promoting or disrupting isoform-



specific protein-protein interactions may prove a viable approach to therapeutically target PDEs in an isoform-specific manner, a level of specificity that has not been achieved with pharmacological inhibitors to date (Figure 4).

Proof of principle for such an approach first emerged with studies using dominant negative (DN) PDEs, catalytically inactive mutants that would displace their endogenous PDE. Using specific DN-PDE4 isoforms, *in vitro* studies have successfully altered perinuclear cAMP signaling (250),  $\beta$ -arrestin-dependent desensitization of the beta2-adrenergic receptor (251, 252), growth control of prostate cancer cells (204), prostanoid receptor-mediated cAMP signaling (253), glucagon-like peptide-1 release (254), and cAMP gradients at the centrosome (255). DN-PDE4 tools have also yielded beneficial effects *in vivo*. For example, viral delivery of a DN-PDE4A5 to the mouse hippocampus was able to rescue localized cAMP signaling deficits and hippocampus-dependent memory impairments that were caused by sleep deprivation (256-258). In contrast, overexpression of a DN-PDE4B1 in the forebrain of mice did not affect hippocampus-dependent memory, although it did enhance hippocampal long-term potentiation in male mice (259). This finding underscores the importance of understanding the role of specific PDE isoforms, because a homozygous mutation in PDE4B (Y358C) that greatly reduces activity of all PDE4B isoforms by virtue of attenuating interactions with the scaffold protein Disrupted In Schizophrenia 1 (DISC1) improves both long-term potentiation and memory as well as other mood-related behaviors (260). It is interesting to note that nature has developed its own dominant-negative approach with PDE4A7, a PDE isoform that is targeted to specific subcellular compartments but is catalytically dead (261).

One point to consider in adopting a DN approach is the fact that a single PDE isoform can contribute to more than one function in a cell via its participation in multiple distinct signaling complexes, which involve mutually exclusive protein-protein interactions (262) (Table S1; Figure 4). For instance, PDE4D5 is involved in a number of processes common in almost all cells, such as cell

growth, cell orientation, desensitization of Gs-coupled receptors, and inactivating the phosphorylation of ubiquitous chaperone HSP20 (263). The ability for PDE4D5 to have all these functions in a cell is a result of it being localized in different compartments by different anchors (e.g., RACK1 at leading edge of cells, beta-arrestin at transmembrane receptors, and HSP20 in the cytosol; Figure 4; (263)). It is clear that this is also the case for a number of other isoforms based on proven protein-protein binding interactions (e.g., in heart tissue/cells, PDE4D3 can bind to either the ryanodine receptor, HSP20, or an AKAP9/Potassium channel complex—see Table S1) or based on inference from the fact that the exact same isoform can be found localized to multiple subcellular domains (e.g., ~50% of PDE11A4 in neurons localizes to the cytosol while 25% is localized to the nuclear fraction and another 25% to the membrane compartment (82)). Thus, a non-selective DN approach has the potential to influence multiple domains within the cell. To achieve a compartment-specific manipulation of a given PDE isoform, one could mutate the binding site(s) that mediates a particular protein-protein interaction. Mutating isoform-specific binding sites has also proven a useful approach, revealing an integrin  $\alpha 5$ -PDE4A5 complex regulates endothelial inflammation (264), a PDE3A1-SERCA complex regulates myocardium contractility (265), and DISC1-mediated sequestering of PDE4B regulates hippocampal function (260). An alternative approach is to develop a peptide or small molecule that specifically competes for a given protein-protein binding site (266). This approach would displace only a specific “pool” of a given PDE isoform, while leaving the vast remainder unfettered in their respective signaling complexes (Figure 4).

Indeed, a recent review suggests cell-permeable, peptide disruptors effectively manipulate specific PDE isoforms in a compartment-specific manner (266) and evidence continues to build. More recently, a PDE4D-FAK disrupting peptide prevented direction sensing and invasion of melanoma cells (267, 268) and a PDE8A-Raf1 disruptor retarded cancer cell growth promoted by a Ras mutation (221). Interestingly, the same

PDE8A-Raf1 peptide has also been used to target T cell adhesion and migration and was more potent than a PDE8-specific inhibitor in reducing inflammatory signaling (267). The effectiveness of PDE displacement has also been demonstrated *in vivo*, where intraperitoneal injections of a PDE4-HSP20 disruptor significantly attenuated hypertrophy-induced cardiac remodeling (269). Disrupting PDE homodimerization (that is, a PDE monomer binding to itself) may also prove an effective way to target PDE function in a domain-specific manner. Disrupting PDE11A4 homodimerization using a peptide recognizing its GAF-B domain was shown to selectively remove PDE11A4 from membrane-bound complexes but not the cytosol, which may hold utility for improving responsiveness to the mood stabilizer lithium (187) or age-related cognitive decline (83). Conversely, a peptide or mutation that could stabilize PDE11A4 homodimerization might prove useful in treating the deleterious psychological effects of social isolation (197). Targeting homodimerization of PDE2, PDE4, or PDE5 may also relocate the enzymes by virtue of changing susceptibility to regulatory post-translational modifications (6, 270). Indeed, nature appears to have taken advantage of dimerization as a mechanism to regulate PDE trafficking. For example, when PDE10A2 heterodimerizes with PDE10A19, PDE10A2 is prevented from trafficking to the membrane as it normally does under conditions of homodimerization (271). Such complex-specific targeting of PDE function may be required to achieve efficacy in absence of unwanted side effects, particularly in cases where multiple subfamily isoforms orchestrate a variety of physiologic responses by virtue of different protein-protein interactions (e.g., targeting various PDE3 isoforms for cardiovascular disease (272)).

### ***Targeting post-translational modifications***

As post-translational modifications (PTM) directly regulate PDE activity and location, PTMs could be considered a point of therapeutic control (Figure 5). As described above, PKA or PKG phosphorylation of PDE3 (217, 218), PDE4 (217, 219), PDE5 (220), and PDE8 (221) will stimulate catalytic activity. Phosphorylation

can also influence PDE cellular location by virtue of preventing other PTMs that promote membrane association (e.g., Palmitoylation) or changing protein-protein binding interactions. A great example to illustrate these principals is PDE10A2. PDE10A2 is palmitoylated in its N-terminal region, which directs membrane targeting and trafficking to dendrites (169). If, however, PDE10A2 undergoes isoform-specific phosphorylation by PKA on Thr16 (273), palmitoylation of PDE10A2 is attenuated and the specific membrane localization is lost (169). Interestingly, phosphorylation on the same site also interferes with the scaffolding of PDE10A2 by AKAP150 (274). Hence, although PDE10A catalytic activity is not directly affected by this PTM, cyclic nucleotide levels should increase within this compartment due to the absence of PDE10. Preliminary evidence also suggests that PDE11A4 can similarly be shuttled between membrane and cytosolic compartments by virtue of phosphorylation of N-terminal serines, although this is likely by virtue of altering protein-protein interactions as opposed to a direct insertion into the membrane (275). PKA phosphorylation of PDE4D3 drives an association with the mAKAP signaling complex to evoke rapid signal termination in the muscle compartment (276), which may have therapeutic implications given that polymorphisms in the PDE4D3-mAKAP binding site lead to a higher susceptibility to cardiovascular disease (277). PDE4D enzymes also get phosphorylated by both casein kinase 1 (CK1) and glycogen synthase kinase 3 $\beta$  (GSK3 $\beta$ ) in the catalytic region on a motif known as a “phosphodegron” (278). This action increases the affinity of the PDE for a ubiquitin ligase complex (Cullin 1 containing SCF E3 ligase) which promotes proteosomal degradation of the enzyme (278). Hence PDE phosphorylation not only affects activity, localization, and protein-protein interactions, it also regulates protein turnover.

It has been known for some time that increases in PKA activity promote the proteosomal degradation of short-lived proteins, an action that can be enhanced by PDE inhibitors (c.f., (279)). However, we are just starting to understand that the stability of PDEs can themselves be influenced by the ubiquitin-proteasome system (Figure 5). Ubiquitin conjugation is known to target proteins for degradation by the proteasome and

specificity is introduced at the level of E3 ligase-substrate interaction. We now know of multiple instances where PDEs interact definitively with one of the over 600 E3 ligase types to dramatically shorten PDE half-life and this could be a new point at which to direct innovative therapeutics. As mentioned above, PDE4Ds can be degraded by virtue of an SCF E3 (278), whereas PDE4B levels can be down-regulated by a different E3, Smurf2, to promote anti-fibrotic signaling in the liver (280). PDE4D5 can also be targeted for ubiquitin modification by the RING type MDM2 E3 ligase; however, this beta-adrenergic driven ubiquitination of PDE4D does not signal a degradation of the enzyme. Instead, it shifts PDE4 from binding RACK1 to binding  $\beta$ -arrestin (281). PDE4s are similarly regulated by the ubiquitin-like protein SUMO (small ubiquitin-like modifier) (5). SUMO-conjugation tends to alter the location, activity or protein-protein interactions of a protein rather than tagging for destruction via the ubiquitin-proteasome system (282). Unlike ubiquitination, sites of SUMOylation can be predicted in the amino acid sequence of putative substrates as conjugation usually occurs on a lysine residue within the consensus h-K-X-D/E (where h is a bulky hydrophobic and X is any residue) (282). PDE4s from subfamilies A and D contain the consensus motif, whereas subfamilies B and C do not. This adds an extra layer of sub-family-specific regulation as SUMOylation serves both to protect against the inhibitory phosphorylation by ERK MAPkinases (283) and further enhances activity of the PKA phosphorylated longform PDE4 by locking it in the “open” non-UCR inhibited conformation (5).

Two additional PTMs that trigger PDEs for destruction include S-nitrosylation and proline hydroxylation (Figure 5). PDE5 can be S-nitrosylated by NO on Cys220 (284), which targets the enzyme to the proteasome and reduces PDE activity. Under conditions of reduced NO bioavailability, as in heart disease, PDE5 is upregulated due to a loss of this S-nitrosylation-induced degradation (284). Proline hydroxylation has also been identified as a modification that can tag substrates for recognition by E3 ligase complexes (285). In the heart, proline hydroxylases domain-containing proteins (PHDs) hydroxylate surface-associated prolines on

PDE4D enzymes, triggering their degradation (286). In this way, direct binding of PHDs to PDE4s increase cAMP without affecting adenylate cyclase activity.

## Challenges

Although this is clearly an exciting time in the PDE field, there is much work that remains to be done. For therapeutics to be efficiently developed, we need to have a more thorough understanding of exactly where cyclic nucleotide signaling is disrupted in a given disease—in which tissue, cell types, and subcellular compartments. We then need to target a PDE in a defined locale, with the understanding that subcellular compartmentalization of a given PDE may vary depending on species, age, tissue type, or disease status (10-19). This consideration is equally important in the evaluation of potential efficacy and potential side effects. To maximize potential efficacy while minimizing potential side effects, one would target a PDE that is enriched, if not exclusively expressed, in the tissue of interest and that controls the same pool of cyclic nucleotides that is altered by the disease. At the same time, efforts to unravel the intramolecular signals responsible for trafficking each PDE also need to continue to inform more sophisticated therapeutic approaches that can preferentially target a given PDE in a given subcellular compartment. Along these same lines, we need to grow our understanding of how to stimulate PDE activity and how to target the PDE catalytic activity of dual-specificity PDEs in a functionally-selective manner (i.e., target only its cAMP- or cGMP-hydrolytic activity, see (216) for further discussion). Perhaps by increasing the specificity of our approach, we can retain efficacy while mitigating the numerous side effects described above that have plagued PDE inhibitors to date.

An additional challenge is gain a better understanding of which physiological/disease processes are governed by PDE regulation of canonical versus non-canonical cyclic nucleotides. Research into the role of non-canonical cyclic nucleotides is rapidly evolving as new techniques and reagents facilitate functional studies (9). Cyclic cytidine monophosphate (cCMP) and cyclic uridine monophosphate (cUMP) are

synthesized by soluble guanylate and soluble adenylate cyclases in mammalian systems, although an as-yet-to-be identified generator likely accounts for the majority of production given the dissociation between sGC/sAC and cCMP/cUMP expression patterns (9). ExoY, a bacterial nucleotidyl cyclase, is known to generate cUMP in non-mammalian systems (7). Hydrolysis of cCMP is catalyzed by PDE7A whereas cUMP is broken down by PDE3A, PDE3B and PDE9A (7). Functionally both nucleotides have been shown to activate PKA/PKG (287), cyclic nucleotide gated channels (288), and cCMP is described as a partial agonist of EPAC (289). In a disease context, the non-canonical cyclic nucleotides play roles in promoting virulence of *Pseudomonas aeruginosa* infections (290) and triggering apoptosis of cancer cells (291); however much more research is needed to accurately characterize the pathophysiology involving these signaling molecules. Difficult issues facing the field will be defining specific non-canonical cyclic nucleotide signaling systems that are aberrantly regulated in disease, determining the mechanisms by which PDEs might preferentially degrade non-canonical vs. canonical cyclic nucleotides, and visualising the compartmentalisation of non-canonical signalosomes in specific locations within cells and tissues.

Finally, development of PDE-targeted therapeutics faces the same challenges as does all drug discovery—namely the high rate of failure in clinical trials. A recent study suggests that from 2000-2015, only 13.8% of all compounds made it from Phase I to approval (292). When considering success rates for individual indications, we may gain insight into the likelihood that a PDE-targeted therapeutic will achieve success within a given disease area. For example, oncology saw only 3.4% of compounds made it from Phase 1 to approval; whereas, metabolic/endocrinology, cardiovascular, CNS, autoimmune/inflammation, genitourinary, and ophthalmology saw a success rate of 19.6%, 25.5%, 15%, 15.1%, 21.6%, and 32.6%, respectively (292). This certainly paints a grim picture for pursuing any type of therapeutic in the context of cancer; however, this failure rate also underscores the desperate need to develop novel therapeutic options. It is then important to note that success rates were doubled for cancer compounds when patient selection biomarkers were employed

in the trials; the success rate for cardiovascular compounds similarly benefited (292). Importantly, expression or activity of PDEs themselves may prove viable biomarkers in this context (Box 2).

## Outlook

Although the challenge of targeting localized pools of PDEs for purposes of correcting pockets of aberrant cyclic nucleotide signaling has proven difficult in the past, there are indications that innovative approaches and technological advances are making headway (see Table 4 for recent patent activity that includes PDE activators, biomarkers, and viral approaches). For example, agents that show remarkable selectivity for sub-families of PDE4 are showing promising results in mouse models of learning and memory and translation to human disease would be a game changing advance (135). Additionally, novel delivery systems are being developed that can transport PDE inhibitors to precise tissues or cell types, thereby abrogating complications associated with systemic distribution (e.g., (293, 294)). In the future, novel delivery systems such as these could be employed to deliver agents that specifically disrupt the anchoring of single isoforms. Another approach with potential is the intelligent design of a new generation of PDE inhibitors that preferentially accumulate in or segregate from certain tissues or organs. The mild side-effect profile of Apremilast is largely due to its inability to penetrate the brain and engineering of similar restricted distribution profiles may unlock the latent abilities of other PDE inhibitors. Gene therapy that seeks to abrogate or enhance activity of single PDE isoforms in a cell type-specific manner may provide a way to combat disease or fight complications associated with ageing. There is also the possibility that an improved therapeutic window might be achieved by combining sub-optimal doses of PDEi's with ineffective doses of downstream-target activators, which would result in an effective combined dose only in tissues and subcellular compartments where both molecules were present (e.g., (295)). Indeed, PKA, PKG, and Epacs have been implicated as therapeutic targets in their own right for a number of indications for which PDEi's are being pursued, including diseases of the cardiovascular,



immune, and nervous systems as well as cancer (e.g., (129, 130, 296-300)). Further, several studies in a variety of tissues have attributed the beneficial effects of PDEi's to the activation of PKA, PKG and/or Epac (e.g., (135, 301-303)). As we learn more about the functional role and molecular interactions of each PDE splice variant, and how the function and/or localization of an individual variant may be altered in a given disease, it will become clearer how we can successfully target PDEs in a specific fashion to achieve efficacy while avoiding side effects. Only with this detailed level of knowledge will we be able to realize the full potential of PDEs as therapeutic targets.

## BOXES

### Box 1. Physiological roles of PDEs.

Because PDEs are ubiquitously distributed and are the only enzymes to degrade 3',5'-cyclic nucleotides, this superfamily of enzymes plays a role in numerous biological processes in health and disease. That said, the biological roles played by a given PDE isoform are unique due to its unique expression pattern at the level of tissue/organ, cell-type and subcellular compartment (Table S1).

Most PDEs families are expressed in the **nervous system** where they regulate neurodevelopment and apoptosis, neuronal excitability, synaptic transmission and neuroplasticity (83, 109). Every brain region expresses more than one PDE, but no two PDEs exhibit the exact same regional distribution (83). For instance, PDE11A is the only PDE with brain expression restricted to the hippocampus. While PDE11A regulates how well an individual responds to the mood stabilizer lithium, it does not regulate basal anxiety- and depression-related behaviors (187). In contrast, PDE4D is expressed in most brain regions and does appear to regulate basal depression-related behaviors (e.g., (304)). PDE1B, PDE2A, PDE7B, PDE8B and PDE10A are enriched in the striatum relative to other brain regions (83), and each has been implicated in regulating basic motor function; whereas, PDE5A and PDE9A have not (for review, see (83, 305)). In the **retina**, PDE6 function is central in mediating activation of the light response in rod and cones photoreceptors, and PDE6 mutations cause photoreceptor degeneration in retinitis pigmentosa (237, 306).

In the **cardiovascular system**, PDE2, PDE3 and PDE4 isoforms control different subcellular pools of cyclic nucleotides to regulate important cardiac functions from myocardial contraction/relaxation to chronic cell growth and survival, and disruption of this PDE signaling has been associated with disease (for review, see (1)). For example, heart failure has been associated with reduced levels of PDE3A and PDE4D, which results in myocyte apoptosis and cardiac arrhythmias, respectively (235, 249).

Many **cancers** have been associated with reduced levels of cAMP and/or cGMP secondary to an elevation in PDE activity. For example, chronic lymphocytic leukemia cells exhibit increased PDE7B expression; leukemia, colon cancer, and glioma cells overexpress one or more isoforms of PDE4; and colon cancer cells and adenocarcinomas exhibit elevated PDE5 activity (23, 307, 308).

**Inflammation** of numerous tissue types can be increased by a drop in cAMP levels that is caused by an increase in cAMP-PDE activity. For example, activity of PDE4—the predominant cAMP-hydrolyzing enzyme in the immune system—is elevated in the context of various inflammatory diseases, including psoriasis, COPD and asthma (309, 310).

PDEs are also implicated in **reproductive health**. Several isoforms are present in granulosa cells as well as oocytes in preovulatory follicles of mammalian ovary regulating the meiotic cell cycle (311). Furthermore, many PDEs are expressed in cells of the spermatogenic pathway where they may regulate sperm motility (312, 313), and PDE5 is expressed in the contractile tissues of the male excurrent tract and accessory where its increased activity contributes to erectile dysfunction (e.g., (34)).

## **Box 2. PDEs as disease biomarkers.**

PDEs are also being explored as both diagnostic and patient-selection biomarkers. This super family of enzymes, like other genes, can be genotyped from blood samples to assess risk for specific diseases (e.g., high suicide risk, (314); PDE8A, NCT02855918). PDE mRNA and protein expression can be measured *ex vivo* in an isoform-specific manner from biopsied samples (e.g, excised tumors). Further, imaging compounds can be engineered with relative ease to selectively target a given PDE family/sub-family *in vivo*. Thus, PDEs can be explored as biomarkers in diseases where tissue is readily biopsied (e.g., cancers) and diseases where tissue is not (e.g., diseases of the brain).


*Ex vivo biomarkers.* Measurement of PDE4D7 is seen as a valuable biomarker for both pre-surgical and post-surgical risk stratification to optimize treatment decisions (314, 315) (Table 4). Studies in patient samples showed that PDE4D7 expression is initially upregulated with the development of primary tumours but then is downregulated when the disease progresses to an androgen-independent state (e.g., in castration-resistant tumours) (316, 317), consistent with *in vitro* reports using prostate cancer cells (204). The analysis of PDE4D7 expression in biopsy/surgery samples has been applied to develop InformMDx™ (licensed by MDxHealth from Philips), a tissue-based prognostic prostate cancer biomarker test to stratify patients by risk of disease progression and secondary tumors and, thus, inform post-biopsy/post-surgery treatment decisions (<https://mdxhealth.com/press-release/mdxhealth-launch-agreement-philips-prognostic-prostate-cancer-biomarker>; accessed 12/03/18).

PDE3A may also represent a useful cancer biomarker as it is greatly expressed in certain cancer cell types such as squamous carcinoma cell lines or gastrointestinal stromal tumour (GIST) cells (318, 319). Furthermore, cancer cell lines with the highest PDE3A expression proved the most susceptible to the chemotherapeutic effects of PDE3i's (320). Thus, PDE3A expression could qualify as a biomarker for patient selection which improves patient care by reducing exposure to ineffective drugs and accelerates clinical development of novel therapeutic agents by testing them in targeted populations.

*In vivo biomarkers.* Altered cyclic nucleotide signaling has been implicated in a variety of age-related diseases of the brain (c.f., (248)). PDE10A is widely reported as downregulated in both the striatum and cortex of patients with Huntington's disease, with the extent of PDE10A loss corresponding to the genetic burden associated with the disease (41, 80, 321, 322). A loss of PDE10A expression has also been observed in the basal ganglia of patients with Parkinson's disease (323).


Importantly, highly-specific PDE10A positron emission tomography (PET) tracers shows that PDE10A expression in HD patients continues to decline over years (41). Thus, PET imaging of PDE10A could be a useful biomarker for assessing the initial diagnosis and subsequent progression of these neurodegenerative diseases (324). PET ligands also exist for PDEs 2, 4, 5, and 7 (325).

## FIGURE LEGENDS




**Figure 1.** 11 families of PDEs degrade cyclic nucleotides. Both of the canonical cyclic nucleotide signaling pathways (cAMP and cGMP) are composed of numerous molecules responsible for the synthesis, execution, and breakdown of their signals. cAMP is synthesized by transmembrane adenylyl cyclases (ACs) that are activated by G<sub>s</sub> and inhibited by G<sub>i</sub> (326) as well as soluble ACs that are activated by bicarbonate and calcium (327). cGMP is synthesized by particulate guanylyl cyclases (pGCs) that are activated by natriuretic peptides and soluble guanylyl cyclases (sGCs) that are activated by nitric oxide (NO) (328). Both cAMP and cGMP activate cyclic nucleotide gated channels and allosterically modulate activity of select PDEs (6). In

contrast, only cGMP stimulates protein kinase G (PKG); whereas, cAMP activates protein kinase A (PKA), exchange protein activated by cAMP (Epac) and popeye domain-containing proteins (POPDC)(329). Signaling through either the cAMP or cGMP pathways ultimately leads to phosphorylation of a myriad of downstream targets, including the transcription factor cAMP response element binding protein (CREB). In addition to cAMP and cGMP, several PDEs also hydrolyze the non-canonical cyclic nucleotides (not included) cUMP (PDE3A, PDE3B, PDE9A), cCMP (PDE7A), and c-di-GMP<sub>a</sub> (bacterial PDEs), albeit with much lower affinity (7, 8).



**Figure 2.** The 21 phosphodiesterase (PDE) genes are grouped into families (name and substrate specificity listed to right of each illustration) based on the homology of their C-terminal catalytic domain (represented as a semi-ellipse). Due to alternate promoters and splicing events, each PDE family has multiple isoforms that differ in terms of the length and complexity of their N-terminal regulatory domains (depicted with different


shapes), which are thought to regulate subcellular trafficking, substrate affinity, and catalytic activity. The relative size and domain distances were drawn based on estimations from the Pfam/uniprot database, with the exception of the REC domain of PDE8 (estimated from (330)) and the second CaM domain of PDE1 (estimated from (313)). Illustrations represent the longest isoform for gene A of each PDE family. CaM, calmodulin-binding domain; GAF, cGMP-binding PDEs *Anabaena* adenylyl cyclases and *E. coli* FhlA; TM, transmembrane domain of PDE3; UCR, upstream conserved region; REC, signal receiver domain; PAS, Per-Arnt-Sim domain.



**Figure 3. Mechanisms that activate phosphodiesterase (PDE) catalytic activity.** **A)** Calcium-calmodulin (CaM) binding to the CaM domains of PDE1 relieves N-terminal auto-inhibition of the catalytic site, thereby promoting enzymatic activity (331). **B)** Cyclic nucleotides binding to GAF domains of dimeric PDEs (shown here: cGMP binding the GAF-B domain of PDE2) are thought to promote catalytic activity by inducing an outward rotation of the catalytic domains and, thus, enabling access to substrates (332). **C)** Phosphorylation by PKA or PKG activates several PDEs (6). In the case of PDE4D, phosphorylation of the UCR1 domain by PKA causes UCR1 to bind its own UCR2 domain instead of the catalytic site of the other monomer, thereby locking the enzyme in an active state. **D)** PDE activity can also be modulated by protein-protein binding interactions. One such well-characterized example involves membrane-bound PDE6, where the rhodopsin-activated G-




protein  $\alpha$ -subunit transducin displaces the inhibitory PDE6 $\gamma$  C-termini from the catalytic sites on PDE6 $\alpha\beta$ , thus, promoting cGMP hydrolysis (333).



**Figure 4. Methods for targeting phosphodiesterase signaling with increasing specificity.** Given the vast diversity of PDE isoforms, each with unique tissue expression profiles, subcellular compartmentalization, and protein-protein interactions, it is becoming clear that selective targeting of PDE function will be required to achieve efficacy while diminishing undesirable side effects. **Small molecule inhibitors** (e.g., cilomilast) are readily developed with family-specific selectivity (e.g., targeting PDE4 over PDE3); however, isoform

specificity remains a challenge (e.g., cilomilast inhibits PDE4D with only 7-fold selectivity versus PDE4B) (334). Conversely, **gene therapy** (i.e., expressing a recombinant construct to knock down or restore expression of a given PDE isoform) and **dominant negative** approaches (i.e., expressing a catalytically inactive PDE4D5 that displaces the endogenous isoform from its interacting partners) can target isoform subtypes exclusively (e.g., targeting PDE4D5 but not PDE4D3 nor PDE4B). That said, dominant negative approaches would influence signalling within all microdomains regulated by that isoform. The greatest specificity can be achieved with **peptide/small molecule binding disruptors** or mutagenesis approaches (not shown) that are designed to prevent a specific PDE isoform from binding a specific partner, thus, altering signaling only within one specific complex. As shown here, a disruptor peptide that specifically prevents the interaction between PDE4D5 and  $\beta$ -arrestin would lead to the recruitment of EPAC1 to  $\beta$ 2 adrenergic receptors ( $\beta$ AR), but would leave PDE4D5 regulation of heat shock protein 20 (HSP20) and RACK1 complexes intact (249, 335, 336).



**Figure 5. Phosphodiesterase (PDE) regulation by post-translation modification (PTM).** Cyclic nucleotide dynamics can be modulated by the addition of different functional groups to PDEs. **Phosphorylation** is a very common mechanism to control PDE activity as depicted by the action of PKA on PDE4D3. Both enzymatic activity and binding affinity of PDE4D3 for mAKAP are increased by PKA phosphorylation, allowing a faster signal termination in myocytes (276). **Palmitoylation** of PDE10A2 in its N-terminal region translocates the enzyme to the plasma membrane, although its phosphorylation by PKA can prevent the action of the palmitoyl acyltransferase (zDHHC) (169). **Ubiquitination** can influence PDEs function through the control of their stability. For example, the E3 ubiquitin ligase Smurf2 targets PDE4B for degradation which leads to the attenuation of liver fibrosis (280). **S-nitrosylation** can also tag PDEs for destruction. Thus, the covalent

incorporation of nitric oxide (NO) to the GAF-A domain of a PKG-phosphorylated and active PDE5, directs the enzyme to the proteasome (284). **Hydroxylation** of proline residues has emerged as another PTM to stimulate turnover of PDEs. Prolyl hydroxylase domain protein 2 (PHD2) action on PDE4D increases its recognition by E3 ligase complexes in cardiomyocytes (286). Finally, **SUMOylation** can intensify the activity of PDE4A and PDE4D. The SUMO transfer from the E2 conjugase UBC9-E3 enzyme PIASy complex to the PDEs, enhances their activation by PKA phosphorylation and repress their inhibition induced by ERK activity (5).

**Table 1.** Marketed PDE inhibitors

<b>Generic name (Trade name)</b>	<b>Indication</b>	<b>Approved (year)</b>	<b>Side effects</b>
<b>Nonselective</b>			
<b>Theophylline</b>	Asthma and Bronchoconstriction	FDA (1979), Canada (1965), approved worldwide	Nausea, vomiting, diarrhea, headache, irritability, flushing and palpitations.
<b>Aminophylline</b>	Asthma and Bronchoconstriction	FDA (1940), Canada (1957), several countries	Stomach pain, diarrhea, headache, irritability, restlessness and insomnia
<b>Oxtriphylline</b>	Asthma and Bronchoconstriction	FDA (1981), Canada (1975), Europe	Stomach pain, nausea, vomiting, diarrhea, headache, irritability, restlessness, insomnia flushing, and increased urination
<b>Dyphylline</b>	Asthma and Bronchoconstriction	FDA (1951), Canada (1962), Europe, Japan	Stomach pain, nausea, vomiting, diarrhea, headache, irritability, restlessness, insomnia flushing, and increased urination
<b>Pentoxifylline</b>	Intermittent Claudication	FDA (1984), Canada (1984), approved worldwide	Belching, bloating, upset stomach, nausea, vomiting, indigestion, dizziness, and flushing, headache
<b>PDE1</b>			
<b>Vinpocetine</b>	Cerebral vascular disorders and memory impairment	Europe, Mexico and Asia. USA as an over-the-counter dietary supplement	Flushing, rashes, and minor gastrointestinal disturbances

<b>PDE3</b>			
<b>Cilostazol</b>	Intermittent Claudication	FDA (1998), EMA (2000), Japan (1988), Asia and South America	Headache, palpitations, diarrhea, dizziness, nasal irritation and pharyngitis
<b>Milrinone</b>	Congestive Heart Failure	FDA (1987), EMA (2016), Canada (1995), Japan, China	Ventricular/supraventricular arrhythmias, hypotension and headache
<b>Amrinone</b>	Congestive heart failure	FDA (1984), Canada (1984), China	Thrombocytopenia, nausea, diarrhea, hepatotoxicity, arrhythmias and fever
<b>Enoximone</b>	Congestive heart failure	Some countries in Europe	Headache, diarrhoea, insomnia, hypotension, vomiting, nausea, tachycardia and arrhythmias
<b>Olprinone</b>	Heart failure	Japan (1996)	Cardiac dysrhythmias and thrombocytopenia
<b>Pimobendan</b>	Heart failure	Japan (1994)	Headache, palpitation, nausea and ventricular arrhythmias
<b>Anagrelide</b>	Thrombocythemia	FDA (1997), EMA (2004), Canada (1998), several countries	Headache, diarrhea, unusual weakness/fatigue, hair loss, nausea and dizziness
<b>PDE4</b>			
<b>Roflumilast</b>	Chronic Obstructive Pulmonary Disease (COPD)	FDA (2011), EMA (2010), Canada (2010), Russian Federation, South Korea	Diarrhea, weight loss, nausea, headache, insomnia, decreased appetite
<b>Apremilast</b>	Psoriasis and psoriatic disorders	FDA (2014), EMA (2014), Canada (2014)	Diarrhea and vomiting, weight loss, mood changes
<b>Crisaborole</b>	Moderate Atopic dermatitis (patients >2 years old)	FDA (2016), Canada (2018)	Hypersensitivity reactions of the skin
<b>Drotaverine</b>	Functional bowel disorders and alleviating pain caused by smooth muscle spasm	Asia and Eastern European countries	Fainting, nausea, vomiting and dry mouth
<b>Ibudilast</b> (also inhibits PDE3, 10, 11)	Asthma and dizziness related to cerebral infarction	Japan (1989), South Korea (2002)	Nausea, diarrhea and abdominal pain, depression, rash and fatigue
	Allergic conjunctivitis	Japan (2000)	

<b>Tofisopam</b> (also inhibits PDE10, 3, 2A)	Anxiety	Japan (1985), several European countries (Hungary, 1974), Jamaica, Thailand and Argentina (1982)	Nausea, stomach discomfort, dry mouth, skin rash, insomnia, vomiting and drowsiness
<b>PDE5</b>			
<b>Sildenafil</b>	Erectile Dysfunction	FDA (1998), EMA (1998), Canada (1998), approved worldwide	Headache, flushing, dyspepsia, nasal congestion, and impaired vision, including photophobia and blurred vision
	Pulmonary arterial hypertension (PAH)	FDA (2014), EMA (2005) Canada (2006)	
<b>Vardenafil</b>	Erectile Dysfunction	FDA (2003), EMA (2003), Canada (2004), several countries	Headache, flushing, and dyspepsia
<b>Tadalafil</b>	Erectile Dysfunction, benign prostatic hyperplasia	FDA (2003), EMA (2002), Canada (2003), approved worldwide	Headache, dyspepsia, back pain and myalgia
	PAH	FDA (2009), EMA (2008), Canada (2010)	
<b>Avanafil</b>	Erectile Dysfunction	FDA (2012), EMA (2013)	Headache, flushing, and nasopharyngitis
<b>Udenafil</b>	Erectile dysfunction and hypertension	South Korea (2005), Russian federation (2008), Thailand, Colombia, Malaysia and the Philippines	Headache, dizziness, reddening, nasal congestion, dyspepsia and impaired vision
<b>Mirodenafil</b>	Erectile Dysfunction	South Korea (2007)	Flushing, headache, nasal congestion, eye redness, nausea and dizziness
<b>Dipyridamole</b>	Postoperative thromboembolism	FDA (1961), Canada (1962), several European countries, Japan, Taiwan, Russian Federation	Headache, dizziness, nausea, diarrhea, muscle pain and vomiting
<b>PDE10A</b>			
<b>Papaverine</b>	Visceral spasm and vasospasm and erectile Dysfunction	FDA, Canada (1951), approved worldwide	Ventricular tachycardia, diarrhea, somnolence, vertigo, flushing and headache

**Table 2.** Clinical trials involving PDEs inhibitors that failed to reach the market for the described indication

Compound / Manufacturer	Indication	Phase / Status	Clinical trial ID	Failure cause
<b>PDE2</b>				
PF-05180999 / Pfizer	Healthy volunteers (schizophrenia)	Phase I / Completed 2011	NCT01429740	Safety concerns
	Healthy volunteers	Phase I / Completed 2012	NCT01530529	
	Migraine	Phase I / Terminated early 2014	NCT01981499	
	Migraine	Phase I / Withdrawn prior to enrollment 2014	NCT01981486	
<b>PDE2/5</b>				
Exisulind (Aptosyn) / Cell Pathways	Breast cancer neoplasms and metastases	Phase I/II / Completed 2003	NCT00037609	Safety and efficacy deficiencies
	Breast cancer	Phase II / Completed 2008	NCT00039520	
	Non-small cell lung cancer	Phase I/II/III / Completed 2003-2007	NCT00072618, NCT00085826, NCT00041314	
	Small cell lung cancer	Phase II / Completed 2008	NCT00041054	
	Prostate cancer and prostatic neoplasms	Phase II / Completed 2006-2011	NCT00078910, NCT00166478, NCT00166426, NCT00052845, NCT00283803	
	Melanoma	Phase II / Completed 2011	NCT00841204	
<b>PDE3</b>				
Cilastozol (Pletal) / Otsuka Pharmaceuticals	Type 2 diabetes polyneuropathy	Phase IV / Completed 2009	NCT01076478 (61)	Lack of efficacy
<b>PDE4</b>				
ASP9831 / Astellas	Non-alcoholic	Phase II / Completed	NCT00668070	Lack of



Pharma	steatohepatitis (NASH)	2010	(63)	efficacy
<b>PDE5</b>				
Sildenafil (Viagra or Revatio) or Tadalafil (Cialis or Adcirca) / Pfizer and Eli Lilly, respectively	Duchenne Muscular Dystrophy (DMD)	Early Phase I/Phase I / Completed 2013	NCT01359670, NCT01580501 (70)	Lack of efficacy
Sildenafil (Viagra or Revatio) / Pfizer	DMD and Becker Muscular Dystrophy (BMD)	Phase II / Terminated early 2014	NCT01168908	Safety concerns
	Impaired glucose tolerance	Phase IV / Terminated early 2016	NCT01409993	
Tadalafil (Cialis or Adcirca) / Eli Lilly	BMD	Phase IV / Completed 2012	NCT01070511 (71)	Lack of efficacy
	DMD	Phase III / Terminated early 2017	NCT01865084	
Vardenafil (Levitra) / Bayer/GSK	Type 2 diabetes	Phase II / Completed 2014	NCT02219646 (163)	Lack of efficacy
<b>PDE9</b>				
BI 409306 / Boehringer Ingelheim	AD	Phase II / Completed 2017	NCT02240693, NCT02337907 (76)	Lack of efficacy
PF-04447943 / Pfizer	AD	Phase II / Completed 2010	NCT00930059 (72)	Lack of efficacy
<b>PDE10</b>				
PF-02545920 (a.k.a. MP-10) / Pfizer	Schizophrenia	Phase I / Completed 2007	NCT00463372	Lack of efficacy
	Schizophrenia	Phase II / Terminated early 2008	NCT00570063	
	Healthy volunteers (glucose metabolism)	Phase I / Completed 2011	NCT01103726	
	Schizophrenia	Phase II / Completed 2011	NCT01175135 (79)	
	Schizophrenia	Phase I / Terminated early 2012	NCT01244880	
	Schizophrenia	Phase I / Completed 2013	NCT01829048	



	Schizophrenia	Phase II / Terminated early 2014	NCT01939548	
	Healthy male volunteers (PET imaging)	Phase I / Completed 2014	NCT01918202	
	Huntington's Disease	Phase II / Completed 2015-2016	NCT01806896, NCT02197130	
	Huntington's Disease	Phase II / Terminated early 2017	NCT02342548	
OMS643762 / Omeros	Schizophrenia	Phase II / Completed 2014	NCT01952132	Safety concerns / Lack of efficacy MP-10
	Huntington's Disease	Phase II / Terminated early 2016	NCT02074410	
PBF-999 / Palobiofarma	Huntington's Disease	Phase I / Completed 2015	NCT02208934	Change in therapeutic indication (cancer)
	Huntington's Disease	Phase I / Terminated early 2016	NCT02907294	

Reported on Clinicaltrials.gov (accessed 04/30/19). Information is included for all clinical trials involving molecules whose pursuit was terminated after April 2009.

**Table 3.** Selected clinical trials involving PDEis pursued for new indications

Compound / Manufacturer	Indication	Phase / Status	Clinical trial ID
<b>PDE3, 4, 10, 11</b>			
Ibutilast (AV-411, MN-166) / MediciNova	Opioid withdrawal	Phase II / Completed 2012-2017	NCT00723177, NCT01740414
	Methamphetamine-dependence	Phase I / Completed 2013	NCT01217970 (91, 92)
	Alcohol use disorder	Phase I / Completed 2015	NCT02025998 (94)
	Alcohol use disorder	Phase II / Recruiting	NCT03489850

	Opioid abuse	Phase II / Completed 2017	NCT01740414 (93, 337)
	Amyotrophic lateral sclerosis (ALS) (Biomarker study)	Phase II / Active, not recruiting	NCT02714036
<b>PDE1</b>			
ITI-214 / Intracellular Therapies	Schizophrenia	Phase I / Terminated early 2014	NCT01900522
	Parkinson's Disease	Phase I/II / Completed 2018	NCT03257046
	Healthy volunteers (CNS engagement)	Phase I / Recruiting	NCT03489772
	Systolic heart failure	Phase I/II / Recruiting	NCT03387215
Vinpocetine / Rxmidas Pharmaceuticals/ Nootrobox	Ischemic stroke	Phase II/III / Completed 2013-2015	NCT01400035, NCT02878772 (338)
	Cognition enhancement	Not Applicable / Completed 2017	NCT02857829
<b>PDE2</b>			
TAK-915 / Takeda	Healthy volunteers (PET imaging, schizophrenia)	Phase I / Completed 2016	NCT02584569
	Healthy volunteers	Phase I / Completed 2016	NCT02461160
<b>PDE3</b>			
Cilostazol (Pletal) / Otsuka Pharmaceuticals	Type 2 diabetic atherosclerosis	Phase IV / Completed 2010-2012	NCT01252056, NCT00823849 (339)
	Chronic tinnitus	Not applicable / Completed 2013	NCT01378650 (108)
	Alzheimer's Disease	Phase IV / Completed 2013	NCT01409564 (340)
	Atherosclerotic events in type 2 diabetes	Phase IV / Unknown	NCT00886574
	Mild Cognitive Impairment	Not applicable / Completed 2015	NCT01872858
	Ischemic events in type 2 diabetic artery obstruction	Phase IV / Recruiting	NCT02983214
	Antiplatelet aggregation in type 2 diabetes	Phase IV / Active, not recruiting	NCT03248401
	Antiplatelet aggregation in	Phase IV / Recruiting	NCT02983214

	type 2 diabetes		
	Antiplatelet aggregation in type 2 diabetes	Phase IV / Unknown	NCT02933788
<b>PDE4</b>			
Apremilast (Otezla) / Celgene Corp.	Vitiligo	Phase II / Active, not recruiting	NCT03036995, NCT03123016
	Lichen Planus of Vulva	Phase II / Not yet recruiting	NCT03656666, NCT03836885
BPN14770 / Tetra Discovery	Alzheimer's Disease	Phase I / Completed 2016-2017	NCT02840279, NCT03030105
	Alzheimer's Disease	Phase II / Not yet recruiting	NCT03817684
	Fragile X Syndrome (FXS)	Phase II / Recruiting	NCT03569631
Crisaborole (Eucrisa) / Pfizer	Morphea	Phase II / Recruiting	NCT03351114
GSK356278/ GlaxoSmithKline	Huntington's Disease	Phase I / Completed 2012	NCT01573819, NCT01602900
Roflumilast (Daxas or Daliresp) / AstraZeneca	Polycystic Ovary Syndrome	Phase IV / Completed 2014	NCT02037672, NCT02187250 (122, 123)
	Cognitive deficits in schizophrenia	Phase II / Completed 2015	NCT02079844 (126)
	Cognition (Dementia)	Phase II / Completed 2013-2015	NCT01433666, 2013-001223-39 (EudraCT) (125, 127, 341)
	Insulin and Blood Sugar Levels in Prediabetic Overweight and Obese Individuals	Phase I/II / Completed 2017	NCT01862029 (342)
HT-0712 / Dart Neuroscience	Age-associated memory impairment (AAMI)	Phase II / Completed 2015	NCT02013310
N/A	McCune-Albright Syndrome (PET imaging)	Phase I/II / Recruiting	NCT02743377
TAK-648 / Takeda	Type 2 diabetes	Phase I / Completed 2015	NCT02480439, NCT02684396, NCT02430870
Zembrin / ND	Aged Individuals	Phase I / Completed 2012	NCT01805518 (52)
<b>PDE5</b>			

ND	Contrast Media-induced Nephropathy (CMN)	Not Applicable / Unknown	NCT01564303
ND	Diabetic nephropathy	Not Applicable / Unknown	NCT01566006
Sildenafil (Viagra or Revatio) / Pfizer	Diabetic cardiomyopathy (type 2 diabetes)	Phase IV / Completed 2009	NCT00692237 (159-162)
	Metabolic syndrome (Skeletal muscle insulin signaling)	Phase IV / Completed 2016	NCT02129725
	Urolithiasis/urinary stones	Phase IV / Active, not recruiting	NCT02519153
	Migraine aura	Early Phase I / Recruiting	NCT02795351
	Solid tumors	Phase I / Active, not recruiting	NCT02466802 (165)
	mTBI or concussion	Phase I / Recruiting	NCT03417492, NCT02990078
Sildenafil cream (SST-6007) / Strategic science and technologies/Dare	Sexual arousal disorder	Phase II / Completed 2017	NCT02570282
Tadalafil (Cialis or Adcirca) / Eli Lilly	Type 2 Diabetes (Postprandial Hyperglycemia)	Phase I / Terminated early 2011	NCT01238224
	Head and neck squamous cell carcinoma	Phase II / Completed 2012-2016	NCT00894413 (167)
	Head and neck squamous cell carcinoma	Phase II / Active, not recruiting	NCT01697800
	Obesity	Phase IV / Completed 2015	NCT02554045 (158)
	Insulin secretion/sensitivity in obesity	Phase IV / Completed 2015	NCT02595684 (343)
	Aortic stenosis (AS) left ventricular remodeling/hypertrophy	Phase IV / Terminated early 2017	NCT01275339
	Multiple myeloma (MM)	Phase II / Terminated early 2017	NCT01374217
	Insulin Resistance in Type 2 Diabetes	Phase II / Recruiting	NCT02601989
	Diabetic cardiomyopathy (DC)	Phase IV / Recruiting	NCT01803828
	Endocrine cardiomyopathy	Phase II / Recruiting	NCT02611258 (344)

	in Cushing Syndrome (CS)		
	Access sheath deployment (Nephrolithiasis/kidney stones)	Phase IV / Enrolling 2019	NCT03229889
	Lower urinary tract symptoms (prostatic hyperplasia)	Phase IV / Recruiting	NCT02252367
	Obesity-related cardiometabolic dysfunction	Phase II / Recruiting	NCT02819440
	Anti-tumor Mucin 1 vaccine efficacy in head and neck squamous cell carcinoma (HNSCC)	Phase I/II / Recruiting	NCT02544880
	Small Vessel Disease	Phase II / Active, not recruiting	NCT02450253 (345)
<b>PDE9</b>			
PF-04447943 / Pfizer	Stable sickle cell disease	Phase I / Completed 2016	NCT02114203 (346)
BI 409306 / Boehringer Ingelheim	Healthy volunteers	Phase I / Completed 2011-2018	NCT01343706, NCT01493570, NCT01505894, NCT01611311, NCT01841112, NCT02597998, NCT03505151, NCT02222168, NCT02438683 (74, 347, 348)
	Alzheimer's disease, schizophrenia	Phase I / Completed 2017	NCT02392468
	Schizophrenia	Phase I / Completed 2013-2016	NCT01892384, NCT02281773 (73, 75)
	Schizophrenia or attenuated psychosis syndrome	Phase II / Recruiting	NCT03351244, NCT03230097
	Drug-drug interactions	Phase I / Completed 2016-2017	NCT03151499, NCT03193307, NCT02853136, NCT02635750, NCT02248259
<b>PDE10</b>			

[18F]MNI-659	Huntington's Disease (PET imaging)	Early Phase I / Completed 2016/2017	NCT02061722, NCT02956148, 2012-003808-13 (EudraCT) (349)
PBF-999 / Palobiofarma	Cancer	Phase I / Recruiting	NCT03786484
EVP-6308 (now FRM-6308) / En Vivo Pharmaceuticals (now Forum Pharmaceuticals)	Schizophrenia	Phase I / Completed 2014	NCT02001389, NCT02037074
RO5545965 / Hoffmann-La Roche	Schizophrenia	Phase I / Completed 2013-2017	NCT01923025, NCT01711801, NCT01864226, NCT02019329, NCT02824055
TAK-063 / Takeda	Schizophrenia	Phase I / Completed 2014	NCT02370602, NCT01892189, NCT01879722 (177)
	Schizophrenia	Phase II / Completed 2016	NCT02477020 (350)

Reported on Clinicaltrials.gov (accessed 04/30/19) with an end date after April 2009  
PK/PD, Pharmacokinetics and Pharmacodynamics; ND, not described

**Table 4.** Selected recent patents involving PDEs

Patent #	Subject	Assignee	Author	Priority Date	Publication Date
CN108904493 A	PDE4 inhibitor and purpose for preparing novel anti-inflammatory drugs	Hu Y	Hu Y	12/08/2018	30/11/2018
WO201816714 2	Treatment of idiopathic pulmonary fibrosis [with a PDE4 inhibitor]	Takeda GMBH	Hanauer G, Nikam S, Hazama M	16/03/2017	20/09/2018
CN107163052 A	Immunodetection method for various PDE5 inhibitor drugs	Univ South China Agricult	Shen Y, Hua Y, Xu Z, Yang J, Wang H, Sun Y, Lei H	18/04/2017	15/09/2017
CN107412214 A	Application of PDE4 Inhibitor	Guangzhou Lanssonpharm	Xu L	31/07/2017	01/12/2017

	[FCPR16 for the treatment of PD]	Jianzhi Tech Co Ltd			
US2019046528	Method of preventing hair loss or promoting hair growth by using PDE3 inhibitor	Seoul Nat Univ Hospital	Kwon O, Choi HI, Jo SJ, Kim KH	08/08/2017	14/02/2019
JP2019047763 A	Rhodopsin PDE [as an optogenetic tool for light control of intracellular cyclic nucleotides]	Nagoya Institute Of Technology	Kandori H, Tsunoda SP, Yoshida K	12/09/2017	28/03/2019
US2018369188	Application of PDE4 inhibitor ZL-N-91 in preparation of medications for lung cancer proliferation and metastasis	Guangzhou Sinogen Biomedical Tech Ltd	Zhao AZ, Gong S, Lin Y, Li F, Li X	05/02/2016	27/12/2018
CN107287239	Gene therapy vector and medicine for retinal pigment degeneration [adenovirus encoding PDE6B]	Shenyang Fuming Biological Tech Co Ltd	Pang J	11/04/2016	24/10/2017
CN107312824	Applications of PDE3A in determination of tumor treatment effect of Anagrelide	Shanghai Inst Materia Medica Cas	Yu Q, Liu J	26/04/2016	03/11/2017
CA2975049	PDE inhibitors to repair brain and/or retinal injury in human newborns	Wintermark P	Wintermark P	10/08/2016	10/02/2018
AU2017317575	Treatment of nonalcoholic fatty liver disease [with PDE4 inhibitors]	Takeda GMBH	Hanauer G, Nagabukuro H, Amano Y	26/08/2016	28/03/2019
AU2017330067	T cells with increased immunosuppression resistance [expressing PDEs for the treatment of cancer]	Adaptimmune Ltd	Laugel B, Skibbe K	23/09/2016	18/04/2019
WO201806070 4	Compounds and their use as PDE4 activators [for the treatment of disorders requiring a reduction of cAMP]	Mironid Ltd	Adam JM, Adams DR	28/09/2016	05/04/2018
CN108135886	PDE4 inhibitor for the treatment of diabetic nephropathy	Takeda GMBH	Hanauer G, Vollert S, Hazama M, Matsuo T	29/07/2015	08/06/2018
US2018221373	Method of treating insomnia [with PDE5 inhibitors]	Rosenberg LI	Rosenberg LI	16/09/2015	09/08/2018

WO201707029 3	PDE9 inhibitor and levodopa therapy [for treating PD or Parkinsonism]	Ironwood Pharmaceuticals Inc	Leventhal L, Townsend TM	20/10/2015	27/04/2017
WO201607554 3	Treatment of multiple sclerosis with combination of Laquinimod and a PDE4 inhibitor	Teva Pharma, Piryatinsky V, Kaye J	Piryatinsky V, Kaye J	13/11/2014	19/05/2016
AU2014307802	Treatment of cognitive impairment with combination therapy [of a PDE4 inhibitor and an Acetylcholinesterase inhibitor]	Univ Maastricht	Yamada T, Prickaerts J, Van Duinen M, Sambeth A, Blokland A	16/08/2013	10/03/2016
US2017326145	Composition comprising PDE5 inhibitor for inhibiting apoptosis of nerve cells	Aribio Inc, Sk Chemicals Co Ltd	Kim MH, Choung JJ, Ku SK	04/12/2012	16/11/2017
JP2016199574	Novel composition for the treatment of cystic fibrosis [with a PDE4 inhibitor and a prostacyclin]	Scipharm Sarl	Freissmuth M, Gloeckel C, Koenig X, Keuerleber S	07/02/2011	01/12/2016
HUE036489	PDE inhibitors for transvaginal use in the treatment of infertility	Prokrea Bcn S L	Pardina Palleja MC, Vaz-Romero Una MA	23/06/2011	30/07/2018
US2018289632	Treatment of addiction and impulse-control disorders using PDE7 inhibitors	Omeros Corp	Demopoulos G, Gaitanaris G	08/11/2010	11/10/2018
JP2015212262	PDE1 inhibitors for ophthalmic disorders	Intra Cellular Therapies Inc	Davis R, Fienberg AA	25/02/2009	26/11/2015
US2017051291	RNAi-mediated inhibition of PDE4 for treatment of cAMP-related ocular disorders	Arrowhead Pharmaceuticals Inc	Yanni JM, Chatterton JE, Gamache DA, Miller ST	28/12/2005	23/02/2017
US2018185402	Use of PDE3 inhibitors for the reduction of heart size in mammals suffering from heart disease	Boehringer Ingelheim Vetmedica GMBH	Daemmgen J, Joens O, Kleemann R	25/03/2004	05/07/2018

## REFERENCES



1. Maurice DH, Ke H, Ahmad F, Wang Y, Chung J, Manganiello VC. Advances in targeting cyclic nucleotide phosphodiesterases. *Nature reviews Drug discovery*. 2014;13(4):290-314. doi: 10.1038/nrd4228. PubMed PMID: 24687066; PubMed Central PMCID: PMC4155750.
2. Campolo F, Zevini A, Cardarelli S, Monaco L, Barbagallo F, Pellegrini M, Cornacchione M, Di Grazia A, De Arcangelis V, Gianfrilli D, Giorgi M, Lenzi A, Isidori AM, Naro F. Identification of murine phosphodiesterase 5A isoforms and their functional characterization in HL-1 cardiac cell line. *Journal of cellular physiology*. 2018;233(1):325-37. doi: 10.1002/jcp.25880. PubMed PMID: 28247930.
3. Johner A, Kunz S, Linder M, Shakur Y, Seebeck T. Cyclic nucleotide specific phosphodiesterases of *Leishmania major*. *BMC Microbiol*. 2006;6:25. doi: 10.1186/1471-2180-6-25. PubMed PMID: 16522215; PubMed Central PMCID: PMCPMC1431542.
4. Long T, Rojo-Arreola L, Shi D, El-Sakkary N, Jarnagin K, Rock F, Meewan M, Rascon AA, Jr., Lin L, Cunningham KA, Lemieux GA, Podust L, Abagyan R, Ashrafi K, McKerrow JH, Caffrey CR. Phenotypic, chemical and functional characterization of cyclic nucleotide phosphodiesterase 4 (PDE4) as a potential anthelmintic drug target. *PLoS Negl Trop Dis*. 2017;11(7):e0005680. doi: 10.1371/journal.pntd.0005680. PubMed PMID: 28704396; PubMed Central PMCID: PMCPMC5526615.
5. Li X, Vadrevu S, Dunlop A, Day J, Advant N, Troeger J, Klussmann E, Jaffrey E, Hay RT, Adams DR, Houslay MD, Baillie GS. Selective SUMO modification of cAMP-specific phosphodiesterase-4D5 (PDE4D5) regulates the functional consequences of phosphorylation by PKA and ERK. *The Biochemical journal*. 2010;428(1):55-65. doi: 10.1042/BJ20091672. PubMed PMID: 20196770.
6. Francis SH, Blount MA, Corbin JD. Mammalian cyclic nucleotide phosphodiesterases: molecular mechanisms and physiological functions. *Physiological reviews*. 2011;91(2):651-90. doi: 10.1152/physrev.00030.2010. PubMed PMID: 21527734.
7. Schneider EH, Seifert R. Inactivation of Non-canonical Cyclic Nucleotides: Hydrolysis and Transport. *Handbook of experimental pharmacology*. 2017;238:169-205. doi: 10.1007/164\_2016\_5004. PubMed PMID: 28204955.
8. Herbst S, Lorkowski M, Sarenko O, Nguyen TKL, Jaenicke T, Hengge R. Transmembrane redox control and proteolysis of PdeC, a novel type of c-di-GMP phosphodiesterase. *The EMBO journal*. 2018;37(8). doi: 10.15252/embj.201797825. PubMed PMID: 29514851; PubMed Central PMCID: PMC5897775.
9. Seifert R. cCMP and cUMP Across the Tree of Life: From cCMP and cUMP Generators to cCMP- and cUMP-Regulated Cell Functions. *Handbook of experimental pharmacology*. 2017;238:3-23. doi: 10.1007/164\_2016\_5005. PubMed PMID: 28181008.
10. Patel NS, Klett J, Pilarzyk K, Lee DI, Kass D, Menniti FS, Kelly MP. Identification of new PDE9A isoforms and how their expression and subcellular compartmentalization in the brain change across the life span. *Neurobiology of aging*. 2018;65:217-34. doi: 10.1016/j.neurobiolaging.2018.01.019. PubMed PMID: 29505961; PubMed Central PMCID: PMC5871571.
11. Huston E, Gall I, Houslay TM, Houslay MD. Helix-1 of the cAMP-specific phosphodiesterase PDE4A1 regulates its phospholipase-D-dependent redistribution in response to release of Ca<sup>2+</sup>. *Journal of cell science*. 2006;119(Pt 18):3799-810. doi: 10.1242/jcs.03106. PubMed PMID: 16940352.
12. Nagel DJ, Aizawa T, Jeon KI, Liu W, Mohan A, Wei H, Miano JM, Florio VA, Gao P, Korshunov VA, Berk BC, Yan C. Role of nuclear Ca<sup>2+</sup>/calmodulin-stimulated phosphodiesterase 1A in vascular smooth muscle cell growth and survival. *Circulation research*. 2006;98(6):777-84. doi: 10.1161/01.RES.0000215576.27615.f. PubMed PMID: 16514069; PubMed Central PMCID: PMC4114760.
13. Houslay MD. Underpinning compartmentalised cAMP signalling through targeted cAMP breakdown. *Journal of cell science*. 2010;123(2):91-100.
14. Richter W, Day P, Agrawal R, Bruss MD, Granier S, Wang YL, Rasmussen SG, Horner K, Wang P, Lei T, Patterson AJ, Kobilka B, Conti M. Signaling from beta1- and beta2-adrenergic receptors is defined by differential interactions with PDE4. *The EMBO journal*. 2008;27(2):384-93. doi: 10.1038/sj.emboj.7601968. PubMed PMID: 18188154; PubMed Central PMCID: PMC2196435.

15. Houslay MD, Baillie GS. Beta-arrestin-recruited phosphodiesterase-4 desensitizes the AKAP79/PKA-mediated switching of beta2-adrenoceptor signalling to activation of ERK. *Biochemical Society transactions*. 2005;33(Pt 6):1333-6. doi: 10.1042/BST20051333. PubMed PMID: 16246112.
16. Perera RK, Sprenger JU, Steinbrecher JH, Hubscher D, Lehnart SE, Abesser M, Schuh K, El-Armouche A, Nikolaev VO. Microdomain switch of cGMP-regulated phosphodiesterases leads to ANP-induced augmentation of beta-adrenoceptor-stimulated contractility in early cardiac hypertrophy. *Circulation research*. 2015;116(8):1304-11. doi: 10.1161/CIRCRESAHA.116.306082. PubMed PMID: 25688144.
17. Penmatsa H, Zhang W, Yarlagadda S, Li C, Conoley VG, Yue J, Bahouth SW, Buddington RK, Zhang G, Nelson DJ, Sonecha MD, Manganiello V, Wine JJ, Naren AP. Compartmentalized cyclic adenosine 3',5'-monophosphate at the plasma membrane clusters PDE3A and cystic fibrosis transmembrane conductance regulator into microdomains. *Molecular biology of the cell*. 2010;21(6):1097-110. doi: 10.1091/mbc.E09-08-0655. PubMed PMID: 20089840; PubMed Central PMCID: PMC2836961.
18. Ahmad F, Lindh R, Tang Y, Ruishalme I, Ost A, Sahachartsiri B, Stralfors P, Degerman E, Manganiello VC. Differential regulation of adipocyte PDE3B in distinct membrane compartments by insulin and the beta3-adrenergic receptor agonist CL316243: effects of caveolin-1 knockdown on formation/maintenance of macromolecular signalling complexes. *The Biochemical journal*. 2009;424(3):399-410. doi: 10.1042/BJ20090842. PubMed PMID: 19747167; PubMed Central PMCID: PMC2953723.
19. Al-Tawashi A, Gehring C. Phosphodiesterase activity is regulated by CC2D1A that is implicated in non-syndromic intellectual disability. *Cell communication and signaling : CCS*. 2013;11(1):47. doi: 10.1186/1478-811X-11-47. PubMed PMID: 23826796; PubMed Central PMCID: PMC3704924.
20. Bonkale WL, Winblad B, Ravid R, Cowburn RF. Reduced nitric oxide responsive soluble guanylyl cyclase activity in the superior temporal cortex of patients with Alzheimer's disease. *Neuroscience letters*. 1995;187(1):5-8. PubMed PMID: 7617301.
21. Baltrons MA, Pifarre P, Ferrer I, Carot JM, Garcia A. Reduced expression of NO-sensitive guanylyl cyclase in reactive astrocytes of Alzheimer disease, Creutzfeldt-Jakob disease, and multiple sclerosis brains. *Neurobiology of disease*. 2004;17(3):462-72. doi: 10.1016/j.nbd.2004.07.022. PubMed PMID: 15571982.
22. Baltrons MA, Pedraza CE, Heneka MT, Garcia A. Beta-amyloid peptides decrease soluble guanylyl cyclase expression in astroglial cells. *Neurobiology of disease*. 2002;10(2):139-49. PubMed PMID: 12127152.
23. Yarla NS, Gali H, Pathuri G, Smriti S, Farooqui M, Panneerselvam J, Kumar G, Madka V, Rao CV. Targeting the paracrine hormone-dependent guanylate cyclase/cGMP/phosphodiesterases signaling pathway for colorectal cancer prevention. *Seminars in cancer biology*. 2018. doi: 10.1016/j.semcancer.2018.08.011. PubMed PMID: 30189250.
24. Li N, Chen X, Zhu B, Ramirez-Alcantara V, Canzoneri JC, Lee K, Sigler S, Gary B, Li Y, Zhang W, Moyer MP, Salter EA, Wierzbicki A, Keeton AB, Piazza GA. Suppression of beta-catenin/TCF transcriptional activity and colon tumor cell growth by dual inhibition of PDE5 and 10. *Oncotarget*. 2015;6(29):27403-15. doi: 10.18632/oncotarget.4741. PubMed PMID: 26299804; PubMed Central PMCID: PMC4694998.
25. Lee DI, Zhu G, Sasaki T, Cho GS, Hamdani N, Holewinski R, Jo SH, Danner T, Zhang M, Rainer PP, Bedja D, Kirk JA, Ranek MJ, Dostmann WR, Kwon C, Margulies KB, Van Eyk JE, Paulus WJ, Takimoto E, Kass DA. Phosphodiesterase 9A controls nitric-oxide-independent cGMP and hypertrophic heart disease. *Nature*. 2015;519(7544):472-6. doi: 10.1038/nature14332. PubMed PMID: 25799991; PubMed Central PMCID: PMC4376609.
26. Hartell NA, Furuya S, Jacoby S, Okada D. Intercellular action of nitric oxide increases cGMP in cerebellar Purkinje cells. *Neuroreport*. 2001;12(1):25-8. PubMed PMID: 11201085.
27. Rahman S, Li PP, Young LT, Kofman O, Kish SJ, Warsh JJ. Reduced [<sup>3</sup>H]cyclic AMP binding in postmortem brain from subjects with bipolar affective disorder. *Journal of neurochemistry*. 1997;68(1):297-304. PubMed PMID: 8978738.
28. Fields A, Li PP, Kish SJ, Warsh JJ. Increased cyclic AMP-dependent protein kinase activity in postmortem brain from patients with bipolar affective disorder. *Journal of neurochemistry*. 1999;73(4):1704-10. PubMed PMID: 10501218.

29. Chang A, Li PP, Warsh JJ. Altered cAMP-dependent protein kinase subunit immunolabeling in post-mortem brain from patients with bipolar affective disorder.[erratum appears in J Neurochem. 2003 Apr;85(1):286.]. *Journal of neurochemistry*. 2003;84(4):781-91.
30. Mori S, Tardito D, Dorigo A, Zanardi R, Smeraldi E, Racagni G, Perez J. Effects of lithium on cAMP-dependent protein kinase in rat brain. *Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology*. 1998;19(3):233-40. doi: 10.1016/S0893-133X(98)00018-9. PubMed PMID: 9653711.
31. Jensen JB, Mork A. Altered protein phosphorylation in the rat brain following chronic lithium and carbamazepine treatments. *European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology*. 1997;7(3):173-9. PubMed PMID: 9213075.
32. Casebolt TL, Jope RS. Effects of chronic lithium treatment on protein kinase C and cyclic AMP-dependent protein phosphorylation. *Biological psychiatry*. 1991;29(3):233-43. PubMed PMID: 2015330.
33. Francis SH, Corbin JD. Phosphodiesterase-5 inhibition: the molecular biology of erectile function and dysfunction. *Urol Clin North Am*. 2005;32(4):419-29, vi. doi: 10.1016/j.ucl.2005.08.001. PubMed PMID: 16291034.
34. Schwartz BG, Kloner RA. Drug interactions with phosphodiesterase-5 inhibitors used for the treatment of erectile dysfunction or pulmonary hypertension. *Circulation*. 2010;122(1):88-95. doi: 10.1161/CIRCULATIONAHA.110.944603. PubMed PMID: 20606131.
35. Zoccarato A, Surdo NC, Aronsen JM, Fields LA, Mancuso L, Dodoni G, Stangherlin A, Livie C, Jiang H, Sin YY, Gesellchen F, Terrin A, Baillie GS, Nicklin SA, Graham D, Szabo-Fresnais N, Krall J, Vandeput F, Movsesian M, Furlan L, Corsetti V, Hamilton G, Lefkimmatis K, Sjaastad I, Zaccolo M. Cardiac Hypertrophy Is Inhibited by a Local Pool of cAMP Regulated by Phosphodiesterase 2. *Circ Res*. 2015;117(8):707-19. doi: 10.1161/CIRCRESAHA.114.305892. PubMed PMID: 26243800.
36. Kaname T, Ki CS, Niikawa N, Baillie GS, Day JP, Yamamura K, Ohta T, Nishimura G, Mastuura N, Kim OH, Sohn YB, Kim HW, Cho SY, Ko AR, Lee JY, Kim HW, Ryu SH, Rhee H, Yang KS, Joo K, Lee J, Kim CH, Cho KH, Kim D, Yanagi K, Naritomi K, Yoshiura K, Kondoh T, Nii E, Tonoki H, Houslay MD, Jin DK. Heterozygous mutations in cyclic AMP phosphodiesterase-4D (PDE4D) and protein kinase A (PKA) provide new insights into the molecular pathology of acrodysostosis. *Cell Signal*. 2014;26(11):2446-59. doi: 10.1016/j.cellsig.2014.07.025. PubMed PMID: 25064455.
37. Motte E, Le Stunff C, Briet C, Dumaz N, Silve C. Modulation of signaling through GPCR-cAMP-PKA pathways by PDE4 depends on stimulus intensity: Possible implications for the pathogenesis of acrodysostosis without hormone resistance. *Mol Cell Endocrinol*. 2017;442:1-11. doi: 10.1016/j.mce.2016.11.026. PubMed PMID: 27908835.
38. Briet C, Pereda A, Le Stunff C, Motte E, de Dios Garcia-Diaz J, de Nanclares GP, Dumaz N, Silve C. Mutations causing acrodysostosis-2 facilitate activation of phosphodiesterase 4D3. *Hum Mol Genet*. 2017;26(20):3883-94. doi: 10.1093/hmg/ddx271. PubMed PMID: 29016851.
39. Hoppmann J, Gesing J, Silve C, Leroy C, Bertsche A, Hirsch FW, Kiess W, Pfaffle R, Schuster V. Phenotypic Variability in a Family with Acrodysostosis Type 2 Caused by a Novel PDE4D Mutation Affecting the Serine Target of Protein Kinase-A Phosphorylation. *J Clin Res Pediatr Endocrinol*. 2017;9(4):360-5. doi: 10.4274/jcrpe.4488. PubMed PMID: 28515031; PubMed Central PMCID: PMC5785644.
40. Boscutti G, E AR, Plisson C. PET Radioligands for imaging of the PDE10A in human: current status. *Neurosci Lett*. 2018. doi: 10.1016/j.neulet.2018.08.006. PubMed PMID: 30099081.
41. Russell DS, Jennings DL, Barret O, Tamagnan GD, Carroll VM, Caille F, Alagille D, Morley TJ, Papin C, Seibyl JP, Marek KL. Change in PDE10 across early Huntington disease assessed by [<sup>18</sup>F]MNI-659 and PET imaging. *Neurology*. 2016;86(8):748-54. doi: 10.1212/WNL.0000000000002391. PubMed PMID: 26802091.
42. Heckman PRA, Blokland A, Bollen EPP, Prickaerts J. Phosphodiesterase inhibition and modulation of corticostriatal and hippocampal circuits: Clinical overview and translational considerations. *Neuroscience and biobehavioral reviews*. 2018;87:233-54. doi: 10.1016/j.neubiorev.2018.02.007. PubMed PMID: 29454746.

43. Vinpocetine Monograph. *Alternative medicine review : a journal of clinical therapeutic*. 2002;7(3):240-3.
44. Asal NJ, Wojciak KA. Effect of cilostazol in treating diabetes-associated microvascular complications. *Endocrine*. 2017;56(2):240-4. doi: 10.1007/s12020-017-1279-4. PubMed PMID: 28293857.
45. Chapman TM, Goa KL. Cilostazol: a review of its use in intermittent claudication. *American journal of cardiovascular drugs : drugs, devices, and other interventions*. 2003;3(2):117-38. PubMed PMID: 14727939.
46. Chong LYZ, Satya K, Kim B, Berkowitz R. Milrinone Dosing and a Culture of Caution in Clinical Practice. *Cardiology in review*. 2018;26(1):35-42. doi: 10.1097/CRD.000000000000165. PubMed PMID: 29045285.
47. Celli BR. Pharmacological Therapy of COPD: Reasons for Optimism. *Chest*. 2018. doi: 10.1016/j.chest.2018.07.005. PubMed PMID: 30028967.
48. Cada DJ, Ingram K, Baker DE. Apremilast. *Hospital pharmacy*. 2014;49(8):752-62. doi: 10.1310/hpj4908-752. PubMed PMID: 25477601; PubMed Central PMCID: PMC4252204.
49. Papp K, Reich K, Leonardi CL, Kircik L, Chimenti S, Langley RG, Hu C, Stevens RM, Day RM, Gordon KB, Korman NJ, Griffiths CE. Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1). *Journal of the American Academy of Dermatology*. 2015;73(1):37-49. doi: 10.1016/j.jaad.2015.03.049. PubMed PMID: 26089047.
50. Edwards CJ, Blanco FJ, Crowley J, Birbara CA, Jaworski J, Aelion J, Stevens RM, Vessey A, Zhan X, Bird P. Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement: a phase III, randomised, controlled trial (PALACE 3). *Annals of the rheumatic diseases*. 2016;75(6):1065-73. doi: 10.1136/annrheumdis-2015-207963. PubMed PMID: 26792812; PubMed Central PMCID: PMC4893110.
51. Terburg D, Syal S, Rosenberger LA, Heany S, Phillips N, Gericke N, Stein DJ, van Honk J. Acute effects of Scelletium tortuosum (Zembrin), a dual 5-HT reuptake and PDE4 inhibitor, in the human amygdala and its connection to the hypothalamus. *Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology*. 2013;38(13):2708-16. doi: 10.1038/npp.2013.183. PubMed PMID: 23903032; PubMed Central PMCID: PMC3828542.
52. Chiu S, Gericke N, Farina-Woodbury M, Badmaev V, Raheb H, Terpstra K, Antongiorgi J, Bureau Y, Cernovsky Z, Hou J, Sanchez V, Williams M, Copen J, Husni M, Goble L. Proof-of-Concept Randomized Controlled Study of Cognition Effects of the Proprietary Extract Scelletium tortuosum (Zembrin) Targeting Phosphodiesterase-4 in Cognitively Healthy Subjects: Implications for Alzheimer's Dementia. *Evidence-based complementary and alternative medicine : eCAM*. 2014;2014:682014. doi: 10.1155/2014/682014. PubMed PMID: 25389443; PubMed Central PMCID: PMC4217361.
53. Campbell HE. Clinical monograph for drug formulary review: erectile dysfunction agents. *Journal of managed care pharmacy : JMCP*. 2005;11(2):151-71. doi: 10.18553/jmcp.2005.11.2.151. PubMed PMID: 15766322.
54. Cho MC, Paick JS. Udenafil for the treatment of erectile dysfunction. *Therapeutics and clinical risk management*. 2014;10:341-54. doi: 10.2147/TCRM.S39727. PubMed PMID: 24868160; PubMed Central PMCID: PMC4027935.
55. Kang SG, Kim JJ. Udenafil: efficacy and tolerability in the management of erectile dysfunction. *Therapeutic advances in urology*. 2013;5(2):101-10. doi: 10.1177/1756287212470019. PubMed PMID: 23554845; PubMed Central PMCID: PMC3607490.
56. Shim YS, Pae CU, Cho KJ, Kim SW, Kim JC, Koh JS. Effects of daily low-dose treatment with phosphodiesterase type 5 inhibitor on cognition, depression, somatization and erectile function in patients with erectile dysfunction: a double-blind, placebo-controlled study. *International journal of impotence research*. 2014;26(2):76-80. doi: 10.1038/ijir.2013.38. PubMed PMID: 24285284.
57. Shim YS, Pae CU, Kim SW, Kim HW, Kim JC, Koh JS. Effects of repeated dosing with Udenafil (Zydena) on cognition, somatization and erection in patients with erectile dysfunction: a pilot study.

- International journal of impotence research. 2011;23(3):109-14. doi: 10.1038/ijir.2011.13. PubMed PMID: 21544084.
58. Helal CJ, Arnold E, Boyden T, Chang C, Chappie TA, Fisher E, Hajos M, Harms JF, Hoffman WE, Humphrey JM, Pandit J, Kang Z, Kleiman RJ, Kormos BL, Lee CW, Lu J, Maklad N, McDowell L, McGinnis D, O'Connor RE, O'Donnell CJ, Ogden A, Piotrowski M, Schmidt CJ, Seymour PA, Ueno H, Vansell N, Verhoest PR, Yang EX. Identification of a Potent, Highly Selective, and Brain Penetrant Phosphodiesterase 2A Inhibitor Clinical Candidate. *Journal of medicinal chemistry*. 2018;61(3):1001-18. doi: 10.1021/acs.jmedchem.7b01466. PubMed PMID: 29293004.
59. Exisulind: Aptosyn, FGN 1, Prevatac, sulindac sulfone. *Drugs in R&D*. 2004;5(4):220-6. PubMed PMID: 15230629.
60. Griffiths GJ. Exisulind Cell Pathways. *Current opinion in investigational drugs*. 2000;1(3):386-91. PubMed PMID: 11249724.
61. Rosales RL, Santos MM, Mercado-Asis LB. Cilostazol: a pilot study on safety and clinical efficacy in neuropathies of diabetes mellitus type 2 (ASCEND). *Angiology*. 2011;62(8):625-35. doi: 10.1177/0003319711410594. PubMed PMID: 21733952.
62. Giembycz MA. An update and appraisal of the cilomilast Phase III clinical development programme for chronic obstructive pulmonary disease. *British journal of clinical pharmacology*. 2006;62(2):138-52. doi: 10.1111/j.1365-2125.2006.02640.x. PubMed PMID: 16842388; PubMed Central PMCID: PMC1885082.
63. Ratziu V, Bedossa P, Francque SM, Larrey D, Aithal GP, Serfaty L, Voiculescu M, Preotescu L, Nevens F, De Ledingen V, Kirchner GI, Trunecka P, Ryder SD, Day CP, Takeda J, Traudtner K. Lack of efficacy of an inhibitor of PDE4 in phase 1 and 2 trials of patients with nonalcoholic steatohepatitis. *Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association*. 2014;12(10):1724-30 e5. doi: 10.1016/j.cgh.2014.01.040. PubMed PMID: 24530600.
64. Schultheiss D, Muller SV, Nager W, Stief CG, Schlote N, Jonas U, Asvestis C, Johannes S, Munte TF. Central effects of sildenafil (Viagra) on auditory selective attention and verbal recognition memory in humans: a study with event-related brain potentials. *World journal of urology*. 2001;19(1):46-50. PubMed PMID: 11289570.
65. Grass H, Klotz T, Fathian-Sabet B, Berghaus G, Engelmann U, Kaferstein H. Sildenafil (Viagra): is there an influence on psychological performance? *International urology and nephrology*. 2001;32(3):409-12. PubMed PMID: 11583362.
66. Reneerkens OA, Sambeth A, Ramaekers JG, Steinbusch HW, Blokland A, Prickaerts J. The effects of the phosphodiesterase type 5 inhibitor vardenafil on cognitive performance in healthy adults: a behavioral-electroencephalography study. *Journal of psychopharmacology*. 2013;27(7):600-8. doi: 10.1177/0269881113477747. PubMed PMID: 23427190.
67. Reneerkens OA, Sambeth A, Van Duinen MA, Blokland A, Steinbusch HW, Prickaerts J. The PDE5 inhibitor vardenafil does not affect auditory sensory gating in rats and humans. *Psychopharmacology*. 2013;225(2):303-12. doi: 10.1007/s00213-012-2817-7. PubMed PMID: 22855271.
68. Goff DC, Cather C, Freudenreich O, Henderson DC, Evins AE, Culhane MA, Walsh JP. A placebo-controlled study of sildenafil effects on cognition in schizophrenia. *Psychopharmacology*. 2009;202(1-3):411-7. PubMed PMID: 18716761.
69. Akhondzadeh S, Ghayyoumi R, Rezaei F, Salehi B, Modabbernia AH, Maroufi A, Esfandiari GR, Naderi M, Ghebleh F, Tabrizi M, Rezazadeh SA. Sildenafil adjunctive therapy to risperidone in the treatment of the negative symptoms of schizophrenia: a double-blind randomized placebo-controlled trial. *Psychopharmacology*. 2011;213(4):809-15. doi: 10.1007/s00213-010-2044-z. PubMed PMID: 20949350.
70. Nelson MD, Rader F, Tang X, Tavyev J, Nelson SF, Miceli MC, Elashoff RM, Sweeney HL, Victor RG. PDE5 inhibition alleviates functional muscle ischemia in boys with Duchenne muscular dystrophy. *Neurology*. 2014;82(23):2085-91. doi: 10.1212/WNL.0000000000000498. PubMed PMID: 24808022; PubMed Central PMCID: PMC4118495.
71. Martin EA, Barresi R, Byrne BJ, Tsimerinov EI, Scott BL, Walker AE, Gurudevan SV, Anene F, Elashoff RM, Thomas GD, Victor RG. Tadalafil alleviates muscle ischemia in patients with Becker muscular

- dystrophy. *Science translational medicine*. 2012;4(162):162ra55. doi: 10.1126/scitranslmed.3004327. PubMed PMID: 23197572; PubMed Central PMCID: PMC3935430.
72. Schwam EM, Nicholas T, Chew R, Billing CB, Davidson W, Ambrose D, Altstiel LD. A multicenter, double-blind, placebo-controlled trial of the PDE9A inhibitor, PF-04447943, in Alzheimer's disease. *Current Alzheimer research*. 2014;11(5):413-21. PubMed PMID: 24801218.
73. Brown D, Nakagome K, Cordes J, Brenner R, Grunder G, Keefe RSE, Riesenberger R, Walling DP, Daniels K, Wang L, McGinniss J, Sand M. Evaluation of the Efficacy, Safety, and Tolerability of BI 409306, a Novel Phosphodiesterase 9 Inhibitor, in Cognitive Impairment in Schizophrenia: A Randomized, Double-Blind, Placebo-Controlled, Phase II Trial. *Schizophrenia bulletin*. 2018. doi: 10.1093/schbul/sby049. PubMed PMID: 29718385.
74. Moschetti V, Kim M, Sand M, Wunderlich G, Andersen G, Feifel U, Jang JJ, Timmer W, Rosenbrock H, Boland K. The safety, tolerability and pharmacokinetics of BI 409306, a novel and potent PDE9 inhibitor: Overview of three Phase I randomised trials in healthy volunteers. *European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology*. 2018;28(5):643-55. doi: 10.1016/j.euroneuro.2018.01.003. PubMed PMID: 29567399.
75. Brown D, Daniels K, Pichereau S, Sand M. A Phase IC Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Cognitive Outcomes of BI 409306 in Patients with Mild-to-Moderate Schizophrenia. *Neurology and therapy*. 2018;7(1):129-39. doi: 10.1007/s40120-017-0085-5. PubMed PMID: 29177699; PubMed Central PMCID: PMC5990500.
76. Wunderlich G, Thamer C, Roehrl M, Barcia M, Frolich L, Dubois B. Study design and characteristics of two phase II proof-of-concept clinical trials of the pde9 inhibitor BI 409306 in early alzheimer's disease. *Alzheimers Dementia: J Alzheimers Associ*. 2016;12(7):P820-P1.
77. Grauer SM, Pulito VL, Navarra RL, Kelly MP, Kelley C, Graf R, Langen B, Logue S, Brennan J, Jiang L, Charych E, Egerland U, Liu F, Marquis KL, Malamas M, Hage T, Comery TA, Brandon NJ. Phosphodiesterase 10A inhibitor activity in preclinical models of the positive, cognitive, and negative symptoms of schizophrenia. *The Journal of pharmacology and experimental therapeutics*. 2009;331(2):574-90. Epub 2009/08/08. doi: 10.1124/jpet.109.155994. PubMed PMID: 19661377.
78. Schmidt CJ, Chapin DS, Cianfrogna J, Corman ML, Hajos M, Harms JF, Hoffman WE, Lebel LA, McCarthy SA, Nelson FR, Proulx-LaFrance C, Majchrzak MJ, Ramirez AD, Schmidt K, Seymour PA, Siuciak JA, Tingley FD, 3rd, Williams RD, Verhoest PR, Menniti FS. Preclinical characterization of selective phosphodiesterase 10A inhibitors: a new therapeutic approach to the treatment of schizophrenia. *The Journal of pharmacology and experimental therapeutics*. 2008;325(2):681-90. doi: 10.1124/jpet.107.132910. PubMed PMID: 18287214.
79. DeMartinis N, Banerjee A, Kumar V, Boyer S, Schmidt CJ, Arroyo S. Results of a Phase 2A Proof-of-Concept Trial with a PDE10A Inhibitor in the Treatment of Acute Exacerbation of Schizophrenia. *Schizophrenia research*. 2012;136(Suppl. 1):S262.
80. Russell DS, Barret O, Jennings DL, Friedman JH, Tamagnan GD, Thomae D, Alagille D, Morley TJ, Papin C, Papapetropoulos S, Waterhouse RN, Seibyl JP, Marek KL. The phosphodiesterase 10 positron emission tomography tracer, [18F]MNI-659, as a novel biomarker for early Huntington disease. *JAMA neurology*. 2014;71(12):1520-8. doi: 10.1001/jamaneurol.2014.1954. PubMed PMID: 25322077.
81. Beaumont V, Zhong S, Lin H, Xu W, Bradaia A, Steidl E, Gleyzes M, Wadel K, Buisson B, Padovan-Neto FE, Chakroborty S, Ward KM, Harms JF, Beltran J, Kwan M, Ghavami A, Haggkvist J, Toth M, Halldin C, Varrone A, Schaab C, Dybowski JN, Elschenbroich S, Lehtimaki K, Heikkinen T, Park L, Rosinski J, Mrzljak L, Lavery D, West AR, Schmidt CJ, Zaleska MM, Munoz-Sanjuan I. Phosphodiesterase 10A Inhibition Improves Cortico-Basal Ganglia Function in Huntington's Disease Models. *Neuron*. 2016;92(6):1220-37. doi: 10.1016/j.neuron.2016.10.064. PubMed PMID: 27916455.
82. Kelly MP. PDE11A. In: Choi S, editor. *Encyclopedia of Signaling Molecules*. Cham: Springer International Publishing; 2018. p. 3804-26.

83. Kelly MP, Adamowicz W, Bove S, Hartman AJ, Mariga A, Pathak G, Reinhart V, Romegialli A, Kleiman RJ. Select 3',5'-cyclic nucleotide phosphodiesterases exhibit altered expression in the aged rodent brain. *Cellular signalling*. 2014;26(2):383-97. doi: 10.1016/j.cellsig.2013.10.007. PubMed PMID: 24184653.
84. Raheem IT, Schreier JD, Fuerst J, Gantert L, Hostetler ED, Huszar S, Joshi A, Kandebo M, Kim SH, Li J, Ma B, McGaughey G, Sharma S, Shipe WD, Uslaner J, Vandever GH, Yan Y, Renger JJ, Smith SM, Coleman PJ, Cox CD. Discovery of pyrazolopyrimidine phosphodiesterase 10A inhibitors for the treatment of schizophrenia. *Bioorganic & medicinal chemistry letters*. 2016;26(1):126-32. doi: 10.1016/j.bmcl.2015.11.013. PubMed PMID: 26602277.
85. Burgin AB, Magnusson OT, Singh J, Witte P, Staker BL, Bjornsson JM, Thorsteinsdottir M, Hrafnisdottir S, Hagen T, Kiselyov AS, Stewart LJ, Gurney ME. Design of phosphodiesterase 4D (PDE4D) allosteric modulators for enhancing cognition with improved safety. *Nature biotechnology*. 2010;28(1):63-70. doi: 10.1038/nbt.1598. PubMed PMID: 20037581.
86. Fox D, 3rd, Burgin AB, Gurney ME. Structural basis for the design of selective phosphodiesterase 4B inhibitors. *Cellular signalling*. 2014;26(3):657-63. doi: 10.1016/j.cellsig.2013.12.003. PubMed PMID: 24361374; PubMed Central PMCID: PMC4057648.
87. Hagen TJ, Mo X, Burgin AB, Fox D, 3rd, Zhang Z, Gurney ME. Discovery of triazines as selective PDE4B versus PDE4D inhibitors. *Bioorganic & medicinal chemistry letters*. 2014;24(16):4031-4. doi: 10.1016/j.bmcl.2014.06.002. PubMed PMID: 24998378; PubMed Central PMCID: PMC4142572.
88. Pushpakom S, Iorio F, Eyers PA, Escott KJ, Hopper S, Wells A, Doig A, Guilliams T, Latimer J, McNamee C, Norris A, Sanseau P, Cavalla D, Pirmohamed M. Drug repurposing: progress, challenges and recommendations. *Nature reviews Drug discovery*. 2018. doi: 10.1038/nrd.2018.168. PubMed PMID: 30310233.
89. Ledebor A, Hutchinson MR, Watkins LR, Johnson KW. Ibudilast (AV-411). A new class therapeutic candidate for neuropathic pain and opioid withdrawal syndromes. *Expert opinion on investigational drugs*. 2007;16(7):935-50. doi: 10.1517/13543784.16.7.935. PubMed PMID: 17594181.
90. Schwenkgrub J, Zaremba M, Mirowska-Guzel D, Kurkowska-Jastrzebska I. Ibudilast: a nonselective phosphodiesterase inhibitor in brain disorders. *Postepy higieny i medycyny doswiadczalnej*. 2017;71(0):137-48. PubMed PMID: 28258674.
91. DeYoung DZ, Heinzerling KG, Swanson AN, Tsuang J, Furst BA, Yi Y, Wu YN, Moody DE, Andrenyak DM, Shoptaw SJ. Safety of Intravenous Methamphetamine Administration During Ibudilast Treatment. *Journal of clinical psychopharmacology*. 2016;36(4):347-54. doi: 10.1097/JCP.0000000000000511. PubMed PMID: 27269956; PubMed Central PMCID: PMC4927401.
92. Worley MJ, Swanson AN, Heinzerling KG, Roche DJ, Shoptaw S. Ibudilast attenuates subjective effects of methamphetamine in a placebo-controlled inpatient study. *Drug and alcohol dependence*. 2016;162:245-50. doi: 10.1016/j.drugalcdep.2016.02.036. PubMed PMID: 26993372; PubMed Central PMCID: PMC5349508.
93. Cooper ZD, Johnson KW, Vosburg SK, Sullivan MA, Manubay J, Martinez D, Jones JD, Saccone PA, Comer SD. Effects of ibudilast on oxycodone-induced analgesia and subjective effects in opioid-dependent volunteers. *Drug and alcohol dependence*. 2017;178:340-7. doi: 10.1016/j.drugalcdep.2017.04.029. PubMed PMID: 28688296.
94. Ray LA, Bujarski S, Shoptaw S, Roche DJ, Heinzerling K, Miotto K. Development of the Neuroimmune Modulator Ibudilast for the Treatment of Alcoholism: A Randomized, Placebo-Controlled, Human Laboratory Trial. *Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology*. 2017;42(9):1776-88. doi: 10.1038/npp.2017.10. PubMed PMID: 28091532; PubMed Central PMCID: PMC5520778.
95. Snyder GL, Prickaerts J, Wadenberg ML, Zhang L, Zheng H, Yao W, Akkerman S, Zhu H, Hendrick JP, Vanover KE, Davis R, Li P, Mates S, Wennogle LP. Preclinical profile of ITI-214, an inhibitor of phosphodiesterase 1, for enhancement of memory performance in rats. *Psychopharmacology*. 2016;233(17):3113-24. doi: 10.1007/s00213-016-4346-2. PubMed PMID: 27342643; PubMed Central PMCID: PMC4980415.

96. Li P, Zheng H, Zhao J, Zhang L, Yao W, Zhu H, Beard JD, Ida K, Lane W, Snell G, Sogabe S, Heyser CJ, Snyder GL, Hendrick JP, Vanover KE, Davis RE, Wennogle LP. Discovery of Potent and Selective Inhibitors of Phosphodiesterase 1 for the Treatment of Cognitive Impairment Associated with Neurodegenerative and Neuropsychiatric Diseases. *Journal of medicinal chemistry*. 2016;59(3):1149-64. doi: 10.1021/acs.jmedchem.5b01751. PubMed PMID: 26789933.
97. Pekcec A, Schulert N, Stierstorfer B, Deiana S, Dorner-Ciossek C, Rosenbrock H. Targeting the dopamine D1 receptor or its downstream signalling by inhibiting phosphodiesterase-1 improves cognitive performance. *British journal of pharmacology*. 2018;175(14):3021-33. doi: 10.1111/bph.14350. PubMed PMID: 29726015; PubMed Central PMCID: PMC6016630.
98. Dyck B, Branstetter B, Gharbaoui T, Hudson AR, Breitenbucher JG, Gomez L, Botrous I, Marrone T, Barido R, Allerston CK, Cedervall EP, Xu R, Sridhar V, Barker R, Aertgeerts K, Schmelzer K, Neul D, Lee D, Massari ME, Andersen CB, Sebring K, Zhou X, Petroski R, Limberis J, Augustin M, Chun LE, Edwards TE, Peters M, Tabatabaei A. Discovery of Selective Phosphodiesterase 1 Inhibitors with Memory Enhancing Properties. *Journal of medicinal chemistry*. 2017;60(8):3472-83. doi: 10.1021/acs.jmedchem.7b00302. PubMed PMID: 28406621.
99. Hashimoto T, Kim GE, Tunin RS, Adesiyun T, Hsu S, Nakagawa R, Zhu G, O'Brien JJ, Hendrick JP, Davis RE, Yao W, Beard D, Hoxie HR, Wennogle LP, Lee DI, Kass DA. Acute Enhancement of Cardiac Function by Phosphodiesterase Type 1 Inhibition: A Translational Study in the Dog and Rabbit. *Circulation*. 2018. doi: 10.1161/CIRCULATIONAHA.117.030490. PubMed PMID: 30030415.
100. Zhang C, Lueptow LM, Zhang HT, O'Donnell JM, Xu Y. The Role of Phosphodiesterase-2 in Psychiatric and Neurodegenerative Disorders. *Advances in neurobiology*. 2017;17:307-47. doi: 10.1007/978-3-319-58811-7\_12. PubMed PMID: 28956338.
101. Mikami S, Kawasaki M, Ikeda S, Negoro N, Nakamura S, Nomura I, Ashizawa T, Kokubo H, Hoffman ID, Zou H, Oki H, Uchiyama N, Hiura Y, Miyamoto M, Ito Y, Nakashima M, Iwashita H, Taniguchi T. Discovery of a Novel Series of Pyrazolo[1,5-a]pyrimidine-Based Phosphodiesterase 2A Inhibitors Structurally Different from N-((1S)-1-(3-Fluoro-4-(trifluoromethoxy)phenyl)-2-methoxyethyl)-7-methoxy-2-oxo-2,3-dihydropyrido[2,3-b]pyrazine-4(1H)-carboxamide (TAK-915), for the Treatment of Cognitive Disorders. *Chemical & pharmaceutical bulletin*. 2017;65(11):1058-77. doi: 10.1248/cpb.c17-00564. PubMed PMID: 29093293.
102. Mikami S, Nakamura S, Ashizawa T, Nomura I, Kawasaki M, Sasaki S, Oki H, Kokubo H, Hoffman ID, Zou H, Uchiyama N, Nakashima K, Kamiguchi N, Imada H, Suzuki N, Iwashita H, Taniguchi T. Discovery of Clinical Candidate N-((1S)-1-(3-Fluoro-4-(trifluoromethoxy)phenyl)-2-methoxyethyl)-7-methoxy-2-oxo-2,3-dihydropyrido[2,3-b]pyrazine-4(1H)-carboxamide (TAK-915): A Highly Potent, Selective, and Brain-Penetrating Phosphodiesterase 2A Inhibitor for the Treatment of Cognitive Disorders. *Journal of medicinal chemistry*. 2017;60(18):7677-702. doi: 10.1021/acs.jmedchem.7b00807. PubMed PMID: 28796496.
103. Mikami S, Sasaki S, Asano Y, Ujikawa O, Fukumoto S, Nakashima K, Oki H, Kamiguchi N, Imada H, Iwashita H, Taniguchi T. Discovery of an Orally Bioavailable, Brain-Penetrating, in Vivo Active Phosphodiesterase 2A Inhibitor Lead Series for the Treatment of Cognitive Disorders. *Journal of medicinal chemistry*. 2017;60(18):7658-76. doi: 10.1021/acs.jmedchem.7b00709. PubMed PMID: 28759228.
104. Weber S, Zeller M, Guan K, Wunder F, Wagner M, El-Armouche A. PDE2 at the crossway between cAMP and cGMP signalling in the heart. *Cellular signalling*. 2017;38:76-84. doi: 10.1016/j.cellsig.2017.06.020. PubMed PMID: 28668721.
105. Zhang C, Yu Y, Ruan L, Wang C, Pan J, Klabnik J, Lueptow L, Zhang HT, O'Donnell JM, Xu Y. The roles of phosphodiesterase 2 in the central nervous and peripheral systems. *Current pharmaceutical design*. 2015;21(3):274-90. PubMed PMID: 25159070.
106. Bundhun PK, Qin T, Chen MH. Comparing the effectiveness and safety between triple antiplatelet therapy and dual antiplatelet therapy in type 2 diabetes mellitus patients after coronary stents implantation: a systematic review and meta-analysis of randomized controlled trials. *BMC cardiovascular disorders*. 2015;15:118. doi: 10.1186/s12872-015-0114-1. PubMed PMID: 26450578; PubMed Central PMCID: PMC4599328.



107. Neel JD, Kruse RL, Dombrovskiy VY, Vogel TR. Cilostazol and freedom from amputation after lower extremity revascularization. *Journal of vascular surgery*. 2015;61(4):960-4. doi: 10.1016/j.jvs.2014.11.067. PubMed PMID: 25595396.
108. Lim HW, Kim TS, Kang WS, Song CI, Baek S, Chung JW. Effect of a 4-Week Treatment with Cilostazol in Patients with Chronic Tinnitus: A Randomized, Prospective, Placebo-controlled, Double-blind, Pilot Study. *The journal of international advanced otology*. 2016;12(2):170-6. doi: 10.5152/iao.2016.2682. PubMed PMID: 27716604.
109. Lakics V, Karran EH, Boess FG. Quantitative comparison of phosphodiesterase mRNA distribution in human brain and peripheral tissues. *Neuropharmacology*. 2010;59(6):367-74. doi: 10.1016/j.neuropharm.2010.05.004. PubMed PMID: 20493887.
110. Mochizuki Y, Oishi M, Mizutani T. Effects of cilostazol on cerebral blood flow, P300, and serum lipid levels in the chronic stage of cerebral infarction. *Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association*. 2001;10(2):63-9. doi: 10.1053/jscd.2001.24657. PubMed PMID: 17903802.
111. Jung KI, Kim JH, Park HY, Park CK. Neuroprotective effects of cilostazol on retinal ganglion cell damage in diabetic rats. *The Journal of pharmacology and experimental therapeutics*. 2013;345(3):457-63. doi: 10.1124/jpet.113.203067. PubMed PMID: 23536314.
112. Masciarelli S, Horner K, Liu C, Park SH, Hinckley M, Hockman S, Nedachi T, Jin C, Conti M, Manganiello V. Cyclic nucleotide phosphodiesterase 3A-deficient mice as a model of female infertility. *The Journal of clinical investigation*. 2004;114(2):196-205. doi: 10.1172/JCI21804. PubMed PMID: 15254586; PubMed Central PMCID: PMC449752.
113. Taiyeb AM, Muhsen-Alanssari SA, Kraemer DC, Ash O, Fajt V, Ridha-Albarzanchi MT. Cilostazol blocks pregnancy in naturally cycling swine: An animal model. *Life sciences*. 2015;142:92-6. doi: 10.1016/j.lfs.2015.10.017. PubMed PMID: 26477292.
114. Taiyeb AM, Muhsen-Alanssari SA, Dees WL, Ridha-Albarzanchi MT, Kraemer DC. Improvement in in vitro fertilization outcome following in vivo synchronization of oocyte maturation in mice. *Experimental biology and medicine*. 2015;240(4):519-26. doi: 10.1177/1535370214549533. PubMed PMID: 25245076; PubMed Central PMCID: PMC4935383.
115. Duan LM, Yu HY, Li YL, Jia CJ. Design and discovery of 2-(4-(1H-tetrazol-5-yl)-1H-pyrazol-1-yl)-4-(4-phenyl)thiazole derivatives as cardiogenic agents via inhibition of PDE3. *Bioorganic & medicinal chemistry*. 2015;23(18):6111-7. doi: 10.1016/j.bmc.2015.08.002. PubMed PMID: 26319621.
116. Kim KY, Lee H, Yoo SE, Kim SH, Kang NS. Discovery of new inhibitor for PDE3 by virtual screening. *Bioorganic & medicinal chemistry letters*. 2011;21(6):1617-20. doi: 10.1016/j.bmcl.2011.01.120. PubMed PMID: 21330134.
117. Nikpour M, Sadeghian H, Saberi MR, Nick RS, Seyedi SM, Hosseini A, Parsaee H, Bozorg AT. Design, synthesis and biological evaluation of 6-(benzyloxy)-4-methylquinolin-2(1H)-one derivatives as PDE3 inhibitors. *Bioorganic & medicinal chemistry*. 2010;18(2):855-62. doi: 10.1016/j.bmc.2009.11.044. PubMed PMID: 20005117.
118. Huff SB, Gottwald LD. Repigmentation of Tenacious Vitiligo on Apremilast. *Case reports in dermatological medicine*. 2017;2017:2386234. doi: 10.1155/2017/2386234. PubMed PMID: 29234546; PubMed Central PMCID: PMC5694993.
119. AbuHilal M, Walsh S, Shear N. Treatment of recalcitrant erosive oral lichen planus and desquamative gingivitis with oral apremilast. *Journal of dermatological case reports*. 2016;10(3):56-7. doi: 10.3315/jdcr.2016.1232. PubMed PMID: 28400896; PubMed Central PMCID: PMC5385266.
120. Hafner J, Gubler C, Kaufmann K, Nobbe S, Navarini AA, French LE. Apremilast Is Effective in Lichen Planus Mucosae-Associated Stenotic Esophagitis. *Case reports in dermatology*. 2016;8(2):224-6. doi: 10.1159/000447051. PubMed PMID: 27721755; PubMed Central PMCID: PMC5043249.
121. Bettencourt M. Oral Lichen Planus Treated With Apremilast. *Journal of drugs in dermatology : JDD*. 2016;15(8):1026-8. PubMed PMID: 27538007.

122. Jensterle M, Kocjan T, Janez A. Phosphodiesterase 4 inhibition as a potential new therapeutic target in obese women with polycystic ovary syndrome. *The Journal of clinical endocrinology and metabolism*. 2014;99(8):E1476-81. doi: 10.1210/jc.2014-1430. PubMed PMID: 24823465.
123. Jensterle M, Salamun V, Kocjan T, Vrtacnik Bokal E, Janez A. Short term monotherapy with GLP-1 receptor agonist liraglutide or PDE 4 inhibitor roflumilast is superior to metformin in weight loss in obese PCOS women: a pilot randomized study. *Journal of ovarian research*. 2015;8:32. doi: 10.1186/s13048-015-0161-3. PubMed PMID: 26032655; PubMed Central PMCID: PMC4506413.
124. Plock N, Vollert S, Mayer M, Hanauer G, Lahu G. Pharmacokinetic/Pharmacodynamic Modeling of the PDE4 Inhibitor TAK-648 in Type 2 Diabetes: Early Translational Approaches for Human Dose Prediction. *Clinical and translational science*. 2017;10(3):185-93. doi: 10.1111/cts.12436. PubMed PMID: 28088839; PubMed Central PMCID: PMC5421726.
125. Van Duinen MA, Sambeth A, Heckman PRA, Smit S, Tsai M, Lahu G, Uz T, Blokland A, Prickaerts J. Acute administration of roflumilast enhances immediate recall of verbal word memory in healthy young adults. *Neuropharmacology*. 2018;131:31-8. doi: 10.1016/j.neuropharm.2017.12.019. PubMed PMID: 29241652.
126. Gilleen J, Farah Y, Davison C, Kerins S, Valdearenas L, Uz T, Lahu G, Tsai M, Ogrinc F, Reichenberg A, Williams SC, Mehta MA, Shergill SS. An experimental medicine study of the phosphodiesterase-4 inhibitor, roflumilast, on working memory-related brain activity and episodic memory in schizophrenia patients. *Psychopharmacology*. 2018. doi: 10.1007/s00213-018-5134-y. PubMed PMID: 30536081.
127. Blokland A, Van Duinen MA, Sambeth A, Heckman PRA, Tsai M, Lahu G, Uz T, Prickaerts J. Acute treatment with the PDE4 inhibitor roflumilast improves verbal word memory in healthy old individuals: a double-blind placebo-controlled study. *Neurobiology of aging*. 2019;77:37-43. doi: 10.1016/j.neurobiolaging.2019.01.014. PubMed PMID: 30776650.
128. Kanes SJ, Tokarczyk J, Siegel SJ, Bilker W, Abel T, Kelly MP. Rolipram: a specific phosphodiesterase 4 inhibitor with potential antipsychotic activity. *Neuroscience*. 2007;144(1):239-46. doi: 10.1016/j.neuroscience.2006.09.026. PubMed PMID: 17081698; PubMed Central PMCID: PMC3313447.
129. Kelly MP, Isiegas C, Cheung YF, Tokarczyk J, Yang X, Esposito MF, Rapoport DA, Fabian SA, Siegel SJ, Wand G, Houslay MD, Kanes SJ, Abel T. Constitutive activation of Galphas within forebrain neurons causes deficits in sensorimotor gating because of PKA-dependent decreases in cAMP. *Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology*. 2007;32(3):577-88. doi: 10.1038/sj.npp.1301099. PubMed PMID: 16738544; PubMed Central PMCID: PMC3303872.
130. Kelly MP, Stein JM, Vecsey CG, Favilla C, Yang X, Bizily SF, Esposito MF, Wand G, Kanes SJ, Abel T. Developmental etiology for neuroanatomical and cognitive deficits in mice overexpressing Galphas, a G-protein subunit genetically linked to schizophrenia. *Molecular psychiatry*. 2009;14(4):398-415, 347. Epub 2008/11/26. doi: 10.1038/mp.2008.124. PubMed PMID: 19030002; PubMed Central PMCID: PMC3312743.
131. Rodefer JS, Saland SK, Eckrich SJ. Selective phosphodiesterase inhibitors improve performance on the ED/ID cognitive task in rats. *Neuropharmacology*. 2012;62(3):1182-90. doi: 10.1016/j.neuropharm.2011.08.008. PubMed PMID: 21856317.
132. MacDonald E, Van der Lee H, Pocock D, Cole C, Thomas N, VandenBerg PM, Bourtchouladze R, Kleim JA. A novel phosphodiesterase type 4 inhibitor, HT-0712, enhances rehabilitation-dependent motor recovery and cortical reorganization after focal cortical ischemia. *Neurorehabilitation and neural repair*. 2007;21(6):486-96. doi: 10.1177/1545968307305521. PubMed PMID: 17823313.
133. Peters M, Bletsch M, Stanley J, Wheeler D, Scott R, Tully T. The PDE4 inhibitor HT-0712 improves hippocampus-dependent memory in aged mice. *Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology*. 2014;39(13):2938-48. doi: 10.1038/npp.2014.154. PubMed PMID: 24964813; PubMed Central PMCID: PMC4229572.
134. Gurney ME, Cogram P, Deacon RM, Rex C, Tranfaglia M. Multiple Behavior Phenotypes of the Fragile-X Syndrome Mouse Model Respond to Chronic Inhibition of Phosphodiesterase-4D (PDE4D). *Scientific reports*. 2017;7(1):14653. doi: 10.1038/s41598-017-15028-x. PubMed PMID: 29116166; PubMed Central PMCID: PMC5677090.

135. Zhang C, Xu Y, Chowdhary A, Fox D, 3rd, Gurney ME, Zhang HT, Auerbach BD, Salvi RJ, Yang M, Li G, O'Donnell JM. Memory enhancing effects of BPN14770, an allosteric inhibitor of phosphodiesterase-4D, in wild-type and humanized mice. *Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology*. 2018;43(11):2299-309. doi: 10.1038/s41386-018-0178-6. PubMed PMID: 30131563; PubMed Central PMCID: PMC6135860.
136. Rutter AR, Poffe A, Cavallini P, Davis TG, Schneck J, Negri M, Vicentini E, Montanari D, Arban R, Gray FA, Davies CH, Wren PB. GSK356278, a potent, selective, brain-penetrant phosphodiesterase 4 inhibitor that demonstrates anxiolytic and cognition-enhancing effects without inducing side effects in preclinical species. *The Journal of pharmacology and experimental therapeutics*. 2014;350(1):153-63. doi: 10.1124/jpet.114.214155. PubMed PMID: 24784567.
137. Munshi A, Das S. Genetic Understanding of Stroke Treatment: Potential Role for Phosphodiesterase Inhibitors. *Advances in neurobiology*. 2017;17:445-61. doi: 10.1007/978-3-319-58811-7\_16. PubMed PMID: 28956342.
138. Chen J, Yu H, Zhong J, Feng H, Wang H, Cheng Y, Zou Z, Huang C, Zhou Z, Zheng W, Xu J. The phosphodiesterase-4 inhibitor, FCPR16, attenuates ischemia-reperfusion injury in rats subjected to middle cerebral artery occlusion and reperfusion. *Brain research bulletin*. 2018;137:98-106. doi: 10.1016/j.brainresbull.2017.11.010. PubMed PMID: 29155261.
139. Soares LM, De Vry J, Steinbusch HWM, Milani H, Prickaerts J, Weffort de Oliveira RM. Rolipram improves cognition, reduces anxiety- and despair-like behaviors and impacts hippocampal neuroplasticity after transient global cerebral ischemia. *Neuroscience*. 2016;326:69-83. doi: 10.1016/j.neuroscience.2016.03.062. PubMed PMID: 27058148.
140. Li LX, Cheng YF, Lin HB, Wang C, Xu JP, Zhang HT. Prevention of cerebral ischemia-induced memory deficits by inhibition of phosphodiesterase-4 in rats. *Metabolic brain disease*. 2011;26(1):37-47. doi: 10.1007/s11011-011-9235-0. PubMed PMID: 21327879.
141. Titus DJ, Wilson NM, Alcazar O, Calixte DA, Dietrich WD, Gurney ME, Atkins CM. A negative allosteric modulator of PDE4D enhances learning after traumatic brain injury. *Neurobiology of learning and memory*. 2018;148:38-49. doi: 10.1016/j.nlm.2017.12.008. PubMed PMID: 29294383; PubMed Central PMCID: PMC5844849.
142. Knott EP, Assi M, Rao SN, Ghosh M, Pearse DD. Phosphodiesterase Inhibitors as a Therapeutic Approach to Neuroprotection and Repair. *International journal of molecular sciences*. 2017;18(4). doi: 10.3390/ijms18040696. PubMed PMID: 28338622; PubMed Central PMCID: PMC5412282.
143. Olsen CM, Liu QS. Phosphodiesterase 4 inhibitors and drugs of abuse: current knowledge and therapeutic opportunities. *Frontiers in biology*. 2016;11(5):376-86. doi: 10.1007/s11515-016-1424-0. PubMed PMID: 28974957; PubMed Central PMCID: PMC5617368.
144. Logrip ML. Phosphodiesterase regulation of alcohol drinking in rodents. *Alcohol*. 2015;49(8):795-802. doi: 10.1016/j.alcohol.2015.03.007. PubMed PMID: 26095589; PubMed Central PMCID: PMC4663182.
145. Avila DV, Barker DF, Zhang J, McClain CJ, Barve S, Gobejishvili L. Dysregulation of hepatic cAMP levels via altered Pde4b expression plays a critical role in alcohol-induced steatosis. *The Journal of pathology*. 2016;240(1):96-107. doi: 10.1002/path.4760. PubMed PMID: 27287961; PubMed Central PMCID: PMC4993672.
146. Avila DV, Myers SA, Zhang J, Kharebava G, McClain CJ, Kim HY, Whittemore SR, Gobejishvili L, Barve S. Phosphodiesterase 4b expression plays a major role in alcohol-induced neuro-inflammation. *Neuropharmacology*. 2017;125:376-85. doi: 10.1016/j.neuropharm.2017.08.011. PubMed PMID: 28807677; PubMed Central PMCID: PMC5797427.
147. Favilla C, Abel T, Kelly MP. Chronic Galphas signaling in the striatum increases anxiety-related behaviors independent of developmental effects. *The Journal of neuroscience : the official journal of the Society for Neuroscience*. 2008;28(51):13952-6. Epub 2008/12/19. doi: 10.1523/JNEUROSCI.4986-08.2008. PubMed PMID: 19091983; PubMed Central PMCID: PMC2688724.
148. Kelly MP, Cheung YF, Favilla C, Siegel SJ, Kanes SJ, Houslay MD, Abel T. Constitutive activation of the G-protein subunit Galphas within forebrain neurons causes PKA-dependent alterations in fear conditioning

- and cortical Arc mRNA expression. *Learning & memory*. 2008;15(2):75-83. doi: 10.1101/lm.723708. PubMed PMID: 18230676; PubMed Central PMCID: PMC2216679.
149. Cooney JD, Aguiar RC. Phosphodiesterase 4 inhibitors have wide-ranging activity in B-cell malignancies. *Blood*. 2016;128(25):2886-90. doi: 10.1182/blood-2016-09-737676. PubMed PMID: 27756749; PubMed Central PMCID: PMC5179339.
150. Wang W, Li Y, Zhu JY, Fang D, Ding HF, Dong Z, Jing Q, Su SB, Huang S. Triple negative breast cancer development can be selectively suppressed by sustaining an elevated level of cellular cyclic AMP through simultaneously blocking its efflux and decomposition. *Oncotarget*. 2016;7(52):87232-45. doi: 10.18632/oncotarget.13601. PubMed PMID: 27901486; PubMed Central PMCID: PMC5349984.
151. Nishi K, Luo H, Ishikura S, Doi K, Iwaihara Y, Wills L, Baillie GS, Sakata T, Shirasawa S, Tsunoda T. Apremilast Induces Apoptosis of Human Colorectal Cancer Cells with Mutant KRAS. *Anticancer research*. 2017;37(7):3833-9. doi: 10.21873/anticancer.11762. PubMed PMID: 28668883.
152. Mishra RR, Belder N, Ansari SA, Kayhan M, Bal H, Raza U, Ersan PG, Tokat UM, Eyupoglu E, Saatci O, Jandaghi P, Wiemann S, Uner A, Cekic C, Riazalhosseini Y, Sahin O. Reactivation of cAMP Pathway by PDE4D Inhibition Represents a Novel Druggable Axis for Overcoming Tamoxifen Resistance in ER-positive Breast Cancer. *Clinical cancer research : an official journal of the American Association for Cancer Research*. 2018;24(8):1987-2001. doi: 10.1158/1078-0432.CCR-17-2776. PubMed PMID: 29386221.
153. Wortsman X, Del Barrio-Diaz P, Meza-Romero R, Poehls-Risco C, Vera-Kellet C. Nifedipine cream versus sildenafil cream for patients with secondary Raynaud phenomenon: A randomized, double-blind, controlled pilot study. *Journal of the American Academy of Dermatology*. 2018;78(1):189-90. doi: 10.1016/j.jaad.2017.08.018. PubMed PMID: 29241781.
154. Maged M, Wageh A, Shams M, Elmetwally A. Use of sildenafil citrate in cases of intrauterine growth restriction (IUGR); a prospective trial. *Taiwanese journal of obstetrics & gynecology*. 2018;57(4):483-6. doi: 10.1016/j.tjog.2018.06.002. PubMed PMID: 30122565.
155. Pels A, Kenny LC, Alfirevic Z, Baker PN, von Dadelszen P, Glud C, Kariya CT, Mol BW, Papageorgiou AT, van Wassenaer-Leemhuis AG, Ganzevoort W, Groom KM, international SC. STRIDER (Sildenafil TheRapy in dismal prognosis early onset fetal growth restriction): an international consortium of randomised placebo-controlled trials. *BMC pregnancy and childbirth*. 2017;17(1):440. doi: 10.1186/s12884-017-1594-z. PubMed PMID: 29282009; PubMed Central PMCID: PMC5745923.
156. El-Sayed MA, Saleh SA, Maher MA, Khidre AM. Utero-placental perfusion Doppler indices in growth restricted fetuses: effect of sildenafil citrate. *The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstet*. 2018;31(8):1045-50. doi: 10.1080/14767058.2017.1306509. PubMed PMID: 28345432.
157. Paauw ND, Terstappen F, Ganzevoort W, Joles JA, Gremmels H, Lely AT. Sildenafil During Pregnancy: A Preclinical Meta-Analysis on Fetal Growth and Maternal Blood Pressure. *Hypertension*. 2017;70(5):998-1006. doi: 10.1161/HYPERTENSIONAHA.117.09690. PubMed PMID: 28893896.
158. Aversa A, Fittipaldi S, Francomano D, Bimonte VM, Greco EA, Crescioli C, Di Luigi L, Lenzi A, Migliaccio S. Tadalafil improves lean mass and endothelial function in nonobese men with mild ED/LUTS: in vivo and in vitro characterization. *Endocrine*. 2017;56(3):639-48. doi: 10.1007/s12020-016-1208-y. PubMed PMID: 28133708.
159. Giannetta E, Isidori AM, Galea N, Carbone I, Mandosi E, Vizza CD, Naro F, Morano S, Fedele F, Lenzi A. Chronic Inhibition of cGMP phosphodiesterase 5A improves diabetic cardiomyopathy: a randomized, controlled clinical trial using magnetic resonance imaging with myocardial tagging. *Circulation*. 2012;125(19):2323-33. doi: 10.1161/CIRCULATIONAHA.111.063412. PubMed PMID: 22496161.
160. Di Luigi L, Corinaldesi C, Colletti M, Scolletta S, Antinozzi C, Vannelli GB, Giannetta E, Gianfrilli D, Isidori AM, Migliaccio S, Poerio N, Fraziano M, Lenzi A, Crescioli C. Phosphodiesterase Type 5 Inhibitor Sildenafil Decreases the Proinflammatory Chemokine CXCL10 in Human Cardiomyocytes and in Subjects with Diabetic Cardiomyopathy. *Inflammation*. 2016;39(3):1238-52. doi: 10.1007/s10753-016-0359-6. PubMed PMID: 27165639; PubMed Central PMCID: PMC4883282.

161. Fiore D, Gianfrilli D, Giannetta E, Galea N, Panio G, di Dato C, Pofi R, Pozza C, Sbardella E, Carbone I, Naro F, Lenzi A, Venneri MA, Isidori AM. PDE5 Inhibition Ameliorates Visceral Adiposity Targeting the miR-22/SIRT1 Pathway: Evidence From the CECSID Trial. *The Journal of clinical endocrinology and metabolism*. 2016;101(4):1525-34. doi: 10.1210/jc.2015-4252. PubMed PMID: 26964730.
162. Mandosi E, Giannetta E, Filardi T, Lococo M, Bertolini C, Fallarino M, Gianfrilli D, Venneri MA, Lenti L, Lenzi A, Morano S. Endothelial dysfunction markers as a therapeutic target for Sildenafil treatment and effects on metabolic control in type 2 diabetes. *Expert opinion on therapeutic targets*. 2015;19(12):1617-22. doi: 10.1517/14728222.2015.1066337. PubMed PMID: 26178526.
163. Santi D, Locaso M, Granata AR, Trenti T, Roli L, Pacchioni C, Rochira V, Carani C, Simoni M. Could chronic Vardenafil administration influence the cardiovascular risk in men with type 2 diabetes mellitus? *PloS one*. 2018;13(6):e0199299. doi: 10.1371/journal.pone.0199299. PubMed PMID: 29953477; PubMed Central PMCID: PMC6023114.
164. Montes Cardona CE, Garcia-Perdomo HA. Efficacy of phosphodiesterase type 5 inhibitors for the treatment of distal ureteral calculi: A systematic review and meta-analysis. *Investigative and clinical urology*. 2017;58(2):82-9. doi: 10.4111/icu.2017.58.2.82. PubMed PMID: 28261676; PubMed Central PMCID: PMC5330375.
165. Booth L, Roberts JL, Rais R, Cutler RE, Jr., Diala I, Lalani AS, Hancock JF, Poklepovic A, Dent P. Neratinib augments the lethality of [regorafenib + sildenafil]. *Journal of cellular physiology*. 2018. doi: 10.1002/jcp.27276. PubMed PMID: 30203445.
166. Islam BN, Sharman SK, Hou Y, Bridges AE, Singh N, Kim S, Kolhe R, Trillo-Tinoco J, Rodriguez PC, Berger FG, Sridhar S, Browning DD. Sildenafil Suppresses Inflammation-Driven Colorectal Cancer in Mice. *Cancer prevention research*. 2017;10(7):377-88. doi: 10.1158/1940-6207.CAPR-17-0015. PubMed PMID: 28468928; PubMed Central PMCID: PMC5530733.
167. Califano JA, Khan Z, Noonan KA, Rudraraju L, Zhang Z, Wang H, Goodman S, Gourin CG, Ha PK, Fakhry C, Saunders J, Levine M, Tang M, Neuner G, Richmon JD, Blanco R, Agrawal N, Koch WM, Marur S, Weed DT, Serafini P, Borrello I. Tadalafil augments tumor specific immunity in patients with head and neck squamous cell carcinoma. *Clinical cancer research : an official journal of the American Association for Cancer Research*. 2015;21(1):30-8. doi: 10.1158/1078-0432.CCR-14-1716. PubMed PMID: 25564570; PubMed Central PMCID: PMC4329916.
168. Weed DT, Vella JL, Reis IM, De la Fuente AC, Gomez C, Sargi Z, Nazarian R, Califano J, Borrello I, Serafini P. Tadalafil reduces myeloid-derived suppressor cells and regulatory T cells and promotes tumor immunity in patients with head and neck squamous cell carcinoma. *Clinical cancer research : an official journal of the American Association for Cancer Research*. 2015;21(1):39-48. doi: 10.1158/1078-0432.CCR-14-1711. PubMed PMID: 25320361; PubMed Central PMCID: PMC4322895.
169. Charych EI, Jiang LX, Lo F, Sullivan K, Brandon NJ. Interplay of palmitoylation and phosphorylation in the trafficking and localization of phosphodiesterase 10A: implications for the treatment of schizophrenia. *The Journal of neuroscience : the official journal of the Society for Neuroscience*. 2010;30(27):9027-37. Epub 2010/07/09. doi: 10.1523/JNEUROSCI.1635-10.2010. PubMed PMID: 20610737.
170. Lee K, Lindsey AS, Li N, Gary B, Andrews J, Keeton AB, Piazza GA. beta-catenin nuclear translocation in colorectal cancer cells is suppressed by PDE10A inhibition, cGMP elevation, and activation of PKG. *Oncotarget*. 2016;7(5):5353-65. doi: 10.18632/oncotarget.6705. PubMed PMID: 26713600; PubMed Central PMCID: PMC4868691.
171. Li N, Lee K, Xi Y, Zhu B, Gary BD, Ramirez-Alcantara V, Gurpinar E, Canzoneri JC, Fajardo A, Sigler S, Piazza JT, Chen X, Andrews J, Thomas M, Lu W, Li Y, Laan DJ, Moyer MP, Russo S, Eberhardt BT, Yet L, Keeton AB, Grizzle WE, Piazza GA. Phosphodiesterase 10A: a novel target for selective inhibition of colon tumor cell growth and beta-catenin-dependent TCF transcriptional activity. *Oncogene*. 2015;34(12):1499-509. doi: 10.1038/onc.2014.94. PubMed PMID: 24704829; PubMed Central PMCID: PMC4212019.
172. Barone I, Giordano C, Bonofiglio D, Ando S, Catalano S. Phosphodiesterase type 5 and cancers: progress and challenges. *Oncotarget*. 2017;8(58):99179-202. doi: 10.18632/oncotarget.21837. PubMed PMID: 29228762; PubMed Central PMCID: PMC5716802.

173. Aoun F, Slaoui A, Walid AHO, Albisinni S, Assenmacher G, de Plaen E, Azzo JM, Peltier A, Roumeguere T. Association between phosphodiesterase type 5 inhibitors and prostate cancer: A systematic review. *Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie*. 2018;28(12):560-6. doi: 10.1016/j.purol.2018.07.004. PubMed PMID: 30201551.
174. Arozarena I, Sanchez-Laorden B, Packer L, Hidalgo-Carcedo C, Hayward R, Viros A, Sahai E, Marais R. Oncogenic BRAF induces melanoma cell invasion by downregulating the cGMP-specific phosphodiesterase PDE5A. *Cancer cell*. 2011;19(1):45-57. doi: 10.1016/j.ccr.2010.10.029. PubMed PMID: 21215707.
175. Feng S, Zhou L, Liu Q, He Q, Liao B, Wei X, Li H, Wang K, Zhu Y. Are phosphodiesterase type 5 inhibitors associated with increased risk of melanoma?: A systematic review and meta-analysis. *Medicine*. 2018;97(3):e9601. doi: 10.1097/MD.00000000000009601. PubMed PMID: 29504984; PubMed Central PMCID: PMC5779753.
176. Almeida CB, Scheiermann C, Jang JE, Prophete C, Costa FF, Conran N, Frenette PS. Hydroxyurea and a cGMP-amplifying agent have immediate benefits on acute vaso-occlusive events in sickle cell disease mice. *Blood*. 2012;120(14):2879-88. doi: 10.1182/blood-2012-02-409524. PubMed PMID: 22833547; PubMed Central PMCID: PMC3466969.
177. Goldsmith P, Affinito J, McCue M, Tsai M, Roepcke S, Xie J, Gertsik L, Macek TA. A Randomized Multiple Dose Pharmacokinetic Study of a Novel PDE10A Inhibitor TAK-063 in Subjects with Stable Schizophrenia and Japanese Subjects and Modeling of Exposure Relationships to Adverse Events. *Drugs in R&D*. 2017;17(4):631-43. doi: 10.1007/s40268-017-0214-8. PubMed PMID: 29103081; PubMed Central PMCID: PMC5694427.
178. Macek TA, McCue M, Dong X, Hanson E, Goldsmith P, Affinito J, Mahableshwarkar AR. A phase 2, randomized, placebo-controlled study of the efficacy and safety of TAK-063 in subjects with an acute exacerbation of schizophrenia. *Schizophrenia research*. 2018. doi: 10.1016/j.schres.2018.08.028. PubMed PMID: 30190165.
179. Suzuki K, Harada A, Suzuki H, Miyamoto M, Kimura H. TAK-063, a PDE10A Inhibitor with Balanced Activation of Direct and Indirect Pathways, Provides Potent Antipsychotic-Like Effects in Multiple Paradigms. *Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology*. 2016;41(9):2252-62. doi: 10.1038/npp.2016.20. PubMed PMID: 26849714; PubMed Central PMCID: PMC4946053.
180. Wilson JM, Ogden AM, Loomis S, Gilmour G, Baucum AJ, 2nd, Belecky-Adams TL, Merchant KM. Phosphodiesterase 10A inhibitor, MP-10 (PF-2545920), produces greater induction of c-Fos in dopamine D2 neurons than in D1 neurons in the neostriatum. *Neuropharmacology*. 2015;99:379-86. doi: 10.1016/j.neuropharm.2015.08.008. PubMed PMID: 26256420.
181. Padovan-Neto FE, West AR. Regulation of Striatal Neuron Activity by Cyclic Nucleotide Signaling and Phosphodiesterase Inhibition: Implications for the Treatment of Parkinson's Disease. *Advances in neurobiology*. 2017;17:257-83. doi: 10.1007/978-3-319-58811-7\_10. PubMed PMID: 28956336.
182. Jankowska A, Swierczek A, Chlon-Rzepa G, Pawlowski M, Wyska E. PDE7-Selective and Dual Inhibitors: Advances in Chemical and Biological Research. *Current medicinal chemistry*. 2017;24(7):673-700. doi: 10.2174/0929867324666170116125159. PubMed PMID: 28093982.
183. Redondo M, Brea J, Perez DI, Soteras I, Val C, Perez C, Morales-Garcia JA, Alonso-Gil S, Paul-Fernandez N, Martin-Alvarez R, Cadavid MI, Loza MI, Perez-Castillo A, Mengod G, Campillo NE, Martinez A, Gil C. Effect of phosphodiesterase 7 (PDE7) inhibitors in experimental autoimmune encephalomyelitis mice. Discovery of a new chemically diverse family of compounds. *Journal of medicinal chemistry*. 2012;55(7):3274-84. doi: 10.1021/jm201720d. PubMed PMID: 22385507.
184. Morales-Garcia JA, Aguilar-Morante D, Hernandez-Encinas E, Alonso-Gil S, Gil C, Martinez A, Santos A, Perez-Castillo A. Silencing phosphodiesterase 7B gene by lentiviral-shRNA interference attenuates neurodegeneration and motor deficits in hemiparkinsonian mice. *Neurobiology of aging*. 2015;36(2):1160-73. doi: 10.1016/j.neurobiolaging.2014.10.008. PubMed PMID: 25457552.
185. Morales-Garcia JA, Echeverry-Alzate V, Alonso-Gil S, Sanz-SanCristobal M, Lopez-Moreno JA, Gil C, Martinez A, Santos A, Perez-Castillo A. Phosphodiesterase7 Inhibition Activates Adult Neurogenesis in

- Hippocampus and Subventricular Zone In Vitro and In Vivo. *Stem cells*. 2017;35(2):458-72. doi: 10.1002/stem.2480. PubMed PMID: 27538853.
186. Tsai LC, Chan GC, Nangle SN, Shimizu-Albergine M, Jones GL, Storm DR, Beavo JA, Zweifel LS. Inactivation of Pde8b enhances memory, motor performance, and protects against age-induced motor coordination decay. *Genes, brain, and behavior*. 2012;11(7):837-47. doi: 10.1111/j.1601-183X.2012.00836.x. PubMed PMID: 22925203; PubMed Central PMCID: PMC3467314.
187. Pathak G, Agostino MJ, Bishara K, Capell WR, Fisher JL, Hegde S, Ibrahim BA, Pilarzyk K, Sabin C, Tuczkewycz T, Wilson S, Kelly MP. PDE11A negatively regulates lithium responsiveness. *Molecular psychiatry*. 2017;22(12):1714-24. doi: 10.1038/mp.2016.155. PubMed PMID: 27646265; PubMed Central PMCID: PMC5359083.
188. Mertens J, Wang QW, Kim Y, Yu DX, Pham S, Yang B, Zheng Y, Diffenderfer KE, Zhang J, Soltani S, Eames T, Schafer ST, Boyer L, Marchetto MC, Nurnberger JI, Calabrese JR, Odegaard KJ, McCarthy MJ, Zandi PP, Alda M, Nievergelt CM, Pharmacogenomics of Bipolar Disorder S, Mi S, Brennand KJ, Kelsoe JR, Gage FH, Yao J. Differential responses to lithium in hyperexcitable neurons from patients with bipolar disorder. *Nature*. 2015;527(7576):95-9. doi: 10.1038/nature15526. PubMed PMID: 26524527; PubMed Central PMCID: PMC4742055.
189. Dong H, Zitt C, Auriga C, Hatzelmann A, Epstein PM. Inhibition of PDE3, PDE4 and PDE7 potentiates glucocorticoid-induced apoptosis and overcomes glucocorticoid resistance in CEM T leukemic cells. *Biochemical pharmacology*. 2010;79(3):321-9. doi: 10.1016/j.bcp.2009.09.001. PubMed PMID: 19737543.
190. de Medeiros AS, Wyman AR, Alaamery MA, Allain C, Ivey FD, Wang L, Le H, Morken JP, Habara A, Le C, Cui S, Lerner A, Hoffman CS. Identification and characterization of a potent and biologically-active PDE4/7 inhibitor via fission yeast-based assays. *Cellular signalling*. 2017;40:73-80. doi: 10.1016/j.cellsig.2017.08.011. PubMed PMID: 28867658; PubMed Central PMCID: PMC5651194.
191. Tsai LC, Shimizu-Albergine M, Beavo JA. The high-affinity cAMP-specific phosphodiesterase 8B controls steroidogenesis in the mouse adrenal gland. *Molecular pharmacology*. 2011;79(4):639-48. doi: 10.1124/mol.110.069104. PubMed PMID: 21187369; PubMed Central PMCID: PMC3063732.
192. Shimizu-Albergine M, Tsai LC, Patrucco E, Beavo JA. cAMP-specific phosphodiesterases 8A and 8B, essential regulators of Leydig cell steroidogenesis. *Molecular pharmacology*. 2012;81(4):556-66. doi: 10.1124/mol.111.076125. PubMed PMID: 22232524; PubMed Central PMCID: PMC3310417.
193. Jang IS, Rhim JH, Kim KT, Cho KA, Yeo EJ, Park SC. Lysophosphatidic acid-induced changes in cAMP profiles in young and senescent human fibroblasts as a clue to the ageing process. *Mech Ageing Dev*. 2006;127(5):481-9. doi: 10.1016/j.mad.2006.01.004. PubMed PMID: 16516270.
194. Ramos BP, Birnbaum SG, Lindenmayer I, Newton SS, Duman RS, Arnsten AF. Dysregulation of protein kinase a signaling in the aged prefrontal cortex: new strategy for treating age-related cognitive decline. *Neuron*. 2003;40(4):835-45. PubMed PMID: 14622586.
195. Wang M, Ramos BP, Paspalas CD, Shu Y, Simen A, Duque A, Vijayraghavan S, Brennan A, Dudley A, Nou E, Mazer JA, McCormick DA, Arnsten AF. Alpha2A-adrenoceptors strengthen working memory networks by inhibiting cAMP-HCN channel signaling in prefrontal cortex. *Cell*. 2007;129(2):397-410. doi: 10.1016/j.cell.2007.03.015. PubMed PMID: 17448997.
196. Giralt A, Saavedra A, Carreton O, Xifro X, Alberch J, Perez-Navarro E. Increased PKA signaling disrupts recognition memory and spatial memory: role in Huntington's disease. *Human molecular genetics*. 2011;20(21):4232-47. doi: 10.1093/hmg/ddr351. PubMed PMID: 21835884.
197. Hegde S, Ji H, Oliver D, Patel NS, Poupore N, Shtutman M, Kelly MP. PDE11A regulates social behaviors and is a key mechanism by which social experience sculpts the brain. *Neuroscience*. 2016;335:151-69. doi: 10.1016/j.neuroscience.2016.08.019. PubMed PMID: 27544407; PubMed Central PMCID: PMC5031549.
198. Guo S, Olesen J, Ashina M. Phosphodiesterase 3 inhibitor cilostazol induces migraine-like attacks via cyclic AMP increase. *Brain : a journal of neurology*. 2014;137(Pt 11):2951-9. doi: 10.1093/brain/awu244. PubMed PMID: 25161294.

199. Holland PR, Strother L. Cilostazol as a chemically induced preclinical model of migraine. *Cephalalgia : an international journal of headache*. 2018;38(3):415-6. doi: 10.1177/0333102417693832. PubMed PMID: 28952338.
200. Khan S, Deen M, Hougaard A, Amin FM, Ashina M. Reproducibility of migraine-like attacks induced by phosphodiesterase-3-inhibitor cilostazol. *Cephalalgia : an international journal of headache*. 2018;38(5):892-903. doi: 10.1177/0333102417719753. PubMed PMID: 28677994.
201. Hansen EK, Guo S, Ashina M, Olesen J. Toward a pragmatic migraine model for drug testing: I. Cilostazol in healthy volunteers. *Cephalalgia : an international journal of headache*. 2016;36(2):172-8. doi: 10.1177/0333102415583986. PubMed PMID: 25934317.
202. Birk S, Kruuse C, Petersen KA, Tfelt-Hansen P, Olesen J. The headache-inducing effect of cilostazol in human volunteers. *Cephalalgia : an international journal of headache*. 2006;26(11):1304-9. doi: 10.1111/j.1468-2982.2006.01218.x. PubMed PMID: 17059437.
203. Mowat FM, Ocelli LM, Bartoe JT, Gervais KJ, Bruewer AR, Querubin J, Dinculescu A, Boye SL, Hauswirth WW, Petersen-Jones SM. Gene Therapy in a Large Animal Model of PDE6A-Retinitis Pigmentosa. *Front Neurosci*. 2017;11:342. doi: 10.3389/fnins.2017.00342. PubMed PMID: 28676737; PubMed Central PMCID: PMC5476745.
204. Henderson DJ, Byrne A, Dulla K, Jenster G, Hoffmann R, Baillie GS, Houslay MD. The cAMP phosphodiesterase-4D7 (PDE4D7) is downregulated in androgen-independent prostate cancer cells and mediates proliferation by compartmentalising cAMP at the plasma membrane of VCaP prostate cancer cells. *Br J Cancer*. 2014;110(5):1278-87. doi: 10.1038/bjc.2014.22. PubMed PMID: 24518597; PubMed Central PMCID: PMC3950871.
205. Abi-Gerges A, Richter W, Lefebvre F, Mateo P, Varin A, Heymes C, Samuel JL, Lugnier C, Conti M, Fischmeister R, Vandecasteele G. Decreased expression and activity of cAMP phosphodiesterases in cardiac hypertrophy and its impact on beta-adrenergic cAMP signals. *Circ Res*. 2009;105(8):784-92. doi: 10.1161/CIRCRESAHA.109.197947. PubMed PMID: 19745166; PubMed Central PMCID: PMC2792993.
206. Wang X, Ward CJ, Harris PC, Torres VE. Cyclic nucleotide signaling in polycystic kidney disease. *Kidney Int*. 2010;77(2):129-40. doi: 10.1038/ki.2009.438. PubMed PMID: 19924104; PubMed Central PMCID: PMC3725619.
207. Malekshahi T, Khoshdel Rad N, Serra AL, Moghadasali R. Autosomal dominant polycystic kidney disease: Disrupted pathways and potential therapeutic interventions. *Journal of cellular physiology*. 2019;234(8):12451-70. doi: 10.1002/jcp.28094. PubMed PMID: 30644092.
208. Zoraghi R, Corbin JD, Francis SH. Properties and functions of GAF domains in cyclic nucleotide phosphodiesterases and other proteins. *Mol Pharmacol*. 2004;65(2):267-78. doi: 10.1124/mol.65.2.267. PubMed PMID: 14742667.
209. Schultz JE. Structural and biochemical aspects of tandem GAF domains. *Handb Exp Pharmacol*. 2009(191):93-109. doi: 10.1007/978-3-540-68964-5\_6. PubMed PMID: 19089327.
210. Jager R, Schwede F, Genieser HG, Koesling D, Russwurm M. Activation of PDE2 and PDE5 by specific GAF ligands: delayed activation of PDE5. *British journal of pharmacology*. 2010;161(7):1645-60. Epub 2010/08/12. doi: 10.1111/j.1476-5381.2010.00977.x. PubMed PMID: 20698857; PubMed Central PMCID: PMC3010573.
211. Martinez SE, Wu AY, Glavas NA, Tang XB, Turley S, Hol WG, Beavo JA. The two GAF domains in phosphodiesterase 2A have distinct roles in dimerization and in cGMP binding. *Proceedings of the National Academy of Sciences of the United States of America*. 2002;99(20):13260-5. doi: 10.1073/pnas.192374899. PubMed PMID: 12271124; PubMed Central PMCID: PMC130621.
212. Beavo JA, Hardman JG, Sutherland EW. Stimulation of adenosine 3',5'-monophosphate hydrolysis by guanosine 3',5'-monophosphate. *The Journal of biological chemistry*. 1971;246(12):3841-6. PubMed PMID: 4327188.



213. Jager R, Russwurm C, Schwede F, Genieser HG, Koesling D, Russwurm M. Activation of PDE10 and PDE11 phosphodiesterases. *The Journal of biological chemistry*. 2012;287(2):1210-9. doi: 10.1074/jbc.M111.263806. PubMed PMID: 22105073; PubMed Central PMCID: PMC3256904.
214. D'Amours MR, Cote RH. Regulation of photoreceptor phosphodiesterase catalysis by its non-catalytic cGMP-binding sites. *The Biochemical journal*. 1999;340 ( Pt 3):863-9. PubMed PMID: 10359674; PubMed Central PMCID: PMC1220321.
215. Schultz JE, Dunkern T, Gawlitta-Gorka E, Sorg G. The GAF-tandem domain of phosphodiesterase 5 as a potential drug target. *Handb Exp Pharmacol*. 2011(204):151-66. doi: 10.1007/978-3-642-17969-3\_6. PubMed PMID: 21695639.
216. Kelly MP. Does phosphodiesterase 11A (PDE11A) hold promise as a future therapeutic target? *Current pharmaceutical design*. 2015;21(3):389-416. PubMed PMID: 25159071.
217. Murthy KS, Zhou H, Makhlof GM. PKA-dependent activation of PDE3A and PDE4 and inhibition of adenylyl cyclase V/VI in smooth muscle. *Am J Physiol Cell Physiol*. 2002;282(3):C508-17. doi: 10.1152/ajpcell.00373.2001. PubMed PMID: 11832336.
218. Manganiello VC, Taira M, Degerman E, Belfrage P. Type III cGMP-inhibited cyclic nucleotide phosphodiesterases (PDE3 gene family). *Cell Signal*. 1995;7(5):445-55. PubMed PMID: 8562305.
219. MacKenzie SJ, Baillie GS, McPhee I, MacKenzie C, Seamons R, McSorley T, Millen J, Beard MB, van Heeke G, Houslay MD. Long PDE4 cAMP specific phosphodiesterases are activated by protein kinase A-mediated phosphorylation of a single serine residue in Upstream Conserved Region 1 (UCR1). *Br J Pharmacol*. 2002;136(3):421-33. doi: 10.1038/sj.bjp.0704743. PubMed PMID: 12023945; PubMed Central PMCID: PMC1573369.
220. Corbin JD, Turko IV, Beasley A, Francis SH. Phosphorylation of phosphodiesterase-5 by cyclic nucleotide-dependent protein kinase alters its catalytic and allosteric cGMP-binding activities. *Eur J Biochem*. 2000;267(9):2760-7. PubMed PMID: 10785399.
221. Brown KM, Lee LC, Findlay JE, Day JP, Baillie GS. Cyclic AMP-specific phosphodiesterase, PDE8A1, is activated by protein kinase A-mediated phosphorylation. *FEBS letters*. 2012;586(11):1631-7. doi: 10.1016/j.febslet.2012.04.033. PubMed PMID: 22673573.
222. Jacobitz S, McLaughlin MM, Livi GP, Burman M, Torphy TJ. Mapping the functional domains of human recombinant phosphodiesterase 4A: structural requirements for catalytic activity and rolipram binding. *Mol Pharmacol*. 1996;50(4):891-9. PubMed PMID: 8863835.
223. Marcoz P, Nemoz G, Prigent AF, Lagarde M. Phosphatidic acid stimulates the rolipram-sensitive cyclic nucleotide phosphodiesterase from rat thymocytes. *Biochim Biophys Acta*. 1993;1176(1-2):129-36. PubMed PMID: 8452869.
224. Norambuena A, Metz C, Jung JE, Silva A, Otero C, Cancino J, Retamal C, Valenzuela JC, Soza A, Gonzalez A. Phosphatidic acid induces ligand-independent epidermal growth factor receptor endocytic traffic through PDE4 activation. *Mol Biol Cell*. 2010;21(16):2916-29. doi: 10.1091/mbc.E10-02-0167. PubMed PMID: 20554760; PubMed Central PMCID: PMC2921116.
225. Grange M, Sette C, Cuomo M, Conti M, Lagarde M, Prigent AF, Nemoz G. The cAMP-specific phosphodiesterase PDE4D3 is regulated by phosphatidic acid binding. Consequences for cAMP signaling pathway and characterization of a phosphatidic acid binding site. *J Biol Chem*. 2000;275(43):33379-87. doi: 10.1074/jbc.M006329200. PubMed PMID: 10938092.
226. Wang L, Burmeister BT, Johnson KR, Baillie GS, Karginov AV, Skidgel RA, O'Bryan JP, Carnegie GK. UCR1C is a novel activator of phosphodiesterase 4 (PDE4) long isoforms and attenuates cardiomyocyte hypertrophy. *Cell Signal*. 2015;27(5):908-22. doi: 10.1016/j.cellsig.2015.02.003. PubMed PMID: 25683917; PubMed Central PMCID: PMC4361369.
227. Guo LW, Muradov H, Hajipour AR, Sievert MK, Artemyev NO, Ruoho AE. The inhibitory gamma subunit of the rod cGMP phosphodiesterase binds the catalytic subunits in an extended linear structure. *J Biol Chem*. 2006;281(22):15412-22. doi: 10.1074/jbc.M600595200. PubMed PMID: 16595671.
228. Zhang XJ, Skiba NP, Cote RH. Structural requirements of the photoreceptor phosphodiesterase gamma-subunit for inhibition of rod PDE6 holoenzyme and for its activation by transducin. *J Biol Chem*.

- 2010;285(7):4455-63. doi: 10.1074/jbc.M109.057406. PubMed PMID: 19948718; PubMed Central PMCID: PMC2836051.
229. Slep KC, Kercher MA, He W, Cowan CW, Wensel TG, Sigler PB. Structural determinants for regulation of phosphodiesterase by a G protein at 2.0 Å. *Nature*. 2001;409(6823):1071-7. doi: 10.1038/35059138. PubMed PMID: 11234020.
230. Zhang Z, He F, Constantine R, Baker ML, Baehr W, Schmid MF, Wensel TG, Agosto MA. Domain organization and conformational plasticity of the G protein effector, PDE6. *J Biol Chem*. 2015;290(20):12833-43. doi: 10.1074/jbc.M115.647636. PubMed PMID: 25809480; PubMed Central PMCID: PMC4432299.
231. Lynch MJ, Baillie GS, Mohamed A, Li X, Maisonneuve C, Klussmann E, van Heeke G, Houslay MD. RNA silencing identifies PDE4D5 as the functionally relevant cAMP phosphodiesterase interacting with beta arrestin to control the protein kinase A/AKAP79-mediated switching of the beta2-adrenergic receptor to activation of ERK in HEK293B2 cells. *J Biol Chem*. 2005;280(39):33178-89. doi: 10.1074/jbc.M414316200. PubMed PMID: 16030021.
232. Ren L, Yang C, Dou Y, Zhan R, Sun Y, Yu Y. MiR-541-5p regulates lung fibrosis by targeting cyclic nucleotide phosphodiesterase 1A. *Exp Lung Res*. 2017;43(6-7):249-58. doi: 10.1080/01902148.2017.1349210. PubMed PMID: 28816543.
233. Zhang DD, Li Y, Xu Y, Kim J, Huang S. Phosphodiesterase 7B/microRNA-200c relationship regulates triple-negative breast cancer cell growth. *Oncogene*. 2018. doi: 10.1038/s41388-018-0499-2. PubMed PMID: 30209363.
234. Yang G, McIntyre KW, Townsend RM, Shen HH, Pitts WJ, Dodd JH, Nadler SG, McKinnon M, Watson AJ. Phosphodiesterase 7A-deficient mice have functional T cells. *J Immunol*. 2003;171(12):6414-20. PubMed PMID: 14662840.
235. Ding B, Abe JI, Wei H, Huang Q, Walsh RA, Molina CA, Zhao A, Sadoshima J, Blaxall BC, Berk BC, Yan C. Functional role of phosphodiesterase 3 in cardiomyocyte apoptosis: implication in heart failure. *Circulation*. 2005;111(19):2469-76. doi: 10.1161/01.CIR.0000165128.39715.87. PubMed PMID: 15867171; PubMed Central PMCID: PMC4108189.
236. Wu WH, Tsai YT, Justus S, Lee TT, Zhang L, Lin CS, Bassuk AG, Mahajan VB, Tsang SH. CRISPR Repair Reveals Causative Mutation in a Preclinical Model of Retinitis Pigmentosa. *Mol Ther*. 2016;24(8):1388-94. doi: 10.1038/mt.2016.107. PubMed PMID: 27203441; PubMed Central PMCID: PMC45023380.
237. Wensel TG, Zhang Z, Anastassov IA, Gilliam JC, He F, Schmid MF, Robichaux MA. Structural and molecular bases of rod photoreceptor morphogenesis and disease. *Prog Retin Eye Res*. 2016;55:32-51. doi: 10.1016/j.preteyeres.2016.06.002. PubMed PMID: 27352937; PubMed Central PMCID: PMC45112133.
238. Deng WT, Sakurai K, Kolandaivelu S, Kolesnikov AV, Dinculescu A, Li J, Zhu P, Liu X, Pang J, Chiodo VA, Boye SL, Chang B, Ramamurthy V, Kefalov VJ, Hauswirth WW. Cone phosphodiesterase-6alpha' restores rod function and confers distinct physiological properties in the rod phosphodiesterase-6beta-deficient rd10 mouse. *J Neurosci*. 2013;33(29):11745-53. doi: 10.1523/JNEUROSCI.1536-13.2013. PubMed PMID: 23864662; PubMed Central PMCID: PMC3713718.
239. Pang JJ, Boye SL, Kumar A, Dinculescu A, Deng W, Li J, Li Q, Rani A, Foster TC, Chang B, Hawes NL, Boatright JH, Hauswirth WW. AAV-mediated gene therapy for retinal degeneration in the rd10 mouse containing a recessive PDEbeta mutation. *Invest Ophthalmol Vis Sci*. 2008;49(10):4278-83. doi: 10.1167/iovs.07-1622. PubMed PMID: 18586879; PubMed Central PMCID: PMC3595574.
240. Wert KJ, Davis RJ, Sancho-Pelluz J, Nishina PM, Tsang SH. Gene therapy provides long-term visual function in a pre-clinical model of retinitis pigmentosa. *Hum Mol Genet*. 2013;22(3):558-67. doi: 10.1093/hmg/dd5466. PubMed PMID: 23108158; PubMed Central PMCID: PMC3542865.
241. Deng WT, Kolandaivelu S, Dinculescu A, Li J, Zhu P, Chiodo VA, Ramamurthy V, Hauswirth WW. Cone Phosphodiesterase-6gamma' Subunit Augments Cone PDE6 Holoenzyme Assembly and Stability in a Mouse Model Lacking Both Rod and Cone PDE6 Catalytic Subunits. *Front Mol Neurosci*. 2018;11:233. doi: 10.3389/fnmol.2018.00233. PubMed PMID: 30038560; PubMed Central PMCID: PMC6046437.
242. Carvalho LS, Xiao R, Wassmer SJ, Langsdorf A, Zinn E, Pacouret S, Shah S, Comander JI, Kim LA, Lim L, Vandenberghe LH. Synthetic Adeno-Associated Viral Vector Efficiently Targets Mouse and Nonhuman

- Primate Retina In Vivo. *Hum Gene Ther.* 2018;29(7):771-84. doi: 10.1089/hum.2017.154. PubMed PMID: 29325457; PubMed Central PMCID: PMC6066192.
243. Ye H, Fussenegger M. Optogenetic Medicine: Synthetic Therapeutic Solutions Precision-Guided by Light. *Cold Spring Harbor perspectives in medicine.* 2018. doi: 10.1101/cshperspect.a034371. PubMed PMID: 30291146.
244. Yoshida K, Tsunoda SP, Brown LS, Kandori H. A unique choanoflagellate enzyme rhodopsin exhibits light-dependent cyclic nucleotide phosphodiesterase activity. *The Journal of biological chemistry.* 2017;292(18):7531-41. doi: 10.1074/jbc.M117.775569. PubMed PMID: 28302718; PubMed Central PMCID: PMC5418051.
245. Lamarche LB, Kumar RP, Trieu MM, Devine EL, Cohen-Abeles LE, Theobald DL, Oprian DD. Purification and Characterization of RhoPDE, a Retinylidene/Phosphodiesterase Fusion Protein and Potential Optogenetic Tool from the Choanoflagellate *Salpingoeca rosetta*. *Biochemistry.* 2017;56(43):5812-22. doi: 10.1021/acs.biochem.7b00519. PubMed PMID: 28976747; PubMed Central PMCID: PMC5685503.
246. Tian Y, Gao S, Yang S, Nagel G. A novel rhodopsin phosphodiesterase from *Salpingoeca rosetta* shows light-enhanced substrate affinity. *The Biochemical journal.* 2018;475(6):1121-8. doi: 10.1042/BCJ20180010. PubMed PMID: 29483295.
247. Gasser C, Taiber S, Yeh CM, Wittig CH, Hegemann P, Ryu S, Wunder F, Moglich A. Engineering of a red-light-activated human cAMP/cGMP-specific phosphodiesterase. *Proceedings of the National Academy of Sciences of the United States of America.* 2014;111(24):8803-8. doi: 10.1073/pnas.1321600111. PubMed PMID: 24889611; PubMed Central PMCID: PMC4066486.
248. Kelly MP. Cyclic nucleotide signaling changes associated with normal aging and age-related diseases of the brain. *Cellular signalling.* 2018;42:281-91. doi: 10.1016/j.cellsig.2017.11.004. PubMed PMID: 29175000; PubMed Central PMCID: PMC5732030.
249. Fertig BA, Baillie GS. PDE4-Mediated cAMP Signalling. *Journal of cardiovascular development and disease.* 2018;5(1). doi: 10.3390/jcdd5010008. PubMed PMID: 29385021; PubMed Central PMCID: PMC5872356.
250. McCahill A, McSorley T, Huston E, Hill EV, Lynch MJ, Gall I, Keryer G, Lygren B, Tasken K, van Heeke G, Houslay MD. In resting COS1 cells a dominant negative approach shows that specific, anchored PDE4 cAMP phosphodiesterase isoforms gate the activation, by basal cyclic AMP production, of AKAP-tethered protein kinase A type II located in the centrosomal region. *Cellular signalling.* 2005;17(9):1158-73. doi: 10.1016/j.cellsig.2005.04.003. PubMed PMID: 15905070.
251. Bolger GB, Baillie GS, Li X, Lynch MJ, Herzyk P, Mohamed A, Mitchell LH, McCahill A, Hundsrucker C, Klussmann E, Adams DR, Houslay MD. Scanning peptide array analyses identify overlapping binding sites for the signalling scaffold proteins, beta-arrestin and RACK1, in cAMP-specific phosphodiesterase PDE4D5. *The Biochemical journal.* 2006;398(1):23-36. Epub 2006/05/13. doi: 10.1042/BJ20060423. PubMed PMID: 16689683; PubMed Central PMCID: PMC1525009.
252. Baillie GS, Sood A, McPhee I, Gall I, Perry SJ, Lefkowitz RJ, Houslay MD. beta-Arrestin-mediated PDE4 cAMP phosphodiesterase recruitment regulates beta-adrenoceptor switching from Gs to Gi. *Proceedings of the National Academy of Sciences of the United States of America.* 2003;100(3):940-5. doi: 10.1073/pnas.262787199. PubMed PMID: 12552097; PubMed Central PMCID: PMC298705.
253. Willoughby D, Baillie GS, Lynch MJ, Ciruela A, Houslay MD, Cooper DM. Dynamic regulation, desensitization, and cross-talk in discrete subcellular microdomains during beta2-adrenoceptor and prostanoid receptor cAMP signaling. *J Biol Chem.* 2007;282(47):34235-49. doi: 10.1074/jbc.M706765200. PubMed PMID: 17855344.
254. Ong WK, Gribble FM, Reimann F, Lynch MJ, Houslay MD, Baillie GS, Furman BL, Pyne NJ. The role of the PDE4D cAMP phosphodiesterase in the regulation of glucagon-like peptide-1 release. *Br J Pharmacol.* 2009;157(4):633-44. doi: 10.1111/j.1476-5381.2009.00194.x. PubMed PMID: 19371330; PubMed Central PMCID: PMC62707975.
255. Terrin A, Monterisi S, Stangherlin A, Zoccarato A, Koschinski A, Surdo NC, Mongillo M, Sawa A, Jordanides NE, Mountford JC, Zaccolo M. PKA and PDE4D3 anchoring to AKAP9 provides distinct regulation

- of cAMP signals at the centrosome. *The Journal of cell biology*. 2012;198(4):607-21. doi: 10.1083/jcb.201201059. PubMed PMID: 22908311; PubMed Central PMCID: PMC3514031.
256. Vecsey CG, Baillie GS, Jaganath D, Havekes R, Daniels A, Wimmer M, Huang T, Brown KM, Li XY, Descalzi G, Kim SS, Chen T, Shang YZ, Zhuo M, Houslay MD, Abel T. Sleep deprivation impairs cAMP signalling in the hippocampus. *Nature*. 2009;461(7267):1122-5. doi: 10.1038/nature08488. PubMed PMID: 19847264; PubMed Central PMCID: PMCPMC2783639.
257. Havekes R, Park AJ, Tudor JC, Luczak VG, Hansen RT, Ferri SL, Bruinenberg VM, Poplawski SG, Day JP, Aton SJ, Radwanska K, Meerlo P, Houslay MD, Baillie GS, Abel T. Sleep deprivation causes memory deficits by negatively impacting neuronal connectivity in hippocampal area CA1. *Elife*. 2016;5. doi: 10.7554/eLife.13424. PubMed PMID: 27549340; PubMed Central PMCID: PMCPMC4996653.
258. Havekes R, Park AJ, Tolentino RE, Bruinenberg VM, Tudor JC, Lee Y, Hansen RT, Guercio LA, Linton E, Neves-Zaph SR, Meerlo P, Baillie GS, Houslay MD, Abel T. Compartmentalized PDE4A5 Signaling Impairs Hippocampal Synaptic Plasticity and Long-Term Memory. *J Neurosci*. 2016;36(34):8936-46. doi: 10.1523/JNEUROSCI.0248-16.2016. PubMed PMID: 27559174; PubMed Central PMCID: PMCPMC4995304.
259. Campbell SL, van Groen T, Kadish I, Smoot LHM, Bolger GB. Altered phosphorylation, electrophysiology, and behavior on attenuation of PDE4B action in hippocampus. *BMC neuroscience*. 2017;18(1):77. doi: 10.1186/s12868-017-0396-6. PubMed PMID: 29197324; PubMed Central PMCID: PMC5712142.
260. McGirr A, Lipina TV, Mun HS, Georgiou J, Al-Amri AH, Ng E, Zhai D, Elliott C, Cameron RT, Mullins JG, Liu F, Baillie GS, Clapcote SJ, Roder JC. Specific Inhibition of Phosphodiesterase-4B Results in Anxiolysis and Facilitates Memory Acquisition. *Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology*. 2016;41(4):1080-92. doi: 10.1038/npp.2015.240. PubMed PMID: 26272049; PubMed Central PMCID: PMC4748432.
261. Johnston LA, Erdogan S, Cheung YF, Sullivan M, Barber R, Lynch MJ, Baillie GS, Van Heeke G, Adams DR, Huston E, Houslay MD. Expression, intracellular distribution and basis for lack of catalytic activity of the PDE4A7 isoform encoded by the human PDE4A cAMP-specific phosphodiesterase gene. *The Biochemical journal*. 2004;380(Pt 2):371-84. doi: 10.1042/BJ20031662. PubMed PMID: 15025561; PubMed Central PMCID: PMC1224194.
262. Lynch MJ, Baillie GS, Houslay MD. cAMP-specific phosphodiesterase-4D5 (PDE4D5) provides a paradigm for understanding the unique non-redundant roles that PDE4 isoforms play in shaping compartmentalized cAMP cell signalling. *Biochem Soc Trans*. 2007;35(Pt 5):938-41. doi: 10.1042/BST0350938. PubMed PMID: 17956250.
263. Wills L, Ehsan M, Whiteley EL, Baillie GS. Location, location, location: PDE4D5 function is directed by its unique N-terminal region. *Cellular signalling*. 2016;28(7):701-5. doi: 10.1016/j.cellsig.2016.01.008. PubMed PMID: 26808969.
264. Yun S, Budatha M, Dahlman JE, Coon BG, Cameron RT, Langer R, Anderson DG, Baillie G, Schwartz MA. Interaction between integrin  $\alpha 5$  and PDE4D regulates endothelial inflammatory signalling. *Nature cell biology*. 2016;18(10):1043-53. doi: 10.1038/ncb3405. PubMed PMID: 27595237; PubMed Central PMCID: PMC5301150.
265. Ahmad F, Shen W, Vandeput F, Szabo-Fresnais N, Krall J, Degerman E, Goetz F, Klussmann E, Movsesian M, Manganiello V. Regulation of sarcoplasmic reticulum  $\text{Ca}^{2+}$  ATPase 2 (SERCA2) activity by phosphodiesterase 3A (PDE3A) in human myocardium: phosphorylation-dependent interaction of PDE3A1 with SERCA2. *The Journal of biological chemistry*. 2015;290(11):6763-76. doi: 10.1074/jbc.M115.638585. PubMed PMID: 25593322; PubMed Central PMCID: PMC4358103.
266. Lee LC, Maurice DH, Baillie GS. Targeting protein-protein interactions within the cyclic AMP signaling system as a therapeutic strategy for cardiovascular disease. *Future Med Chem*. 2013;5(4):451-64. doi: 10.4155/fmc.12.216. PubMed PMID: 23495691.
267. Delyon J, Servy A, Laugier F, Andre J, Ortonne N, Battistella M, Mourah S, Bensussan A, Lebbe C, Dumaz N. PDE4D promotes FAK-mediated cell invasion in BRAF-mutated melanoma. *Oncogene*. 2017;36(23):3252-62. doi: 10.1038/onc.2016.469. PubMed PMID: 28092671.

268. Serrels B, Sandilands E, Serrels A, Baillie G, Houslay MD, Brunton VG, Canel M, Machesky LM, Anderson KI, Frame MC. A complex between FAK, RACK1, and PDE4D5 controls spreading initiation and cancer cell polarity. *Current biology : CB*. 2010;20(12):1086-92. doi: 10.1016/j.cub.2010.04.042. PubMed PMID: 20493699.
269. Martin TP, Hortigon-Vinagre MP, Findlay JE, Elliott C, Currie S, Baillie GS. Targeted disruption of the heat shock protein 20-phosphodiesterase 4D (PDE4D) interaction protects against pathological cardiac remodelling in a mouse model of hypertrophy. *FEBS open bio*. 2014;4:923-7. doi: 10.1016/j.fob.2014.10.011. PubMed PMID: 25426411; PubMed Central PMCID: PMC4239479.
270. Keravis T, Lugnier C. Cyclic nucleotide phosphodiesterases (PDE) and peptide motifs. *Current pharmaceutical design*. 2010;16(9):1114-25. PubMed PMID: 20030615.
271. MacMullen CM, Vick K, Pacifico R, Fallahi-Sichani M, Davis RL. Novel, primate-specific PDE10A isoform highlights gene expression complexity in human striatum with implications on the molecular pathology of bipolar disorder. *Translational psychiatry*. 2016;6:e742. doi: 10.1038/tp.2016.3. PubMed PMID: 26905414; PubMed Central PMCID: PMC4872433.
272. Movsesian M. Novel approaches to targeting PDE3 in cardiovascular disease. *Pharmacology & therapeutics*. 2016;163:74-81. doi: 10.1016/j.pharmthera.2016.03.014. PubMed PMID: 27108947.
273. Kotera J, Sasaki T, Kobayashi T, Fujishige K, Yamashita Y, Omori K. Subcellular localization of cyclic nucleotide phosphodiesterase type 10A variants, and alteration of the localization by cAMP-dependent protein kinase-dependent phosphorylation. *The Journal of biological chemistry*. 2004;279(6):4366-75. doi: 10.1074/jbc.M308471200. PubMed PMID: 14604994.
274. Russwurm C, Koesling D, Russwurm M. Phosphodiesterase 10A Is Tethered to a Synaptic Signaling Complex in Striatum. *The Journal of biological chemistry*. 2015;290(19):11936-47. doi: 10.1074/jbc.M114.595769. PubMed PMID: 25762721; PubMed Central PMCID: PMC4424333.
275. Kelly MP. A Role for Phosphodiesterase 11A (PDE11A) in the Formation of Social Memories and the Stabilization of Mood. *Advances in neurobiology*. 2017;17:201-30. doi: 10.1007/978-3-319-58811-7\_8. PubMed PMID: 28956334; PubMed Central PMCID: PMC5652326.
276. Carlisle Michel JJ, Dodge KL, Wong W, Mayer NC, Langeberg LK, Scott JD. PKA-phosphorylation of PDE4D3 facilitates recruitment of the mAKAP signalling complex. *The Biochemical journal*. 2004;381(Pt 3):587-92. doi: 10.1042/BJ20040846. PubMed PMID: 15182229; PubMed Central PMCID: PMC1133866.
277. Suryavanshi SV, Jadhav SM, Anderson KL, Katsonis P, Lichtarge O, McConnell BK. Human muscle-specific A-kinase anchoring protein polymorphisms modulate the susceptibility to cardiovascular diseases by altering cAMP/PKA signaling. *Am J Physiol Heart Circ Physiol*. 2018;315(1):H109-H21. doi: 10.1152/ajpheart.00034.2018. PubMed PMID: 29600899; PubMed Central PMCID: PMCPMC6087776.
278. Zhu H, Suk HY, Yu RY, Brancho D, Olabisi O, Yang TT, Yang X, Zhang J, Moussaif M, Durand JL, Jelicks LA, Kim JY, Scherer PE, Frank PG, Lisanti MP, Calvert JW, Duranski MR, Lefer DJ, Huston E, Baillie GS, Houslay MD, Molkenkin JD, Jin J, Chow CW. Evolutionarily conserved role of calcineurin in phosphodegron-dependent degradation of phosphodiesterase 4D. *Molecular and cellular biology*. 2010;30(18):4379-90. doi: 10.1128/MCB.01193-09. PubMed PMID: 20647544; PubMed Central PMCID: PMC2937537.
279. VerPlank JJS, Goldberg AL. Regulating protein breakdown through proteasome phosphorylation. *Biochem J*. 2017;474(19):3355-71. doi: 10.1042/BCJ20160809. PubMed PMID: 28947610; PubMed Central PMCID: PMCPMC5831125.
280. Cai Y, Huang G, Ma L, Dong L, Chen S, Shen X, Zhang S, Xue R, Sun D, Zhang S. Smurf2, an E3 ubiquitin ligase, interacts with PDE4B and attenuates liver fibrosis through miR-132 mediated CTGF inhibition. *Biochimica et biophysica acta Molecular cell research*. 2018;1865(2):297-308. doi: 10.1016/j.bbamcr.2017.10.011. PubMed PMID: 29100790.
281. Li X, Baillie GS, Houslay MD. Mdm2 directs the ubiquitination of beta-arrestin-sequestered cAMP phosphodiesterase-4D5. *J Biol Chem*. 2009;284(24):16170-82. doi: 10.1074/jbc.M109.008078. PubMed PMID: 19372219; PubMed Central PMCID: PMCPMC2713507.

282. Hay RT. Decoding the SUMO signal. *Biochem Soc Trans.* 2013;41(2):463-73. doi: 10.1042/BST20130015. PubMed PMID: 23514139.
283. Hoffmann R, Baillie GS, MacKenzie SJ, Yarwood SJ, Houslay MD. The MAP kinase ERK2 inhibits the cyclic AMP-specific phosphodiesterase HSPDE4D3 by phosphorylating it at Ser579. *EMBO J.* 1999;18(4):893-903. doi: 10.1093/emboj/18.4.893. PubMed PMID: 10022832; PubMed Central PMCID: PMCPMC1171182.
284. Wang Y, Zhang P, Xu Z, Yue W, Zhuang Y, Chen Y, Lu Z. S-nitrosylation of PDE5 increases its ubiquitin-proteasomal degradation. *Free radical biology & medicine.* 2015;86:343-51. doi: 10.1016/j.freeradbiomed.2015.05.037. PubMed PMID: 26093192.
285. Garcia JA. Aiming straight for the heart: prolyl hydroxylases set the BAR. *Sci Signal.* 2009;2(96):pe70. doi: 10.1126/scisignal.296pe70. PubMed PMID: 19903936.
286. Huo Z, Ye JC, Chen J, Lin X, Zhou ZN, Xu XR, Li CM, Qi M, Liang D, Liu Y, Li J. Prolyl hydroxylase domain protein 2 regulates the intracellular cyclic AMP level in cardiomyocytes through its interaction with phosphodiesterase 4D. *Biochemical and biophysical research communications.* 2012;427(1):73-9. doi: 10.1016/j.bbrc.2012.09.005. PubMed PMID: 22975349.
287. Lorenz R, Bertinetti D, Herberg FW. cAMP-Dependent Protein Kinase and cGMP-Dependent Protein Kinase as Cyclic Nucleotide Effectors. *Handbook of experimental pharmacology.* 2017;238:105-22. doi: 10.1007/164\_2015\_36. PubMed PMID: 27885524.
288. VanSchouwen B, Melacini G. Regulation of HCN Ion Channels by Non-canonical Cyclic Nucleotides. *Handbook of experimental pharmacology.* 2017;238:123-33. doi: 10.1007/164\_2016\_5006. PubMed PMID: 28181007.
289. Rehmann H. Interaction of Epac with Non-canonical Cyclic Nucleotides. *Handbook of experimental pharmacology.* 2017;238:135-47. doi: 10.1007/164\_2015\_37. PubMed PMID: 27900608.
290. Hauser AR. The type III secretion system of *Pseudomonas aeruginosa*: infection by injection. *Nature reviews Microbiology.* 2009;7(9):654-65. doi: 10.1038/nrmicro2199. PubMed PMID: 19680249; PubMed Central PMCID: PMC2766515.
291. Wolter S, Kloth C, Golombek M, Dittmar F, Forsterling L, Seifert R. cCMP causes caspase-dependent apoptosis in mouse lymphoma cell lines. *Biochemical pharmacology.* 2015;98(1):119-31. doi: 10.1016/j.bcp.2015.08.096. PubMed PMID: 26300059.
292. Wong CH, Siah KW, Lo AW. Estimation of clinical trial success rates and related parameters. *Biostatistics.* 2019;20(2):273-86. doi: 10.1093/biostatistics/kxx069. PubMed PMID: 29394327; PubMed Central PMCID: PMC6409418.
293. Liu FC, Yu HP, Lin CY, Elzoghby AO, Hwang TL, Fang JY. Use of cilomilast-loaded phosphatiosomes to suppress neutrophilic inflammation for attenuating acute lung injury: the effect of nanovesicular surface charge. *Journal of nanobiotechnology.* 2018;16(1):35. doi: 10.1186/s12951-018-0364-z. PubMed PMID: 29602314; PubMed Central PMCID: PMC5877390.
294. Yu S, Pearson AD, Lim RK, Rodgers DT, Li S, Parker HB, Weglarz M, Hampton EN, Bollong MJ, Shen J, Zambaldo C, Wang D, Woods AK, Wright TM, Schultz PG, Kazane SA, Young TS, Tremblay MS. Targeted Delivery of an Anti-inflammatory PDE4 Inhibitor to Immune Cells via an Antibody-drug Conjugate. *Molecular therapy : the journal of the American Society of Gene Therapy.* 2016;24(12):2078-89. doi: 10.1038/mt.2016.175. PubMed PMID: 27731313; PubMed Central PMCID: PMC5167782.
295. Raymond DR, Wilson LS, Carter RL, Maurice DH. Numerous distinct PKA-, or EPAC-based, signalling complexes allow selective phosphodiesterase 3 and phosphodiesterase 4 coordination of cell adhesion. *Cellular signalling.* 2007;19(12):2507-18. doi: 10.1016/j.cellsig.2007.08.005. PubMed PMID: 17884339.
296. Sapio L, Di Maiolo F, Illiano M, Esposito A, Chiosi E, Spina A, Naviglio S. Targeting protein kinase A in cancer therapy: an update. *EXCLI journal.* 2014;13:843-55. PubMed PMID: 26417307; PubMed Central PMCID: PMC4464521.
297. Raker VK, Becker C, Steinbrink K. The cAMP Pathway as Therapeutic Target in Autoimmune and Inflammatory Diseases. *Frontiers in immunology.* 2016;7:123. doi: 10.3389/fimmu.2016.00123. PubMed PMID: 27065076; PubMed Central PMCID: PMC4814577.

298. Kumar N, Prasad P, Jash E, Saini M, Husain A, Goldman A, Sehrawat S. Insights into exchange factor directly activated by cAMP (EPAC) as potential target for cancer treatment. *Molecular and cellular biochemistry*. 2018;447(1-2):77-92. doi: 10.1007/s11010-018-3294-z. PubMed PMID: 29417338.
299. Parnell E, Palmer TM, Yarwood SJ. The future of EPAC-targeted therapies: agonism versus antagonism. *Trends in pharmacological sciences*. 2015;36(4):203-14. doi: 10.1016/j.tips.2015.02.003. PubMed PMID: 25744542; PubMed Central PMCID: PMC4392396.
300. Holland NA, Francisco JT, Johnson SC, Morgan JS, Dennis TJ, Gadireddy NR, Tulis DA. Cyclic Nucleotide-Directed Protein Kinases in Cardiovascular Inflammation and Growth. *Journal of cardiovascular development and disease*. 2018;5(1). doi: 10.3390/jcdd5010006. PubMed PMID: 29367584; PubMed Central PMCID: PMC5872354.
301. Bollen E, Puzzo D, Rutten K, Privitera L, De Vry J, Vanmierlo T, Kenis G, Palmeri A, D'Hooge R, Balschun D, Steinbusch HM, Blokland A, Prickaerts J. Improved long-term memory via enhancing cGMP-PKG signaling requires cAMP-PKA signaling. *Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology*. 2014;39(11):2497-505. doi: 10.1038/npp.2014.106. PubMed PMID: 24813825; PubMed Central PMCID: PMC4207334.
302. Joshi R, Kadeer N, Sheriff S, Friend LA, James JH, Balasubramaniam A. Phosphodiesterase (PDE) inhibitor torbafylline (HWA 448) attenuates burn-induced rat skeletal muscle proteolysis through the PDE4/cAMP/EPAC/PI3K/Akt pathway. *Molecular and cellular endocrinology*. 2014;393(1-2):152-63. doi: 10.1016/j.mce.2014.06.012. PubMed PMID: 24973766.
303. Miller CL, Cai Y, Oikawa M, Thomas T, Dostmann WR, Zaccolo M, Fujiwara K, Yan C. Cyclic nucleotide phosphodiesterase 1A: a key regulator of cardiac fibroblast activation and extracellular matrix remodeling in the heart. *Basic research in cardiology*. 2011;106(6):1023-39. doi: 10.1007/s00395-011-0228-2. PubMed PMID: 22012077; PubMed Central PMCID: PMC4114346.
304. Zhang HT, Huang Y, Jin SL, Frith SA, Suvarna N, Conti M, O'Donnell JM. Antidepressant-like profile and reduced sensitivity to rolipram in mice deficient in the PDE4D phosphodiesterase enzyme. *Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology*. 2002;27(4):587-95. doi: 10.1016/S0893-133X(02)00344-5. PubMed PMID: 12377395.
305. Salpietro V, Perez-Duenas B, Nakashima K, San Antonio-Arce V, Manole A, Efthymiou S, Vandrovicova J, Bettencourt C, Mencacci NE, Klein C, Kelly MP, Davies CH, Kimura H, Macaya A, Houlden H. A homozygous loss-of-function mutation in PDE2A associated to early-onset hereditary chorea. *Movement disorders : official journal of the Movement Disorder Society*. 2018;33(3):482-8. doi: 10.1002/mds.27286. PubMed PMID: 29392776; PubMed Central PMCID: PMC5873427.
306. Iribarne M, Masai I. Neurotoxicity of cGMP in the vertebrate retina: from the initial research on rd mutant mice to zebrafish genetic approaches. *J Neurogenet*. 2017;31(3):88-101. doi: 10.1080/01677063.2017.1358268. PubMed PMID: 28812418.
307. Savai R, Pullamsetti SS, Banat GA, Weissmann N, Ghofrani HA, Grimminger F, Schermuly RT. Targeting cancer with phosphodiesterase inhibitors. *Expert Opin Investig Drugs*. 2010;19(1):117-31. doi: 10.1517/13543780903485642. PubMed PMID: 20001559.
308. Ahmad F, Murata T, Shimizu K, Degerman E, Maurice D, Manganiello V. Cyclic nucleotide phosphodiesterases: important signaling modulators and therapeutic targets. *Oral diseases*. 2015;21(1):e25-50. doi: 10.1111/odi.12275. PubMed PMID: 25056711; PubMed Central PMCID: PMC4275405.
309. Zuo H, Cattani-Cavaliere I, Musheshe N, Nikolaev VO, Schmidt M. Phosphodiesterases as therapeutic targets for respiratory diseases. *Pharmacol Ther*. 2019. doi: 10.1016/j.pharmthera.2019.02.002. PubMed PMID: 30759374.
310. Pincelli C, Schafer PH, French LE, Augustin M, Krueger JG. Mechanisms Underlying the Clinical Effects of Apremilast for Psoriasis. *J Drugs Dermatol*. 2018;17(8):835-40. PubMed PMID: 30124722.
311. Gupta A, Tiwari M, Prasad S, Chaube SK. Role of Cyclic Nucleotide Phosphodiesterases During Meiotic Resumption From Diplotene Arrest in Mammalian Oocytes. *J Cell Biochem*. 2017;118(3):446-52. doi: 10.1002/jcb.25748. PubMed PMID: 27662514.

312. Drobnis EZ, Nangia AK. Phosphodiesterase Inhibitors (PDE Inhibitors) and Male Reproduction. *Adv Exp Med Biol.* 2017;1034:29-38. doi: 10.1007/978-3-319-69535-8\_5. PubMed PMID: 29256125.
313. Vasta V, Sonnenburg WK, Yan C, Soderling SH, Shimizu-Albergine M, Beavo JA. Identification of a new variant of PDE1A calmodulin-stimulated cyclic nucleotide phosphodiesterase expressed in mouse sperm. *Biology of reproduction.* 2005;73(4):598-609. doi: 10.1095/biolreprod.104.039180. PubMed PMID: 15901640.
314. Alves de Inda M, van Strijp D, den Biezen-Timmermans E, van Brussel A, Wrobel J, van Zon H, Vos P, Baillie GS, Tennstedt P, Schlomm T, Houslay MD, Bangma C, Hoffmann R. Validation of Cyclic Adenosine Monophosphate Phosphodiesterase-4D7 for its Independent Contribution to Risk Stratification in a Prostate Cancer Patient Cohort with Longitudinal Biological Outcomes. *European urology focus.* 2018;4(3):376-84. doi: 10.1016/j.euf.2017.05.010. PubMed PMID: 28753810.
315. van Strijp D, de Witz C, Vos PC, den Biezen-Timmermans E, van Brussel A, Wrobel J, Baillie GS, Tennstedt P, Schlomm T, Heitkotter B, Huss S, Bogemann M, Houslay MD, Bangma C, Semjonow A, Hoffmann R. The Prognostic PDE4D7 Score in a Diagnostic Biopsy Prostate Cancer Patient Cohort with Longitudinal Biological Outcomes. *Prostate Cancer.* 2018;2018:5821616. doi: 10.1155/2018/5821616. PubMed PMID: 30147955; PubMed Central PMCID: PMC6083737.
316. Bottcher R, Henderson DJ, Dulla K, van Strijp D, Waanders LF, Tevz G, Lehman ML, Merkle D, van Leenders GJ, Baillie GS, Jenster G, Houslay MD, Hoffmann R. Human phosphodiesterase 4D7 (PDE4D7) expression is increased in TMPRSS2-ERG-positive primary prostate cancer and independently adds to a reduced risk of post-surgical disease progression. *Br J Cancer.* 2015;113(10):1502-11. doi: 10.1038/bjc.2015.335. PubMed PMID: 26575822; PubMed Central PMCID: PMC4815894.
317. Bottcher R, Dulla K, van Strijp D, Dits N, Verhoef EI, Baillie GS, van Leenders GJ, Houslay MD, Jenster G, Hoffmann R. Human PDE4D isoform composition is deregulated in primary prostate cancer and indicative for disease progression and development of distant metastases. *Oncotarget.* 2016;7(43):70669-84. doi: 10.18632/oncotarget.12204. PubMed PMID: 27683107; PubMed Central PMCID: PMC5342582.
318. Nazir M, Senkowski W, Nyberg F, Blom K, Edqvist PH, Jarvius M, Andersson C, Gustafsson MG, Nygren P, Larsson R, Fryknas M. Targeting tumor cells based on Phosphodiesterase 3A expression. *Experimental cell research.* 2017;361(2):308-15. doi: 10.1016/j.yexcr.2017.10.032. PubMed PMID: 29107068.
319. Vandenberghe P, Hague P, Hockman SC, Manganiello VC, Demetter P, Erneux C, Vanderwinden JM. Phosphodiesterase 3A: a new player in development of interstitial cells of Cajal and a prospective target in gastrointestinal stromal tumors (GIST). *Oncotarget.* 2017;8(25):41026-43. doi: 10.18632/oncotarget.17010. PubMed PMID: 28454120; PubMed Central PMCID: PMC5522287.
320. Fryknas M, Rickardson L, Wickstrom M, Dhar S, Lovborg H, Gullbo J, Nygren P, Gustafsson MG, Isaksson A, Larsson R. Phenotype-based screening of mechanistically annotated compounds in combination with gene expression and pathway analysis identifies candidate drug targets in a human squamous carcinoma cell model. *J Biomol Screen.* 2006;11(5):457-68. doi: 10.1177/1087057106288048. PubMed PMID: 16928983.
321. Ahmad R, Bourgeois S, Postnov A, Schmidt ME, Bormans G, Van Laere K, Vandenberghe W. PET imaging shows loss of striatal PDE10A in patients with Huntington disease. *Neurology.* 2014;82(3):279-81. doi: 10.1212/WNL.000000000000037. PubMed PMID: 24353339.
322. Wilson H, Nicolini F, Haider S, Marques TR, Pagano G, Coello C, Natesan S, Kapur S, Rabiner EA, Gunn RN, Tabrizi SJ, Politis M. Loss of extra-striatal phosphodiesterase 10A expression in early premanifest Huntington's disease gene carriers. *Journal of the neurological sciences.* 2016;368:243-8. doi: 10.1016/j.jns.2016.07.033. PubMed PMID: 27538642.
323. Nicolini F, Foltynie T, Reis Marques T, Muhlert N, Tziortzi AC, Searle GE, Natesan S, Kapur S, Rabiner EA, Gunn RN, Piccini P, Politis M. Loss of phosphodiesterase 10A expression is associated with progression and severity in Parkinson's disease. *Brain : a journal of neurology.* 2015;138(Pt 10):3003-15. doi: 10.1093/brain/awv219. PubMed PMID: 26210536.
324. Boscutti G, E AR, Plisson C. PET Radioligands for imaging of the PDE10A in human: current status. *Neuroscience letters.* 2019;691:11-7. doi: 10.1016/j.neulet.2018.08.006. PubMed PMID: 30099081.
325. Schroder S, Wenzel B, Deuther-Conrad W, Scheunemann M, Brust P. Novel Radioligands for Cyclic Nucleotide Phosphodiesterase Imaging with Positron Emission Tomography: An Update on Developments



- Since 2012. *Molecules*. 2016;21(5). doi: 10.3390/molecules21050650. PubMed PMID: 27213312; PubMed Central PMCID: PMC6273803.
326. Neves SR, Ram PT, Iyengar R. G protein pathways. *Science*. 2002;296(5573):1636-9. Epub 2002/06/01. doi: 10.1126/science.1071550. PubMed PMID: 12040175.
327. Chen J, Martinez J, Milner TA, Buck J, Levin LR. Neuronal expression of soluble adenylyl cyclase in the mammalian brain. *Brain research*. 2013;1518:1-8. doi: 10.1016/j.brainres.2013.04.027. PubMed PMID: 23611875; PubMed Central PMCID: PMC3679342.
328. Kobialka M, Gorczyca WA. Particulate guanylyl cyclases: multiple mechanisms of activation. *Acta biochimica Polonica*. 2000;47(3):517-28. PubMed PMID: 11310956.
329. Brand T. The Popeye Domain Containing Genes and Their Function as cAMP Effector Proteins in Striated Muscle. *Journal of cardiovascular development and disease*. 2018;5(1). doi: 10.3390/jcdd5010018. PubMed PMID: 29534001; PubMed Central PMCID: PMC5872366.
330. Gamanuma M, Yuasa K, Sasaki T, Sakurai N, Kotera J, Omori K. Comparison of enzymatic characterization and gene organization of cyclic nucleotide phosphodiesterase 8 family in humans. *Cellular signalling*. 2003;15(6):565-74. PubMed PMID: 12681444.
331. Goraya TA, Cooper DM. Ca(2+)-calmodulin-dependent phosphodiesterase (PDE1): Current perspectives. *Cellular signalling*. 2005;17(7):789-97.
332. Pandit J, Forman MD, Fennell KF, Dillman KS, Menniti FS. Mechanism for the allosteric regulation of phosphodiesterase 2A deduced from the X-ray structure of a near full-length construct. *Proceedings of the National Academy of Sciences of the United States of America*. 2009;106(43):18225-30. doi: 10.1073/pnas.0907635106. PubMed PMID: 19828435; PubMed Central PMCID: PMC2775329.
333. Qureshi BM, Behrmann E, Schoneberg J, Loerke J, Burger J, Mielke T, Giesebrecht J, Noe F, Lamb TD, Hofmann KP, Spahn CMT, Heck M. It takes two transducins to activate the cGMP-phosphodiesterase 6 in retinal rods. *Open biology*. 2018;8(8). doi: 10.1098/rsob.180075. PubMed PMID: 30068566; PubMed Central PMCID: PMC6119865.
334. Francis SH, Houslay MD, Conti M. Phosphodiesterase inhibitors: factors that influence potency, selectivity, and action. *Handbook of experimental pharmacology*. 2011(204):47-84. doi: 10.1007/978-3-642-17969-3\_2. PubMed PMID: 21695635.
335. Berthouze-Duquesnes M, Lucas A, Sauliere A, Sin YY, Laurent AC, Gales C, Baillie G, Lezoualc'h F. Specific interactions between Epac1, beta-arrestin2 and PDE4D5 regulate beta-adrenergic receptor subtype differential effects on cardiac hypertrophic signaling. *Cellular signalling*. 2013;25(4):970-80. doi: 10.1016/j.cellsig.2012.12.007. PubMed PMID: 23266473.
336. Bolger GB. RACK1 and beta-arrestin2 attenuate dimerization of PDE4 cAMP phosphodiesterase PDE4D5. *Cellular signalling*. 2016;28(7):706-12. doi: 10.1016/j.cellsig.2015.08.003. PubMed PMID: 26257302; PubMed Central PMCID: PMC4744576.
337. Metz VE, Jones JD, Manubay J, Sullivan MA, Mogali S, Segoshi A, Madera G, Johnson KW, Comer SD. Effects of Ibudilast on the Subjective, Reinforcing, and Analgesic Effects of Oxycodone in Recently Detoxified Adults with Opioid Dependence. *Neuropsychopharmacology*. 2017;42(9):1825-32. doi: 10.1038/npp.2017.70. PubMed PMID: 28393896; PubMed Central PMCID: PMC5520790.
338. Zhang F, Yan C, Wei C, Yao Y, Ma X, Gong Z, Liu S, Zang D, Chen J, Shi FD, Hao J. Vinpocetine Inhibits NF-kappaB-Dependent Inflammation in Acute Ischemic Stroke Patients. *Transl Stroke Res*. 2018;9(2):174-84. doi: 10.1007/s12975-017-0549-z. PubMed PMID: 28691141.
339. Ma XW, Guo XH, Xiao XH, Guo LX, Lv XF, Li QM, Gao Y. A randomized, open-label, multicentre study to evaluate plasma atherosclerotic biomarkers in patients with type 2 diabetes mellitus and arteriosclerosis obliterans when treated with Probuco and Cilostazol. *Journal of geriatric cardiology : JGC*. 2012;9(3):228-36. doi: 10.3724/SP.J.1263.2012.02143. PubMed PMID: 23097651; PubMed Central PMCID: PMC3470020.
340. Lee JY, Lee H, Yoo HB, Choi JS, Jung HY, Yoon EJ, Kim H, Jung YH, Lee HY, Kim YK. Efficacy of Cilostazol Administration in Alzheimer's Disease Patients with White Matter Lesions: A Positron-Emission Tomography Study. *Neurotherapeutics*. 2019. doi: 10.1007/s13311-018-00708-x. PubMed PMID: 30761509.

341. Heckman PRA, Van Duinen MA, Blokland A, Uz T, Prickaerts J, Sambeth A. Acute administration of roflumilast enhances sensory gating in healthy young humans in a randomized trial. *Psychopharmacology*. 2018;235(1):301-8. doi: 10.1007/s00213-017-4770-y. PubMed PMID: 29098341; PubMed Central PMCID: PMC5748397.
342. Wouters EF, Bredenbroeker D, Teichmann P, Brose M, Rabe KF, Fabbri LM, Goke B. Effect of the phosphodiesterase 4 inhibitor roflumilast on glucose metabolism in patients with treatment-naïve, newly diagnosed type 2 diabetes mellitus. *J Clin Endocrinol Metab*. 2012;97(9):E1720-5. doi: 10.1210/jc.2011-2886. PubMed PMID: 22723325.
343. Gonzalez-Ortiz M, Martinez-Abundis E, Hernandez-Corona DM, Ramirez-Rodriguez AM. Effect of tadalafil administration on insulin secretion and insulin sensitivity in obese men. *Acta Clin Belg*. 2017;72(5):326-30. doi: 10.1080/17843286.2017.1293759. PubMed PMID: 28245726.
344. Sbardella E, Minnetti M, D'Aluisio D, Rizza L, Di Giorgio MR, Vinci F, Pofi R, Giannetta E, Venneri MA, Vestri A, Morelli S, Lenzi A, Isidori AM. Cardiovascular features of possible autonomous cortisol secretion in patients with adrenal incidentalomas. *European journal of endocrinology / European Federation of Endocrine Societies*. 2018;178(5):501-11. doi: 10.1530/EJE-17-0986. PubMed PMID: 29510982.
345. Pauls MMH, Clarke N, Trippier S, Betteridge S, Howe FA, Khan U, Kruuse C, Madigan JB, Moynihan B, Pereira AC, Rolfe D, Rostrup E, Haig CE, Barrick TR, Isaacs JD, Hainsworth AH. Perfusion by Arterial Spin labelling following Single dose Tadalafil In Small vessel disease (PASTIS): study protocol for a randomised controlled trial. *Trials*. 2017;18(1):229. doi: 10.1186/s13063-017-1973-9. PubMed PMID: 28532471; PubMed Central PMCID: PMC5440904.
346. Charnigo RJ, Beidler D, Rybin D, Pittman DD, Tan B, Howard J, Michelson AD, Frelinger AI, III, Clarke N. PF-04447943, a Phosphodiesterase 9A Inhibitor, in Stable Sickle Cell Disease Patients: A Phase Ib Randomized, Placebo-Controlled Study. *Clin Transl Sci*. 2019;12(2):180-8. doi: 10.1111/cts.12604. PubMed PMID: 30597771; PubMed Central PMCID: PMC6440678.
347. Moschetti V, Boland K, Feifel U, Hoch A, Zimdahl-Gelling H, Sand M. First-in-human study assessing safety, tolerability and pharmacokinetics of BI 409306, a selective phosphodiesterase 9A inhibitor, in healthy males. *British journal of clinical pharmacology*. 2016;82(5):1315-24. doi: 10.1111/bcp.13060. PubMed PMID: 27378314; PubMed Central PMCID: PMC5061793.
348. Boland K, Moschetti V, Dansirikul C, Pichereau S, Gheyle L, Runge F, Zimdahl-Gelling H, Sand M. A phase I, randomized, proof-of-clinical-mechanism study assessing the pharmacokinetics and pharmacodynamics of the oral PDE9A inhibitor BI 409306 in healthy male volunteers. *Human psychopharmacology*. 2017;32(1). doi: 10.1002/hup.2569. PubMed PMID: 28120486.
349. Fazio P, Schain M, Mrzljak L, Amini N, Nag S, Al-Tawil N, Fitzer-Attas CJ, Bronzova J, Landwehrmeyer B, Sampaio C, Halldin C, Varrone A. Patterns of age related changes for phosphodiesterase type-10A in comparison with dopamine D2/3 receptors and sub-cortical volumes in the human basal ganglia: A PET study with (18)F-MNI-659 and (11)C-raclopride with correction for partial volume effect. *Neuroimage*. 2017;152:330-9. doi: 10.1016/j.neuroimage.2017.02.047. PubMed PMID: 28254508.
350. Macek TA, McCue M, Dong X, Hanson E, Goldsmith P, Affinito J, Mahableshwarkar AR. A phase 2, randomized, placebo-controlled study of the efficacy and safety of TAK-063 in subjects with an acute exacerbation of schizophrenia. *Schizophr Res*. 2019;204:289-94. doi: 10.1016/j.schres.2018.08.028. PubMed PMID: 30190165.